[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiMpp-w-VdPB2Sy-NrwT-rhcn2kR0fmuSShVUzy9vWD0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Columbia University",[4],1117,false,233,46,1772116,79,775,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Obesity",28,{"name":18,"count":19},"Stroke",27,{"name":21,"count":19},"HIV",{"name":23,"count":24},"Breast Cancer",24,{"name":26,"count":27},"HIV\u002FAIDS",19,{"name":29,"count":30},"HIV Infections",16,{"name":32,"count":33},"Heart Failure",15,{"name":35,"count":33},"Asthma",[37,42,46,51,56,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03585114","Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers","2022-12","[F-18] DCFPyL",{"nctId":43,"briefTitle":44,"date":40,"intervention":45},"NCT03824275","18F-DCFPyL Positron Emission Tomography (PET)\u002FComputed Tomography (CT) in Men With Prostate Cancer","18F- DCFPyL PET\u002FCT",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT00408447","Stem Cell Transplant in Sickle Cell Disease and Thalassemia","2025-02","Busulfan",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04375228","Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)","2025-05-14","Rituximab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05836025","Effect of Rapamycin in Ovarian Aging","2025-10-21","Rapamycin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05183490","R-MVST Cells for Treatment of Viral Infections","2025-12","Rapidly generated virus specific T (R-MVST) cells",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07070882","Oral Steroid Taper After Total Knee Arthroplasty","2025-12-01","Methylprednisolone",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04614558","Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance","2026-04","Isatuximab",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04098666","Metformin in Alzheimer's Dementia Prevention","2026-05-12","extended release metformin",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT03389100","Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.","2026-06","18F-MK6240",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,185,224,264,282,306,332,360,378,403,450,487,509,535,563,581,603,633,651,683,701,723,807,835,960,1002,1032,1084,1117,1151,1174,1192,1219,1240,1258,1276,1302,1320,1345,1363,1383,1404,1430,1463,1498,1551,1577,1603,1629,1664,1700,1722,1748,1772,1798,1824,1842,1860,1878,1896,1919,1944,1962,1980,1998,2021,2049,2067,2085,2110,2128,2146,2164,2207,2232,2268,2306,2324,2342,2367,2430,2493,2529,2577,2609,2652,2694,2727,2761,2783,2805,2845,2878,2900,2918,2943,2961,2979,2997,3019,3042,3066,3089,3114,3132,3150,3173,3203,3221,3245,3267,3291,3316,3334,3359,3377,3403,3431,3449,3472,3490,3515,3533,3557,3575,3593,3611,3635,3662,3680,3698,3716,3734,3757,3780,3798,3825,3843,3867,3885,3908,3926,3952,3979,3997,4015,4033,4063,4081,4099,4117,4135,4162,4180,4206,4232,4256,4279,4304,4322,4349,4375,4398,4422,4446,4471,4489,4507,4532,4550,4574,4600,4618,4666,4699,4734,4769,4804,4833,4855,4878,4904,4928,4946,4970,4988,5012,5030,5051,5069,5092,5116,5143,5168,5186,5212,5230,5248,5266,5289,5313,5331,5349,5371,5397,5415,5433,5457,5475,5500,5524,5548,5566,5590,5618,5636,5654,5705,5735,5763,5789,5826,5852,5874,5896,5918,5953,5983,6016,6046,6078,6109,6137,6159,6185,6219,6251,6278,6300,6322,6346,6364,6382,6400,6418,6436,6461,6479,6497,6515,6538,6563,6588,6612,6630,6654,6672,6690,6712,6741,6759,6777,6795,6813,6831,6854,6872,6898,6922,6945,6963,6985,7010,7042,7060,7078,7096,7114,7132,7155,7178,7196,7224,7247,7265,7290,7315,7337,7363,7381,7403,7428,7451,7474,7496,7519,7542,7564,7590,7608,7634,7652,7670,7700,7718,7736,7754,7772,7790,7808,7826,7848,7873,7891,7913,7937,7963,7981,7999,8017,8041,8067,8085,8108,8132,8157,8179,8202,8225,8248,8266,8291,8309,8327,8345,8363,8387,8405,8423,8446,8480,8503,8526,8544,8562,8583,8605,8623,8641,8659,8677,8699,8717,8742,8760,8778,8802,8825,8848,8866,8884,8909,8933,8951,8976,8999,9017,9035,9059,9077,9100,9122,9140,9164,9188,9206,9224,9242,9260,9285,9303,9321,9348,9366,9384,9410,9428,9451,9477,9495,9513,9538,9563,9581,9603,9628,9652,9676,9701,9724,9742,9760,9784,9809,9857,9887,9920,9953,9984,10015,10042,10074,10103,10128,10153,10171,10197,10215,10233,10251,10278,10296,10314,10336,10358,10381,10399,10422,10446,10470,10488,10511,10534,10552,10577,10595,10613,10631,10655,10678,10701,10726,10747,10765,10791,10814,10837,10859,10881,10905,10923,10941,10962,10985,11010,11033,11051,11069,11090],{"intervention":95,"totalTrials":96,"cells":97},"Aspirin",6,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":130,"PHASE4":159,"NA":183},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":129,"soonestReadout":84},[105,116],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":84,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT03667326","Postpartum Low-Dose Aspirin and Preeclampsia","RECRUITING",[89],"2026-12","2019-07-22",100,[114],"Preeclampsia Postpartum",[95],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":33,"conditions":124,"interventions":128},"NCT03008915","Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency","COMPLETED",[89],"2018-07","2020-10","2017-01",[125,126,127],"Alpha-1 Antitrypsin Deficiency","Emphysema","Chronic Obstructive Pulmonary Disease",[95],1,{"trials":131,"activeCount":100},[132,147],{"nctId":133,"briefTitle":134,"status":119,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":144},"NCT00041938","Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial",[90],"2011-08","2014-07","2002-10",2305,[141,18,142,143],"Heart Disease","Ischemic Heart Disease","Myocardial Infarction",[145,146],"aspirin","Warfarin",{"nctId":148,"briefTitle":149,"status":150,"phases":151,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT03192215","AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke","TERMINATED",[90],"2023-03-31","2023-04-17","2018-01-19",1015,[18],[158,95],"Apixaban",{"trials":160,"activeCount":129,"soonestReadout":165},[161,172],{"nctId":162,"briefTitle":163,"status":108,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":171},"NCT06655376","Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device",[91],"2027-04-01","2024-10-02",128,[169,170],"Bleeding","Clot Blood",[95,146],{"nctId":173,"briefTitle":174,"status":119,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":182},"NCT00697151","Patent Foramen Ovale in Cryptogenic Stroke Study",[91],"2000-06","1993-06",630,[180,181],"Ischemic Stroke","Patent Foramen Ovale",[146,95],{"trials":184,"activeCount":100},[],{"intervention":146,"totalTrials":186,"cells":187},4,{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":212,"NA":222},{"trials":189,"activeCount":100},[],{"trials":191,"activeCount":100},[],{"trials":193,"activeCount":100},[],{"trials":195,"activeCount":129,"soonestReadout":205},[196,200],{"nctId":133,"briefTitle":134,"status":119,"phases":197,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":198,"interventions":199},[90],[141,18,142,143],[145,146],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"completion":205,"start":84,"enrollment":206,"conditions":207,"interventions":211},"NCT07471139","SWITCH: Apixaban vs Vitamin K in HM3","NOT_YET_RECRUITING",[90],"2029-06",460,[208,32,169,209,18,210],"LVAD (Left Ventricular Assist Device) Thrombosis","Thrombosis; Artery","Heart Transplant",[146,158],{"trials":213,"activeCount":129,"soonestReadout":165},[214,218],{"nctId":162,"briefTitle":163,"status":108,"phases":215,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":216,"interventions":217},[91],[169,170],[95,146],{"nctId":173,"briefTitle":174,"status":119,"phases":219,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":220,"interventions":221},[91],[180,181],[146,95],{"trials":223,"activeCount":100},[],{"intervention":225,"totalTrials":226,"cells":227},"Clonidine",2,{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":262},{"trials":229,"activeCount":100},[],{"trials":231,"activeCount":100},[],{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":129,"soonestReadout":242},[238,251],{"nctId":239,"briefTitle":240,"status":203,"phases":241,"primaryCompletion":242,"completion":242,"start":84,"enrollment":243,"conditions":244,"interventions":250},"NCT07567495","Adding Dexmedetomidine or Clonidine to Spinal Anesthesia for Cesarean Delivery",[91],"2028-05",150,[245,246,247,248,225,249],"Cesarean Delivery","Cesarean Delivery; Neuraxial Opioids","Spinal Anesthesia for Cesarean Section","Dexmedetomidine","Postoperative Analgesia",[225,248],{"nctId":252,"briefTitle":253,"status":119,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT01846221","Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain",[91],"2017-01-20","2014-07-15",101,[259],"Labor Pain",[225,261],"Fentanyl",{"trials":263,"activeCount":100},[],{"intervention":248,"totalTrials":129,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":100},[],{"trials":269,"activeCount":100},[],{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":129,"soonestReadout":242},[276],{"nctId":239,"briefTitle":240,"status":203,"phases":277,"primaryCompletion":242,"completion":242,"start":84,"enrollment":243,"conditions":278,"interventions":279},[91],[245,246,247,248,225,249],[225,248],{"trials":281,"activeCount":100},[],{"intervention":283,"totalTrials":129,"cells":284},"Naltrexone-Bupropion Combination",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":304},{"trials":286,"activeCount":100},[],{"trials":288,"activeCount":100},[],{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":129,"soonestReadout":299},[295],{"nctId":296,"briefTitle":297,"status":108,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":303},"NCT05919797","Weight Loss Study: Genetics and Response to Naltrexone\u002FBupropion",[91],"2027-06-30","2023-06-08",120,[15],[283],{"trials":305,"activeCount":100},[],{"intervention":307,"totalTrials":129,"cells":308},"Tirzepatide",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":330},{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":129,"soonestReadout":323},[319],{"nctId":320,"briefTitle":321,"status":203,"phases":322,"primaryCompletion":323,"completion":324,"start":84,"enrollment":325,"conditions":326,"interventions":329},"NCT07554638","Incretin Therapies in Obesity-related HFpEF",[91],"2029-04","2030-04",50,[327,328,15],"Heart Failure, Diastolic","Heart Failure With Preserved Ejection Fraction",[307],{"trials":331,"activeCount":100},[],{"intervention":333,"totalTrials":129,"cells":334},"growth hormone and lirglutide",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":358},{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":129,"soonestReadout":349},[345],{"nctId":346,"briefTitle":347,"status":108,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":355},"NCT05681299","Effects of GH and Lirglutide on AgRP",[91],"2028-04-30","2023-05-01",40,[353,354],"Healthy","Growth Hormone Deficiency",[333,356,357],"growth hormone","liraglutide",{"trials":359,"activeCount":100},[],{"intervention":357,"totalTrials":129,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":370,"NA":376},{"trials":363,"activeCount":100},[],{"trials":365,"activeCount":100},[],{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":129,"soonestReadout":349},[372],{"nctId":346,"briefTitle":347,"status":108,"phases":373,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":374,"interventions":375},[91],[353,354],[333,356,357],{"trials":377,"activeCount":100},[],{"intervention":379,"totalTrials":129,"cells":380},"Gadopiclenol",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":401},{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":129,"soonestReadout":395},[391],{"nctId":392,"briefTitle":393,"status":108,"phases":394,"primaryCompletion":395,"completion":396,"start":397,"enrollment":243,"conditions":398,"interventions":400},"NCT06226129","Gadopiclenol in Contrast Enhanced MRI of the Prostate",[91],"2027-02-01","2028-02-01","2024-02-14",[399],"Prostate Cancer",[379],{"trials":402,"activeCount":100},[],{"intervention":404,"totalTrials":186,"cells":405},"Growth Hormone",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":421,"PHASE4":423,"NA":429},{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":100},[],{"trials":411,"activeCount":100},[412],{"nctId":413,"briefTitle":414,"status":415,"phases":416,"start":417,"enrollment":100,"conditions":418,"interventions":420},"NCT01647412","Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease","WITHDRAWN",[89],"2012-03",[419],"Crohn's Disease",[404],{"trials":422,"activeCount":100},[],{"trials":424,"activeCount":129,"soonestReadout":349},[425],{"nctId":346,"briefTitle":347,"status":108,"phases":426,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":427,"interventions":428},[91],[353,354],[333,356,357],{"trials":430,"activeCount":100},[431,440],{"nctId":432,"briefTitle":433,"status":119,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":27,"conditions":438,"interventions":439},"NCT03500913","Adipose Tissue and Serum Inflammation in GH Deficiency",[],"2020-02-12","2020-02-20","2019-05-19",[354],[404],{"nctId":441,"briefTitle":442,"status":119,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":448},"NCT03225755","Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy",[],"2025-04-30","2017-08-01",7,[354],[449],"Growth hormone",{"intervention":451,"totalTrials":226,"cells":452},"Tranexamic Acid",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":472,"NA":485},{"trials":454,"activeCount":100},[],{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":129,"soonestReadout":465},[461],{"nctId":462,"briefTitle":463,"status":108,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":471},"NCT02314988","Tranexamic Acid to Reduce Blood Loss in Spine Surgery",[89,90],"2027-07","2020-06-15",252,[469,470],"Spinal Injuries","Spinal Deformity",[451],{"trials":473,"activeCount":100},[474],{"nctId":475,"briefTitle":476,"status":119,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":484},"NCT02584725","Tranexamic Acid Dosing for Total Joint Arthroplasty",[91],"2015-06","2014-12",84,[482,483],"Arthropathy of Hip","Arthropathy of Knee",[451],{"trials":486,"activeCount":100},[],{"intervention":158,"totalTrials":226,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":505,"NA":507},{"trials":490,"activeCount":100},[],{"trials":492,"activeCount":100},[],{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":129,"soonestReadout":205},[497,501],{"nctId":201,"briefTitle":202,"status":203,"phases":498,"primaryCompletion":205,"completion":205,"start":84,"enrollment":206,"conditions":499,"interventions":500},[90],[208,32,169,209,18,210],[146,158],{"nctId":148,"briefTitle":149,"status":150,"phases":502,"primaryCompletion":152,"completion":153,"start":154,"enrollment":155,"conditions":503,"interventions":504},[90],[18],[158,95],{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":100},[],{"intervention":510,"totalTrials":129,"cells":511},"Dietary supplements - Nicotinamide and Pyruvate",{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":531,"NA":533},{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":129,"soonestReadout":84},[520],{"nctId":521,"briefTitle":522,"status":523,"phases":524,"primaryCompletion":84,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},"NCT05695027","Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study","ACTIVE_NOT_RECRUITING",[89,90],"2028-01","2023-03-14",250,[529],"Primary Open Angle Glaucoma",[510],{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":100},[],{"intervention":536,"totalTrials":129,"cells":537},"Letermovir",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":559,"NA":561},{"trials":539,"activeCount":100},[],{"trials":541,"activeCount":100},[],{"trials":543,"activeCount":100},[],{"trials":545,"activeCount":129,"soonestReadout":550},[546],{"nctId":547,"briefTitle":548,"status":108,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":243,"conditions":553,"interventions":557},"NCT07079735","Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant",[89,90],"2028-01-17","2029-01-17","2025-09-12",[554,555,556],"CMV Viremia","Heart Transplant Infection","Heart Transplant Failure and Rejection",[536,558],"Valganciclovir",{"trials":560,"activeCount":100},[],{"trials":562,"activeCount":100},[],{"intervention":558,"totalTrials":129,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":577,"NA":579},{"trials":566,"activeCount":100},[],{"trials":568,"activeCount":100},[],{"trials":570,"activeCount":100},[],{"trials":572,"activeCount":129,"soonestReadout":550},[573],{"nctId":547,"briefTitle":548,"status":108,"phases":574,"primaryCompletion":550,"completion":551,"start":552,"enrollment":243,"conditions":575,"interventions":576},[89,90],[554,555,556],[536,558],{"trials":578,"activeCount":100},[],{"trials":580,"activeCount":100},[],{"intervention":80,"totalTrials":129,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":599,"NA":601},{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":100},[],{"trials":590,"activeCount":129,"soonestReadout":79},[591],{"nctId":77,"briefTitle":78,"status":523,"phases":592,"primaryCompletion":79,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":598},[89,90],"2027-04-30","2021-03-22",326,[597],"Mild Cognitive Impairment",[80],{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[],{"intervention":604,"totalTrials":129,"cells":605},"Ketamine hydrochloride",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":629,"NA":631},{"trials":607,"activeCount":100},[],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":129,"soonestReadout":618},[614],{"nctId":615,"briefTitle":616,"status":203,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":627},"NCT06835504","Morphine or Ketamine for Analgesia",[90],"2029-04-30","2029-10-31","2026-05-01",1010,[623,624,625,626],"Abdominal Pain","Isolated Extremity Fracture","Pain","Pediatrics",[604,628],"Morphine sulphate",{"trials":630,"activeCount":100},[],{"trials":632,"activeCount":100},[],{"intervention":628,"totalTrials":129,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":636,"activeCount":100},[],{"trials":638,"activeCount":100},[],{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":129,"soonestReadout":618},[643],{"nctId":615,"briefTitle":616,"status":203,"phases":644,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":645,"interventions":646},[90],[623,624,625,626],[604,628],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[],{"intervention":652,"totalTrials":129,"cells":653},"Ferric carboxymaltose IV",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":679,"NA":681},{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":129,"soonestReadout":666},[662],{"nctId":663,"briefTitle":664,"status":108,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":301,"conditions":669,"interventions":677},"NCT07217873","IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study",[89,90],"2027-08-31","2027-10-31","2025-11-21",[670,671,672,673,674,675,676],"Scoliosis Correction","Iron Deficiency","Transfusion Blood","Surgery Complications","Spinal Fusion","Scoliosis Idiopathic Adolescent","Scoliosis Neuromuscular",[652,678],"Normal Saline",{"trials":680,"activeCount":100},[],{"trials":682,"activeCount":100},[],{"intervention":678,"totalTrials":129,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":697,"NA":699},{"trials":686,"activeCount":100},[],{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":129,"soonestReadout":666},[693],{"nctId":663,"briefTitle":664,"status":108,"phases":694,"primaryCompletion":666,"completion":667,"start":668,"enrollment":301,"conditions":695,"interventions":696},[89,90],[670,671,672,673,674,675,676],[652,678],{"trials":698,"activeCount":100},[],{"trials":700,"activeCount":100},[],{"intervention":45,"totalTrials":129,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":719,"NA":721},{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[],{"trials":708,"activeCount":100},[],{"trials":710,"activeCount":129,"soonestReadout":40},[711],{"nctId":43,"briefTitle":44,"status":523,"phases":712,"primaryCompletion":40,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":718},[89,90],"2023-12","2019-02-12",129,[717],"Prostatic Neoplasms",[45],{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":100},[],{"intervention":724,"totalTrials":96,"cells":725},"Cisplatin",{"EARLY_PHASE1":726,"PHASE1":728,"PHASE2":743,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":100},[730],{"nctId":731,"briefTitle":732,"status":119,"phases":733,"primaryCompletion":734,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":740},"NCT00998036","Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors",[88],"2012-06","2012-10","2009-09",9,[739],"Triple Negative Breast Cancer",[741,724,742],"Temsirolimus","Erlotinib",{"trials":744,"activeCount":226,"soonestReadout":110},[745,755,765,776,790],{"nctId":746,"briefTitle":747,"status":150,"phases":748,"primaryCompletion":749,"completion":749,"start":417,"enrollment":186,"conditions":750,"interventions":753},"NCT01659554","A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers",[89],"2014-04",[751,752],"Recurrent Ovarian Cancer","Fallopian Tube Cancer",[724,754],"Doxorubicin",{"nctId":756,"briefTitle":757,"status":150,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":737,"conditions":761,"interventions":763},"NCT00859495","Trimodal Lung-Sparing Treatment of Pleural Mesothelioma",[89],"2012-02","2008-02",[762],"Pleural Mesothelioma",[754,724,764],"Pemetrexed",{"nctId":766,"briefTitle":767,"status":523,"phases":768,"primaryCompletion":110,"completion":110,"start":769,"enrollment":770,"conditions":771,"interventions":774},"NCT03127774","Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma",[89],"2017-09-22",30,[772,773],"Adrenocortical Carcinoma","Peritoneal Carcinomatosis",[724,775],"Sodium thiosulfate",{"nctId":777,"briefTitle":778,"status":108,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":783,"interventions":786},"NCT06571708","Gemcitabine\u002FCisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)",[89],"2028-12","2025-08-14",36,[784,785],"Bladder Cancer","Muscle-Invasive Bladder Carcinoma",[787,724,788,789],"Gemcitabine","Cemiplimab","Fianlimab",{"nctId":791,"briefTitle":792,"status":150,"phases":793,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":799},"NCT00998166","A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy",[89],"2011-10","2009-06",12,[798],"Non-Small Cell Lung Cancer",[764,724,800],"Bevacizumab",{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":100},[],{"intervention":788,"totalTrials":226,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":226,"soonestReadout":525},[815,825],{"nctId":816,"briefTitle":817,"status":108,"phases":818,"primaryCompletion":525,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":824},"NCT07433673","Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)",[89],"2029-01","2026-08",20,[823],"Colon and Rectal Cancer",[788],{"nctId":777,"briefTitle":778,"status":108,"phases":826,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":827,"interventions":828},[89],[784,785],[787,724,788,789],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[],{"intervention":50,"totalTrials":836,"cells":837},8,{"EARLY_PHASE1":838,"PHASE1":855,"PHASE2":884,"PHASE3":939,"PHASE4":956,"NA":958},{"trials":839,"activeCount":100},[840],{"nctId":841,"briefTitle":842,"status":150,"phases":843,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT00881556","Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)",[87],"2015-09","2009-08-20",3,[848],"Epidermolysis Bullosa",[850,851,50,852,853,854],"Palifermin","Fludarabine","Lorazepam","Alemtuzumab","Tacrolimus",{"trials":856,"activeCount":100},[857,874],{"nctId":858,"briefTitle":859,"status":119,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":869},"NCT01020539","Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia",[88],"2011-07-20","2020-12","2002-09-11",18,[866,867,868],"Acute Myelogenous Leukemia","Myelodysplastic Syndrome","Juvenile Myelomonocytic Leukemia",[851,50,870,871,872,873],"GVHD Prophylaxis","Gemtuzumab Ozogamicin","Anti-Thymocyte Globulin","Isotretinoin",{"nctId":875,"briefTitle":876,"status":150,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":33,"conditions":880,"interventions":882},"NCT00670410","Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma",[88],"2010-12","2003-11",[881],"Neuroblastoma",[50,883,851],"Thymoglobulin",{"trials":885,"activeCount":129,"soonestReadout":49},[886,903,914,931],{"nctId":887,"briefTitle":888,"status":415,"phases":889,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":893,"interventions":895},"NCT00002761","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia",[88,89],"2007-02","2007-10","1996-02",[894],"Leukemia",[896,897,898,899,900,901,902],"filgrastim","recombinant interferon gamma","busulfan","cyclophosphamide","cyclosporine","cytarabine","idarubicin",{"nctId":904,"briefTitle":905,"status":119,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":770,"conditions":910,"interventions":913},"NCT00802113","Autologous and Allogeneic Transplant for Relapsed Lymphoma",[88,89],"2014-10","2014-10-22","2003-06",[911,912],"Non-Hodgkin's Lymphoma","Hodgkins Disease",[851,50,872],{"nctId":915,"briefTitle":916,"status":150,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":920,"interventions":924},"NCT00801931","Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders",[88,89],"2009-05-05","2007-09-06",[894,921,881,922,923],"Lymphoma","Immunodeficiencies","Anemia",[853,925,50,926,851,927,928,929,930],"Melphalan","Phenytoin","Cyclophosphamide","Horse Antithymocyte Globulin","Rabbit Antithymocyte Globulin","Thiotepa",{"nctId":47,"briefTitle":48,"status":523,"phases":932,"primaryCompletion":49,"completion":49,"start":933,"enrollment":934,"conditions":935,"interventions":938},[89],"2004-09",53,[936,937],"Sickle Cell Disease","Beta Thalassemia",[50,851,853],{"trials":940,"activeCount":100},[941],{"nctId":942,"briefTitle":943,"status":119,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":953},"NCT01019876","Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases",[89,90],"2021-09-07","2002-09",38,[949,950,951,952],"Bone Marrow Failure","Osteopetrosis","Fanconi Anemia","Severe Combined Immunodeficiency",[851,927,50,853,954,955],"Rabbit Anti-thymocyte Globulin","Horse Anti-thymocyte Globulin",{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"intervention":851,"totalTrials":446,"cells":961},{"EARLY_PHASE1":962,"PHASE1":968,"PHASE2":978,"PHASE3":992,"PHASE4":998,"NA":1000},{"trials":963,"activeCount":100},[964],{"nctId":841,"briefTitle":842,"status":150,"phases":965,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":966,"interventions":967},[87],[848],[850,851,50,852,853,854],{"trials":969,"activeCount":100},[970,974],{"nctId":858,"briefTitle":859,"status":119,"phases":971,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":972,"interventions":973},[88],[866,867,868],[851,50,870,871,872,873],{"nctId":875,"briefTitle":876,"status":150,"phases":975,"primaryCompletion":878,"completion":878,"start":879,"enrollment":33,"conditions":976,"interventions":977},[88],[881],[50,883,851],{"trials":979,"activeCount":129,"soonestReadout":49},[980,984,988],{"nctId":904,"briefTitle":905,"status":119,"phases":981,"primaryCompletion":907,"completion":908,"start":909,"enrollment":770,"conditions":982,"interventions":983},[88,89],[911,912],[851,50,872],{"nctId":915,"briefTitle":916,"status":150,"phases":985,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":986,"interventions":987},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"nctId":47,"briefTitle":48,"status":523,"phases":989,"primaryCompletion":49,"completion":49,"start":933,"enrollment":934,"conditions":990,"interventions":991},[89],[936,937],[50,851,853],{"trials":993,"activeCount":100},[994],{"nctId":942,"briefTitle":943,"status":119,"phases":995,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":996,"interventions":997},[89,90],[949,950,951,952],[851,927,50,853,954,955],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"intervention":853,"totalTrials":186,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1010,"PHASE2":1012,"PHASE3":1022,"PHASE4":1028,"NA":1030},{"trials":1005,"activeCount":100},[1006],{"nctId":841,"briefTitle":842,"status":150,"phases":1007,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":1008,"interventions":1009},[87],[848],[850,851,50,852,853,854],{"trials":1011,"activeCount":100},[],{"trials":1013,"activeCount":129,"soonestReadout":49},[1014,1018],{"nctId":915,"briefTitle":916,"status":150,"phases":1015,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":1016,"interventions":1017},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"nctId":47,"briefTitle":48,"status":523,"phases":1019,"primaryCompletion":49,"completion":49,"start":933,"enrollment":934,"conditions":1020,"interventions":1021},[89],[936,937],[50,851,853],{"trials":1023,"activeCount":100},[1024],{"nctId":942,"briefTitle":943,"status":119,"phases":1025,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":1026,"interventions":1027},[89,90],[949,950,951,952],[851,927,50,853,954,955],{"trials":1029,"activeCount":100},[],{"trials":1031,"activeCount":100},[],{"intervention":787,"totalTrials":186,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[],{"trials":1039,"activeCount":129,"soonestReadout":780},[1040,1051,1055,1066],{"nctId":1041,"briefTitle":1042,"status":119,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":796,"conditions":1047,"interventions":1049},"NCT00860015","Alimta Plus Gemcitabine for Advanced Sarcoma",[89],"2009-08","2012-04","2005-08",[1048],"Sarcoma, Soft Tissue",[1050,787],"Alimta",{"nctId":777,"briefTitle":778,"status":108,"phases":1052,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1053,"interventions":1054},[89],[784,785],[787,724,788,789],{"nctId":1056,"briefTitle":1057,"status":119,"phases":1058,"primaryCompletion":907,"completion":907,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1063},"NCT00882310","A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer",[89],"2006-09",37,[1062],"Pancreatic Cancer",[787,1064,1065],"Docetaxel","Capecitabine",{"nctId":1067,"briefTitle":1068,"status":119,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT00859469","Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma",[89],"2009-03","2013-03","2004-04",29,[1075],"Mesothelioma",[1077,787],"Oxaliplatin",{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[],{"intervention":1085,"totalTrials":226,"cells":1086},"Tocilizumab",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1102,"PHASE3":1111,"PHASE4":1113,"NA":1115},{"trials":1088,"activeCount":100},[],{"trials":1090,"activeCount":100},[1091],{"nctId":1092,"briefTitle":1093,"status":150,"phases":1094,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":129,"conditions":1097,"interventions":1100},"NCT04070781","Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease",[88],"2021-12-13","2020-01-20",[1098,1099],"Steroid Refractory GVHD","Graft Vs Host Disease",[1101,1085],"Itacitinib",{"trials":1103,"activeCount":129,"soonestReadout":54},[1104],{"nctId":52,"briefTitle":53,"status":523,"phases":1105,"primaryCompletion":54,"completion":110,"start":1106,"enrollment":836,"conditions":1107,"interventions":1110},[89],"2020-09-25",[1108,1109],"Immune-related Adverse Events","Advanced Solid Tumor",[55,1085],{"trials":1112,"activeCount":100},[],{"trials":1114,"activeCount":100},[],{"trials":1116,"activeCount":100},[],{"intervention":1118,"totalTrials":226,"cells":1119},"11C-ER176",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":129,"soonestReadout":110},[1126,1136],{"nctId":1127,"briefTitle":1128,"status":523,"phases":1129,"primaryCompletion":110,"completion":110,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT04840979","Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease",[89],"2021-05-11",107,[1133],"Alzheimer Disease",[1118,1135],"18F-florbetaben",{"nctId":1137,"briefTitle":1138,"status":119,"phases":1139,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":737,"conditions":1142,"interventions":1143},"NCT03744312","Imaging Inflammation in Alzheimer's Disease With 11C-ER176",[88,89],"2022-07-20","2018-09-10",[1133],[1118,1144],"Florbetaben",{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[],{"intervention":85,"totalTrials":129,"cells":1152},{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":129,"soonestReadout":84},[1159],{"nctId":82,"briefTitle":83,"status":1160,"phases":1161,"primaryCompletion":84,"completion":84,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1167},"ENROLLING_BY_INVITATION",[89],"2018-07-24",600,[1165,1166],"Diabetes Mellitus, Type 2","Pre-diabetes",[85],{"trials":1169,"activeCount":100},[],{"trials":1171,"activeCount":100},[],{"trials":1173,"activeCount":100},[],{"intervention":55,"totalTrials":129,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":100},[],{"trials":1179,"activeCount":100},[],{"trials":1181,"activeCount":129,"soonestReadout":54},[1182],{"nctId":52,"briefTitle":53,"status":523,"phases":1183,"primaryCompletion":54,"completion":110,"start":1106,"enrollment":836,"conditions":1184,"interventions":1185},[89],[1108,1109],[55,1085],{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"intervention":1193,"totalTrials":129,"cells":1194},"UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":129,"soonestReadout":1205},[1201],{"nctId":1202,"briefTitle":1203,"status":108,"phases":1204,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1212},"NCT05680558","Photopheresis in Early-stage Mycosis Fungoides",[89],"2027-03","2028-07","2021-05-08",74,[1210,1211],"Cutaneous T Cell Lymphoma","Mycosis Fungoides",[1193],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[],{"intervention":60,"totalTrials":129,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":129,"soonestReadout":59},[1227],{"nctId":57,"briefTitle":58,"status":523,"phases":1228,"primaryCompletion":59,"completion":1229,"start":1230,"enrollment":325,"conditions":1231,"interventions":1233},[89],"2026-09","2023-06-01",[1232],"Perimenopausal",[60],{"trials":1235,"activeCount":100},[],{"trials":1237,"activeCount":100},[],{"trials":1239,"activeCount":100},[],{"intervention":775,"totalTrials":129,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":129,"soonestReadout":110},[1248],{"nctId":766,"briefTitle":767,"status":523,"phases":1249,"primaryCompletion":110,"completion":110,"start":769,"enrollment":770,"conditions":1250,"interventions":1251},[89],[772,773],[724,775],{"trials":1253,"activeCount":100},[],{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[],{"intervention":789,"totalTrials":129,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":129,"soonestReadout":780},[1266],{"nctId":777,"briefTitle":778,"status":108,"phases":1267,"primaryCompletion":780,"completion":780,"start":781,"enrollment":782,"conditions":1268,"interventions":1269},[89],[784,785],[787,724,788,789],{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"intervention":1277,"totalTrials":129,"cells":1278},"Axitinib",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":129,"soonestReadout":1289},[1285],{"nctId":1286,"briefTitle":1287,"status":523,"phases":1288,"primaryCompletion":1289,"completion":1290,"start":1291,"enrollment":96,"conditions":1292,"interventions":1295},"NCT03839498","Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma\u002FParaganglioma",[89],"2027-01","2027-02","2019-01-22",[1293,1294],"Pheochromocytoma","Paraganglioma",[1277],{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"intervention":1135,"totalTrials":129,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":129,"soonestReadout":110},[1310],{"nctId":1127,"briefTitle":1128,"status":523,"phases":1311,"primaryCompletion":110,"completion":110,"start":1130,"enrollment":1131,"conditions":1312,"interventions":1313},[89],[1133],[1118,1135],{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":100},[],{"trials":1319,"activeCount":100},[],{"intervention":1321,"totalTrials":129,"cells":1322},"Romosozumab Prefilled Syringe [Evenity]",{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":129,"soonestReadout":1205},[1329],{"nctId":1330,"briefTitle":1331,"status":523,"phases":1332,"primaryCompletion":1205,"completion":1333,"start":1334,"enrollment":770,"conditions":1335,"interventions":1337},"NCT04800367","Romosozumab\u002FDenosumab Study for Premenopausal IOP",[89],"2028-03","2021-03-12",[1336],"Premenopausal Idiopathic Osteoporosis",[1321,1338],"Denosumab 60 MG\u002FML Prefilled Syringe [Prolia]",{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[],{"intervention":1338,"totalTrials":129,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":129,"soonestReadout":1205},[1353],{"nctId":1330,"briefTitle":1331,"status":523,"phases":1354,"primaryCompletion":1205,"completion":1333,"start":1334,"enrollment":770,"conditions":1355,"interventions":1356},[89],[1336],[1321,1338],{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[],{"trials":1362,"activeCount":100},[],{"intervention":75,"totalTrials":129,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":129,"soonestReadout":74},[1371],{"nctId":72,"briefTitle":73,"status":108,"phases":1372,"primaryCompletion":74,"completion":84,"start":1373,"enrollment":19,"conditions":1374,"interventions":1376},[89],"2021-06-08",[1375],"Monoclonal Gammopathy",[75],{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[],{"intervention":41,"totalTrials":129,"cells":1384},{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":100},[],{"trials":1390,"activeCount":129,"soonestReadout":40},[1391],{"nctId":38,"briefTitle":39,"status":523,"phases":1392,"primaryCompletion":40,"completion":40,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1397},[89],"2018-12-11",11,[1396],"Metastatic Prostate Cancer",[41],{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[],{"trials":1403,"activeCount":100},[],{"intervention":1405,"totalTrials":129,"cells":1406},"Thymidine",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1424,"PHASE4":1426,"NA":1428},{"trials":1408,"activeCount":100},[],{"trials":1410,"activeCount":100},[],{"trials":1412,"activeCount":129,"soonestReadout":1417},[1413],{"nctId":1414,"briefTitle":1415,"status":523,"phases":1416,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1423},"NCT03639701","Treatment of TK2 Deficiency With Thymidine and Deoxycytidine",[88,89],"2026-12-31","2017-05-16",23,[1421,1422],"Mitochondrial DNA Depletion Syndrome 2 Myopathic Type","Thymidine Kinase 2 Deficiency",[1405],{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"intervention":65,"totalTrials":226,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1433,"activeCount":100},[],{"trials":1435,"activeCount":226,"soonestReadout":64},[1436,1449],{"nctId":1437,"briefTitle":1438,"status":108,"phases":1439,"primaryCompletion":323,"completion":1440,"start":1441,"enrollment":864,"conditions":1442,"interventions":1448},"NCT06926894","R-MVST Cells for Treatment of Viral Infections in Children and Young Adults",[88],"2030-12","2025-04-20",[1443,1444,1445,1446,1447],"Epstein-Barr Virus","Cytomegalovirus Infections","Adenovirus","BK Virus Infection","Immune Deficiency",[65],{"nctId":62,"briefTitle":63,"status":108,"phases":1450,"primaryCompletion":64,"completion":110,"start":1451,"enrollment":782,"conditions":1452,"interventions":1454},[88],"2022-05-03",[1453,1444,1445,1446],"Epstein-Barr Virus Infections",[65],{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[],{"intervention":70,"totalTrials":226,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1496},{"trials":1466,"activeCount":100},[],{"trials":1468,"activeCount":129,"soonestReadout":69},[1469],{"nctId":67,"briefTitle":68,"status":523,"phases":1470,"primaryCompletion":69,"completion":1471,"start":1472,"enrollment":1473,"conditions":1474,"interventions":1476},[88],"2027-06-20","2025-06-20",116,[1475],"Osteoarthritis, Knee",[70],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":100},[1483],{"nctId":1484,"briefTitle":1485,"status":119,"phases":1486,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":1490,"interventions":1492},"NCT02152345","Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients",[91],"2016-12-31","2014-06",57,[1491],"Implant or Graft; Rejection",[1493,854,1494,1495,70],"Belatacept","Mycophenolate","rATG",{"trials":1497,"activeCount":100},[],{"intervention":1499,"totalTrials":846,"cells":1500},"Insulin human",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1543,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":129,"soonestReadout":1537},[1505,1523,1533],{"nctId":1506,"briefTitle":1507,"status":415,"phases":1508,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":100,"conditions":1512,"interventions":1517},"NCT06126354","Dexamethasone\u002FPancreatic Clamp P&F",[88],"2025-11-30","2026-03-31","2024-07-01",[1513,1514,1515,1516],"Insulin Resistance","Prediabetic State","Non-Alcoholic Fatty Liver Disease","Overweight and Obesity",[1499,1518,1519,1520,1521,1522],"Octreotide Acetate","Glucagon","Human Growth Hormone","Dexamethasone","20% D-glucose",{"nctId":1524,"briefTitle":1525,"status":119,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":864,"conditions":1529,"interventions":1531},"NCT05724134","Pancreatic Clamp in NAFLD",[88],"2025-09-24","2023-08-29",[1513,1514,1530,1515,15],"Hyperinsulinemia",[1499,1518,1519,1532,1522],"Growth Hormone, Human",{"nctId":1534,"briefTitle":1535,"status":203,"phases":1536,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":782,"conditions":1540,"interventions":1542},"NCT06558422","Human Models of Selective Insulin Resistance: Pancreatic Clamp",[88],"2028-12-31","2029-02-28","2027-01-01",[1513,1530,1541,1515,1514,15],"Metabolic Dysfunction Associated Steatotic Liver Disease",[1499,1518,1519,1532,1522],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[],{"intervention":1518,"totalTrials":846,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1569,"PHASE3":1571,"PHASE4":1573,"NA":1575},{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":129,"soonestReadout":1537},[1557,1561,1565],{"nctId":1506,"briefTitle":1507,"status":415,"phases":1558,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":100,"conditions":1559,"interventions":1560},[88],[1513,1514,1515,1516],[1499,1518,1519,1520,1521,1522],{"nctId":1524,"briefTitle":1525,"status":119,"phases":1562,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":864,"conditions":1563,"interventions":1564},[88],[1513,1514,1530,1515,15],[1499,1518,1519,1532,1522],{"nctId":1534,"briefTitle":1535,"status":203,"phases":1566,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":782,"conditions":1567,"interventions":1568},[88],[1513,1530,1541,1515,1514,15],[1499,1518,1519,1532,1522],{"trials":1570,"activeCount":100},[],{"trials":1572,"activeCount":100},[],{"trials":1574,"activeCount":100},[],{"trials":1576,"activeCount":100},[],{"intervention":1519,"totalTrials":846,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1580,"activeCount":100},[],{"trials":1582,"activeCount":129,"soonestReadout":1537},[1583,1587,1591],{"nctId":1506,"briefTitle":1507,"status":415,"phases":1584,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":100,"conditions":1585,"interventions":1586},[88],[1513,1514,1515,1516],[1499,1518,1519,1520,1521,1522],{"nctId":1524,"briefTitle":1525,"status":119,"phases":1588,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":864,"conditions":1589,"interventions":1590},[88],[1513,1514,1530,1515,15],[1499,1518,1519,1532,1522],{"nctId":1534,"briefTitle":1535,"status":203,"phases":1592,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":782,"conditions":1593,"interventions":1594},[88],[1513,1530,1541,1515,1514,15],[1499,1518,1519,1532,1522],{"trials":1596,"activeCount":100},[],{"trials":1598,"activeCount":100},[],{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[],{"intervention":1522,"totalTrials":846,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1621,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":129,"soonestReadout":1537},[1609,1613,1617],{"nctId":1506,"briefTitle":1507,"status":415,"phases":1610,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":100,"conditions":1611,"interventions":1612},[88],[1513,1514,1515,1516],[1499,1518,1519,1520,1521,1522],{"nctId":1524,"briefTitle":1525,"status":119,"phases":1614,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":864,"conditions":1615,"interventions":1616},[88],[1513,1514,1530,1515,15],[1499,1518,1519,1532,1522],{"nctId":1534,"briefTitle":1535,"status":203,"phases":1618,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":782,"conditions":1619,"interventions":1620},[88],[1513,1530,1541,1515,1514,15],[1499,1518,1519,1532,1522],{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"intervention":1630,"totalTrials":226,"cells":1631},"Atorvastatin 10mg",{"EARLY_PHASE1":1632,"PHASE1":1645,"PHASE2":1656,"PHASE3":1658,"PHASE4":1660,"NA":1662},{"trials":1633,"activeCount":100},[1634],{"nctId":1635,"briefTitle":1636,"status":119,"phases":1637,"primaryCompletion":1638,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1644},"NCT03122639","Endothelial Function in Obstructive Sleep Apnea",[87],"2020-01-30","2021-05-07","2017-09-01",106,[1643],"Obstructive Sleep Apnea of Adult",[1630],{"trials":1646,"activeCount":129,"soonestReadout":1651},[1647],{"nctId":1648,"briefTitle":1649,"status":108,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1655},"NCT05289063","Vascular Endothelial Dysfunction in Sleep Apnea",[88],"2027-02-28","2022-10-03",110,[1643],[1630],{"trials":1657,"activeCount":100},[],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[],{"trials":1663,"activeCount":100},[],{"intervention":1665,"totalTrials":226,"cells":1666},"Diazoxide oral suspension, 2 mg per kg per dose",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1692,"PHASE3":1694,"PHASE4":1696,"NA":1698},{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":129,"soonestReadout":1685},[1671,1681],{"nctId":1672,"briefTitle":1673,"status":119,"phases":1674,"primaryCompletion":1675,"completion":1675,"start":1676,"enrollment":24,"conditions":1677,"interventions":1678},"NCT05729282","Glycemic Effect of Diazoxide in NAFLD",[88],"2025-09-10","2023-08-01",[1530,1513,1515,1514],[1679,1665,1680],"Diazoxide oral suspension, 1 mg per kg per dose","Deuterated water",{"nctId":1682,"briefTitle":1683,"status":108,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1689},"NCT07403604","Effect of Insulin Lowering on Lipogenesis",[88],"2029-09-30","2026-05-31",25,[1530,1513,1515,1514,15],[1690,1691],"Diazoxide Oral Suspension, 2 mg per kg per dose","Deuterated water (2H2O\u002FD2O), 70%",{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"intervention":1532,"totalTrials":226,"cells":1701},{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1703,"activeCount":100},[],{"trials":1705,"activeCount":129,"soonestReadout":1537},[1706,1710],{"nctId":1524,"briefTitle":1525,"status":119,"phases":1707,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":864,"conditions":1708,"interventions":1709},[88],[1513,1514,1530,1515,15],[1499,1518,1519,1532,1522],{"nctId":1534,"briefTitle":1535,"status":203,"phases":1711,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":782,"conditions":1712,"interventions":1713},[88],[1513,1530,1541,1515,1514,15],[1499,1518,1519,1532,1522],{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"intervention":1723,"totalTrials":129,"cells":1724},"Etoposide; Oral, 50 Mg",{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":129,"soonestReadout":110},[1729],{"nctId":1730,"briefTitle":1731,"status":108,"phases":1732,"primaryCompletion":110,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1739},"NCT05762419","FUS Etoposide for DMG",[88],"2027-12","2023-06-05",10,[1737,1738],"Diffuse Intrinsic Pontine Glioma","Diffuse Midline Glioma, H3 K27M-Mutant",[1723],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"intervention":1749,"totalTrials":129,"cells":1750},"Imatimib Mesylate",{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1764,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1752,"activeCount":100},[],{"trials":1754,"activeCount":129,"soonestReadout":110},[1755],{"nctId":1756,"briefTitle":1757,"status":108,"phases":1758,"primaryCompletion":110,"completion":1205,"start":1759,"enrollment":821,"conditions":1760,"interventions":1763},"NCT06889168","Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)",[88],"2025-10-20",[1761,1762],"Lymphangioleiomyomatosis (LAM)","Lymphangioleiomyomatosis",[1749],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[],{"intervention":1773,"totalTrials":129,"cells":1774},"Pegcetacoplan Injection [Empaveli]",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1790,"PHASE3":1792,"PHASE4":1794,"NA":1796},{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":129,"soonestReadout":1783},[1779],{"nctId":1780,"briefTitle":1781,"status":203,"phases":1782,"primaryCompletion":1783,"completion":1784,"start":1785,"enrollment":821,"conditions":1786,"interventions":1789},"NCT07495722","Safely Quenching Complement in Stroke Survivors",[88],"2027-04","2027-08","2026-10",[1787,1788],"Acute Ischemic Stroke","Cerebral Infarction",[1773],{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":100},[],{"trials":1795,"activeCount":100},[],{"trials":1797,"activeCount":100},[],{"intervention":1799,"totalTrials":129,"cells":1800},"Insulin regular, 2.0-3.2 mU\u002Fm2\u002Fmin",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":129,"soonestReadout":820},[1805],{"nctId":1806,"briefTitle":1807,"status":108,"phases":1808,"primaryCompletion":820,"completion":820,"start":1809,"enrollment":33,"conditions":1810,"interventions":1811},"NCT06592261","Graded Insulin Suppression Test P&F",[88],"2024-09-16",[1513,1530,15,353],[1799,1812,1813,1814,1815],"Insulin regular, 32 mU\u002Fm2\u002Fmin","Octreotide Acetate, 6-45 ng\u002Fkg\u002Fmin","Dextrose 20 % in Water","Glucagon, 0-0.5 ng\u002Fkg\u002Fmin",{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[],{"intervention":1812,"totalTrials":129,"cells":1825},{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":129,"soonestReadout":820},[1830],{"nctId":1806,"briefTitle":1807,"status":108,"phases":1831,"primaryCompletion":820,"completion":820,"start":1809,"enrollment":33,"conditions":1832,"interventions":1833},[88],[1513,1530,15,353],[1799,1812,1813,1814,1815],{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[],{"trials":1839,"activeCount":100},[],{"trials":1841,"activeCount":100},[],{"intervention":1813,"totalTrials":129,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1852,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":129,"soonestReadout":820},[1848],{"nctId":1806,"briefTitle":1807,"status":108,"phases":1849,"primaryCompletion":820,"completion":820,"start":1809,"enrollment":33,"conditions":1850,"interventions":1851},[88],[1513,1530,15,353],[1799,1812,1813,1814,1815],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[],{"trials":1857,"activeCount":100},[],{"trials":1859,"activeCount":100},[],{"intervention":1814,"totalTrials":129,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1870,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":129,"soonestReadout":820},[1866],{"nctId":1806,"briefTitle":1807,"status":108,"phases":1867,"primaryCompletion":820,"completion":820,"start":1809,"enrollment":33,"conditions":1868,"interventions":1869},[88],[1513,1530,15,353],[1799,1812,1813,1814,1815],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[],{"intervention":1815,"totalTrials":129,"cells":1879},{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1888,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":129,"soonestReadout":820},[1884],{"nctId":1806,"briefTitle":1807,"status":108,"phases":1885,"primaryCompletion":820,"completion":820,"start":1809,"enrollment":33,"conditions":1886,"interventions":1887},[88],[1513,1530,15,353],[1799,1812,1813,1814,1815],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[],{"intervention":1897,"totalTrials":129,"cells":1898},"Diazoxide, 3 mg\u002Fkg per dose",{"EARLY_PHASE1":1899,"PHASE1":1901,"PHASE2":1911,"PHASE3":1913,"PHASE4":1915,"NA":1917},{"trials":1900,"activeCount":100},[],{"trials":1902,"activeCount":129,"soonestReadout":1907},[1903],{"nctId":1904,"briefTitle":1905,"status":108,"phases":1906,"primaryCompletion":1907,"completion":525,"start":1908,"enrollment":1735,"conditions":1909,"interventions":1910},"NCT06606327","Diazoxide Suppression Test P&F Study",[88],"2027-11","2024-10-23",[1513,1530,15],[1897],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[],{"trials":1916,"activeCount":100},[],{"trials":1918,"activeCount":100},[],{"intervention":1920,"totalTrials":129,"cells":1921},"Lumason",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1936,"PHASE3":1938,"PHASE4":1940,"NA":1942},{"trials":1923,"activeCount":100},[],{"trials":1925,"activeCount":129,"soonestReadout":1206},[1926],{"nctId":1927,"briefTitle":1928,"status":203,"phases":1929,"primaryCompletion":1206,"completion":780,"start":1784,"enrollment":96,"conditions":1930,"interventions":1932},"NCT06600880","Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau",[88],[1931],"Alzheimer Disease, Early Onset",[1920,1933,1934,1935],"Amyvid","MK-6240","Dotarem",{"trials":1937,"activeCount":100},[],{"trials":1939,"activeCount":100},[],{"trials":1941,"activeCount":100},[],{"trials":1943,"activeCount":100},[],{"intervention":1933,"totalTrials":129,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1954,"PHASE3":1956,"PHASE4":1958,"NA":1960},{"trials":1947,"activeCount":100},[],{"trials":1949,"activeCount":129,"soonestReadout":1206},[1950],{"nctId":1927,"briefTitle":1928,"status":203,"phases":1951,"primaryCompletion":1206,"completion":780,"start":1784,"enrollment":96,"conditions":1952,"interventions":1953},[88],[1931],[1920,1933,1934,1935],{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"intervention":1934,"totalTrials":129,"cells":1963},{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1972,"PHASE3":1974,"PHASE4":1976,"NA":1978},{"trials":1965,"activeCount":100},[],{"trials":1967,"activeCount":129,"soonestReadout":1206},[1968],{"nctId":1927,"briefTitle":1928,"status":203,"phases":1969,"primaryCompletion":1206,"completion":780,"start":1784,"enrollment":96,"conditions":1970,"interventions":1971},[88],[1931],[1920,1933,1934,1935],{"trials":1973,"activeCount":100},[],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"trials":1979,"activeCount":100},[],{"intervention":1935,"totalTrials":129,"cells":1981},{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1990,"PHASE3":1992,"PHASE4":1994,"NA":1996},{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":129,"soonestReadout":1206},[1986],{"nctId":1927,"briefTitle":1928,"status":203,"phases":1987,"primaryCompletion":1206,"completion":780,"start":1784,"enrollment":96,"conditions":1988,"interventions":1989},[88],[1931],[1920,1933,1934,1935],{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[],{"trials":1997,"activeCount":100},[],{"intervention":1999,"totalTrials":129,"cells":2000},"Cell Therapy",{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2013,"PHASE3":2015,"PHASE4":2017,"NA":2019},{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":129,"soonestReadout":780},[2005],{"nctId":2006,"briefTitle":2007,"status":108,"phases":2008,"primaryCompletion":780,"completion":780,"start":2009,"enrollment":96,"conditions":2010,"interventions":2012},"NCT04804891","Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation",[88],"2021-10-22",[2011],"Intestinal Transplantation",[1999],{"trials":2014,"activeCount":100},[],{"trials":2016,"activeCount":100},[],{"trials":2018,"activeCount":100},[],{"trials":2020,"activeCount":100},[],{"intervention":2022,"totalTrials":129,"cells":2023},"131I-apamistmab",{"EARLY_PHASE1":2024,"PHASE1":2026,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2047},{"trials":2025,"activeCount":100},[],{"trials":2027,"activeCount":129,"soonestReadout":2032},[2028],{"nctId":2029,"briefTitle":2030,"status":108,"phases":2031,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":24,"conditions":2035,"interventions":2037},"NCT07015684","131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)",[88],"2030-03-12","2032-03-12","2025-04-28",[2036],"Sickling Disorder Due to Hemoglobin S",[2022,2038,2039,2040],"Sirolimus","Campath","Total Body Irradiation",{"trials":2042,"activeCount":100},[],{"trials":2044,"activeCount":100},[],{"trials":2046,"activeCount":100},[],{"trials":2048,"activeCount":100},[],{"intervention":2039,"totalTrials":129,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2059,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":129,"soonestReadout":2032},[2055],{"nctId":2029,"briefTitle":2030,"status":108,"phases":2056,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":24,"conditions":2057,"interventions":2058},[88],[2036],[2022,2038,2039,2040],{"trials":2060,"activeCount":100},[],{"trials":2062,"activeCount":100},[],{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"intervention":2040,"totalTrials":129,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":129,"soonestReadout":2032},[2073],{"nctId":2029,"briefTitle":2030,"status":108,"phases":2074,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":24,"conditions":2075,"interventions":2076},[88],[2036],[2022,2038,2039,2040],{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"intervention":2086,"totalTrials":129,"cells":2087},"Alpelisib 300 mg",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":129,"soonestReadout":1417},[2092],{"nctId":2093,"briefTitle":2094,"status":108,"phases":2095,"primaryCompletion":1417,"completion":1417,"start":2096,"enrollment":2097,"conditions":2098,"interventions":2099},"NCT06354088","Human Models of Selective Insulin Resistance: Alpelisib, Part I",[88],"2024-04-24",32,[1513,1514,1516,1515],[2086,2100,2101],"[1-13C] sodium acetate","[6,6-2H2] D-glucose",{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[],{"intervention":2100,"totalTrials":129,"cells":2111},{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2113,"activeCount":100},[],{"trials":2115,"activeCount":129,"soonestReadout":1417},[2116],{"nctId":2093,"briefTitle":2094,"status":108,"phases":2117,"primaryCompletion":1417,"completion":1417,"start":2096,"enrollment":2097,"conditions":2118,"interventions":2119},[88],[1513,1514,1516,1515],[2086,2100,2101],{"trials":2121,"activeCount":100},[],{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"intervention":2101,"totalTrials":129,"cells":2129},{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2138,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":129,"soonestReadout":1417},[2134],{"nctId":2093,"briefTitle":2094,"status":108,"phases":2135,"primaryCompletion":1417,"completion":1417,"start":2096,"enrollment":2097,"conditions":2136,"interventions":2137},[88],[1513,1514,1516,1515],[2086,2100,2101],{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":100},[],{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[],{"intervention":1691,"totalTrials":129,"cells":2147},{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2149,"activeCount":100},[],{"trials":2151,"activeCount":129,"soonestReadout":1685},[2152],{"nctId":1682,"briefTitle":1683,"status":108,"phases":2153,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":1687,"conditions":2154,"interventions":2155},[88],[1530,1513,1515,1514,15],[1690,1691],{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[],{"trials":2161,"activeCount":100},[],{"trials":2163,"activeCount":100},[],{"intervention":2038,"totalTrials":846,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2174,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2167,"activeCount":100},[],{"trials":2169,"activeCount":129,"soonestReadout":2032},[2170],{"nctId":2029,"briefTitle":2030,"status":108,"phases":2171,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":24,"conditions":2172,"interventions":2173},[88],[2036],[2022,2038,2039,2040],{"trials":2175,"activeCount":100},[2176],{"nctId":2177,"briefTitle":2178,"status":150,"phases":2179,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":129,"conditions":2183,"interventions":2185},"NCT06078696","Siplizumab for Sickle Cell Disease Transplant",[88,89],"2024-12-11","2025-12-11","2023-09-28",[2184],"Anemia, Sickle Cell",[2186,2187,2188,2189,2190],"Siplizumab","Cyclophosphamide 50mg","Mesna","Sirolimus Oral","Rituximab or Biosimilar",{"trials":2192,"activeCount":100},[],{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[2197],{"nctId":2198,"briefTitle":2199,"status":119,"phases":2200,"primaryCompletion":2201,"completion":2201,"start":417,"enrollment":351,"conditions":2202,"interventions":2205},"NCT01649609","Using mTOR Inhibitors in the Prevention of BK Nephropathy",[92],"2016-12",[2203,2204],"BK Viremia","BK Nephropathy",[854,2206,2038],"Mycophenolate acid",{"intervention":2208,"totalTrials":129,"cells":2209},"Disulfiram 250 mg",{"EARLY_PHASE1":2210,"PHASE1":2222,"PHASE2":2224,"PHASE3":2226,"PHASE4":2228,"NA":2230},{"trials":2211,"activeCount":129,"soonestReadout":2216},[2212],{"nctId":2213,"briefTitle":2214,"status":108,"phases":2215,"primaryCompletion":2216,"completion":2216,"start":2217,"enrollment":2218,"conditions":2219,"interventions":2221},"NCT06793488","Anxiety During Abstinence in AUD",[87],"2029-08-30","2025-09-15",60,[2220],"Alcohol Use Disorder",[2208],{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[],{"trials":2231,"activeCount":100},[],{"intervention":2233,"totalTrials":226,"cells":2234},"Blood draw",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":226,"soonestReadout":593},[2247,2259],{"nctId":2248,"briefTitle":2249,"status":108,"phases":2250,"primaryCompletion":349,"completion":349,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2258},"NCT04906863","Genetic Studies of Early-onset Dementia",[],"2016-09-14",1000,[2254,2255,2256,2257],"Dementia, Early Onset","Alzheimer Dementia (AD)","Mild Cognitive Impairment (MCI)","Memory Loss",[2233],{"nctId":2260,"briefTitle":2261,"status":108,"phases":2262,"primaryCompletion":593,"completion":593,"start":2263,"enrollment":2264,"conditions":2265,"interventions":2266},"NCT05010603","Late Onset Alzheimer's Disease",[],"2016-11-15",10000,[1133],[2267],"Blood Draw",{"intervention":1065,"totalTrials":846,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2271,"activeCount":100},[],{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[2276,2286],{"nctId":2277,"briefTitle":2278,"status":119,"phases":2279,"primaryCompletion":2280,"completion":907,"start":1046,"enrollment":2281,"conditions":2282,"interventions":2284},"NCT00869050","Capecitabine and Temozolomide for Neuroendocrine Cancers",[89],"2013-12",41,[2283],"Neuroendocrine Tumors",[1065,2285],"Temozolomide",{"nctId":1056,"briefTitle":1057,"status":119,"phases":2287,"primaryCompletion":907,"completion":907,"start":1059,"enrollment":1060,"conditions":2288,"interventions":2289},[89],[1062],[787,1064,1065],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":129,"soonestReadout":1417},[2296],{"nctId":2297,"briefTitle":2298,"status":108,"phases":2299,"primaryCompletion":1417,"completion":1537,"start":2300,"enrollment":821,"conditions":2301,"interventions":2303},"NCT05838391","Adaptive Radiation in Anal Cancer",[92],"2023-05-18",[2302],"Anal Squamous Cell Carcinoma",[2304,2305,1065],"Mitomycin-C","5-Fluorouracil",{"intervention":2304,"totalTrials":129,"cells":2307},{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2312,"PHASE3":2314,"PHASE4":2316,"NA":2318},{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[],{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":129,"soonestReadout":1417},[2320],{"nctId":2297,"briefTitle":2298,"status":108,"phases":2321,"primaryCompletion":1417,"completion":1537,"start":2300,"enrollment":821,"conditions":2322,"interventions":2323},[92],[2302],[2304,2305,1065],{"intervention":2305,"totalTrials":129,"cells":2325},{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2327,"activeCount":100},[],{"trials":2329,"activeCount":100},[],{"trials":2331,"activeCount":100},[],{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":129,"soonestReadout":1417},[2338],{"nctId":2297,"briefTitle":2298,"status":108,"phases":2339,"primaryCompletion":1417,"completion":1537,"start":2300,"enrollment":821,"conditions":2340,"interventions":2341},[92],[2302],[2304,2305,1065],{"intervention":2343,"totalTrials":129,"cells":2344},"Genome Sequencing",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2346,"activeCount":100},[],{"trials":2348,"activeCount":100},[],{"trials":2350,"activeCount":100},[],{"trials":2352,"activeCount":100},[],{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":129,"soonestReadout":2361},[2357],{"nctId":2358,"briefTitle":2359,"status":108,"phases":2360,"primaryCompletion":2361,"completion":2361,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2366},"NCT07610590","guideSEQ: Genomic Understanding, Impact, Decision & Ethics in Prenatal Sequencing",[],"2029-07-31","2026-04-29",1042,[2365],"Prenatal Genetic Diagnosis",[2343],{"intervention":927,"totalTrials":96,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2382,"PHASE3":2409,"PHASE4":2415,"NA":2428},{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[2373],{"nctId":2374,"briefTitle":2375,"status":119,"phases":2376,"primaryCompletion":2377,"completion":2378,"start":736,"enrollment":446,"conditions":2379,"interventions":2380},"NCT00976131","Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer",[88],"2012-09-30","2021-01-20",[23],[2381,754,927],"CoQ10",{"trials":2383,"activeCount":100},[2384,2388,2392],{"nctId":887,"briefTitle":888,"status":415,"phases":2385,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":2386,"interventions":2387},[88,89],[894],[896,897,898,899,900,901,902],{"nctId":915,"briefTitle":916,"status":150,"phases":2389,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":2390,"interventions":2391},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"nctId":2393,"briefTitle":2394,"status":119,"phases":2395,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":2398,"interventions":2400},"NCT01847001","Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy",[89],"2018-12-31","2019-10-16",[2399,23],"Locally Advanced Malignant Neoplasm",[2401,2402,2403,2404,2405,754,927,2406,2407,2408],"Propranolol","Paclitaxel","Nab-paclitaxel","Trastuzumab","Pertuzumab","Premedication","Anti-nausea therapy","Pegfilgrastim",{"trials":2410,"activeCount":100},[2411],{"nctId":942,"briefTitle":943,"status":119,"phases":2412,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":2413,"interventions":2414},[89,90],[949,950,951,952],[851,927,50,853,954,955],{"trials":2416,"activeCount":100},[2417],{"nctId":2418,"briefTitle":2419,"status":119,"phases":2420,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2218,"conditions":2423,"interventions":2425},"NCT01731886","Lenalidomide and Dexamethasone With\u002FWithout Stem Cell Transplant in Patients With Multiple Myeloma",[91],"2017-04-11","2012-09",[2424],"Multiple Myeloma",[2426,1521,925,2427,927,2188],"Lenalidomide","G-CSF",{"trials":2429,"activeCount":100},[],{"intervention":2431,"totalTrials":2432,"cells":2433},"Metformin",5,{"EARLY_PHASE1":2434,"PHASE1":2447,"PHASE2":2457,"PHASE3":2477,"PHASE4":2479,"NA":2491},{"trials":2435,"activeCount":100},[2436],{"nctId":2437,"briefTitle":2438,"status":119,"phases":2439,"primaryCompletion":2440,"completion":40,"start":2441,"enrollment":1419,"conditions":2442,"interventions":2445},"NCT01980823","Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer",[87],"2018-05-24","2013-10",[23,2443,2444],"Breast Tumors","Cancer of Breast",[2431,2446],"Atorvastatin",{"trials":2448,"activeCount":100},[2449],{"nctId":2450,"briefTitle":2451,"status":119,"phases":2452,"primaryCompletion":2453,"completion":2453,"start":2454,"enrollment":836,"conditions":2455,"interventions":2456},"NCT01650506","Study of Erlotinib and Metformin in Triple Negative Breast Cancer",[88],"2016-06","2012-07",[23],[2431,742],{"trials":2458,"activeCount":100},[2459,2469],{"nctId":2460,"briefTitle":2461,"status":119,"phases":2462,"primaryCompletion":2463,"completion":2464,"start":2465,"enrollment":2466,"conditions":2467,"interventions":2468},"NCT00930579","Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation",[89],"2012-05-10","2017-01-09","2009-10-16",35,[23],[2431],{"nctId":2470,"briefTitle":2471,"status":119,"phases":2472,"primaryCompletion":759,"completion":759,"start":2473,"enrollment":2474,"conditions":2475,"interventions":2476},"NCT00620191","Metformin in Amnestic Mild Cognitive Impairment",[89],"2008-06-01",80,[597],[2431],{"trials":2478,"activeCount":100},[],{"trials":2480,"activeCount":100},[2481],{"nctId":2482,"briefTitle":2483,"status":150,"phases":2484,"primaryCompletion":2485,"completion":2485,"start":2486,"enrollment":846,"conditions":2487,"interventions":2490},"NCT02500147","Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)",[91],"2021-03-03","2011-09-08",[2488,1515,2489],"Polycystic Ovary Syndrome","Metabolic Syndrome",[2431],{"trials":2492,"activeCount":100},[],{"intervention":2426,"totalTrials":846,"cells":2494},{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2508,"PHASE3":2519,"PHASE4":2521,"NA":2527},{"trials":2496,"activeCount":100},[],{"trials":2498,"activeCount":100},[2499],{"nctId":2500,"briefTitle":2501,"status":119,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":1046,"enrollment":2504,"conditions":2505,"interventions":2506},"NCT01378091","Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer",[88],"2013-09",64,[399],[2426,1064,2507],"Prednisone",{"trials":2509,"activeCount":100},[2510],{"nctId":2511,"briefTitle":2512,"status":119,"phases":2513,"primaryCompletion":2514,"completion":2515,"start":878,"enrollment":186,"conditions":2516,"interventions":2518},"NCT01274533","Lenalidomide in HTLV-1 Adult T-Cell Leukemia",[89],"2013-01","2013-05",[2517],"Adult T Cell Leukemia\u002FLymphoma",[2426],{"trials":2520,"activeCount":100},[],{"trials":2522,"activeCount":100},[2523],{"nctId":2418,"briefTitle":2419,"status":119,"phases":2524,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2218,"conditions":2525,"interventions":2526},[91],[2424],[2426,1521,925,2427,927,2188],{"trials":2528,"activeCount":100},[],{"intervention":2530,"totalTrials":846,"cells":2531},"Bupivacaine",{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2548,"PHASE4":2550,"NA":2575},{"trials":2533,"activeCount":100},[],{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":100},[2538],{"nctId":2539,"briefTitle":2540,"status":415,"phases":2541,"primaryCompletion":137,"completion":137,"start":2542,"enrollment":100,"conditions":2543,"interventions":2546},"NCT01565512","Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort",[88,89],"2011-11",[399,2544,2545],"Robotic Prostatectomy","Foley Catheter Discomfort",[2530,2547],"Saline",{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[2552,2563],{"nctId":2553,"briefTitle":2554,"status":119,"phases":2555,"primaryCompletion":2556,"completion":2557,"start":2558,"enrollment":2559,"conditions":2560,"interventions":2562},"NCT02777749","Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty",[91],"2017-09-19","2017-11-01","2016-07-19",155,[2561],"Osteoarthritis",[2530],{"nctId":2564,"briefTitle":2565,"status":119,"phases":2566,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2573},"NCT02862912","Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)",[91],"2020-01-31","2016-11-08",43,[2571,2572],"Adverse Reaction to Spinal Anesthetic","Maternal Care for Cervical Incompetence",[2574,2530,261,2547],"Chloroprocaine",{"trials":2576,"activeCount":100},[],{"intervention":1521,"totalTrials":846,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2587,"PHASE3":2599,"PHASE4":2601,"NA":2607},{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[2583],{"nctId":1506,"briefTitle":1507,"status":415,"phases":2584,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":100,"conditions":2585,"interventions":2586},[88],[1513,1514,1515,1516],[1499,1518,1519,1520,1521,1522],{"trials":2588,"activeCount":100},[2589],{"nctId":2590,"briefTitle":2591,"status":119,"phases":2592,"primaryCompletion":2593,"completion":2594,"start":2514,"enrollment":351,"conditions":2595,"interventions":2597},"NCT01222260","Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis",[89],"2019-03","2019-07-03",[2596],"AL Amyloidosis",[2598,1521],"Bendamustine",{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[2603],{"nctId":2418,"briefTitle":2419,"status":119,"phases":2604,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2218,"conditions":2605,"interventions":2606},[91],[2424],[2426,1521,925,2427,927,2188],{"trials":2608,"activeCount":100},[],{"intervention":2610,"totalTrials":846,"cells":2611},"Nicotine",{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2616,"PHASE3":2618,"PHASE4":2620,"NA":2650},{"trials":2613,"activeCount":100},[],{"trials":2615,"activeCount":100},[],{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":100},[2622,2632,2641],{"nctId":2623,"briefTitle":2624,"status":119,"phases":2625,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":1419,"conditions":2629,"interventions":2631},"NCT00232817","Anesthesia and Postoperative Pain",[91],"2005-07","2006-03","2003-07",[2630],"Postoperative Pain",[2610],{"nctId":2633,"briefTitle":2634,"status":119,"phases":2635,"primaryCompletion":2636,"completion":795,"start":2637,"enrollment":821,"conditions":2638,"interventions":2640},"NCT00385216","Nicotine as an Adjuvant Analgesic for Third Molar Surgery",[91],"2009-05","2004-07",[2639],"Dental Crowding",[2610],{"nctId":2642,"briefTitle":2643,"status":119,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":821,"conditions":2647,"interventions":2649},"NCT00440505","Effect of Nicotine on Chronic Pelvic Pain",[91],"2008-06","2004-02",[2648],"Pelvic Pain",[2610,2610],{"trials":2651,"activeCount":100},[],{"intervention":2653,"totalTrials":846,"cells":2654},"Abatacept",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2677,"PHASE4":2679,"NA":2692},{"trials":2656,"activeCount":100},[],{"trials":2658,"activeCount":100},[],{"trials":2660,"activeCount":100},[2661,2669],{"nctId":2662,"briefTitle":2663,"status":119,"phases":2664,"primaryCompletion":2665,"completion":2665,"start":2503,"enrollment":33,"conditions":2666,"interventions":2668},"NCT02018042","An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata",[89],"2017-07-31",[2667],"Alopecia Areata",[2653],{"nctId":2670,"briefTitle":2671,"status":415,"phases":2672,"primaryCompletion":2673,"completion":2673,"start":2674,"enrollment":100,"conditions":2675,"interventions":2676},"NCT01917058","A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata",[89],"2016-08","2013-08",[2667],[2653],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[2681],{"nctId":2682,"briefTitle":2683,"status":150,"phases":2684,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":1394,"conditions":2687,"interventions":2690},"NCT03619876","Effects of Abatacept on Myocarditis in Rheumatoid Arthritis",[91],"2021-09-15","2019-07-10",[2688,2689],"Rheumatoid Arthritis","Myocardial Inflammation",[2653,2691],"Adalimumab",{"trials":2693,"activeCount":100},[],{"intervention":2695,"totalTrials":226,"cells":2696},"Budesonide",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2725},{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"trials":2704,"activeCount":100},[],{"trials":2706,"activeCount":100},[2707,2715],{"nctId":2708,"briefTitle":2709,"status":150,"phases":2710,"primaryCompletion":2422,"completion":2422,"start":417,"enrollment":737,"conditions":2711,"interventions":2713},"NCT01712854","Effects of Symbicort on the Ventilatory Kinematics",[91],[2712],"Chronic Obstructive Lung Disease",[2695,2714],"Symbicort",{"nctId":2716,"briefTitle":2717,"status":415,"phases":2718,"primaryCompletion":2719,"completion":2720,"start":2721,"enrollment":100,"conditions":2722,"interventions":2724},"NCT02357277","The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton",[91],"2017-11","2018-11","2015-03",[2723],"Osteoporosis",[2695],{"trials":2726,"activeCount":100},[],{"intervention":2728,"totalTrials":226,"cells":2729},"ACTHAR gel",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2736,"PHASE4":2738,"NA":2759},{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[2740,2749],{"nctId":2741,"briefTitle":2742,"status":119,"phases":2743,"primaryCompletion":2744,"completion":2744,"start":2745,"enrollment":33,"conditions":2746,"interventions":2748},"NCT01129284","Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)",[91],"2011-09","2009-12",[2747],"Treatment Resistant Nephrotic Syndrome",[2728],{"nctId":2750,"briefTitle":2751,"status":150,"phases":2752,"primaryCompletion":2753,"completion":2753,"start":907,"enrollment":836,"conditions":2754,"interventions":2756},"NCT02226341","ACTHar in the Treatment of Lupus Nephritis",[91],"2024-01-03",[2755],"Lupus Nephritis",[2757,2758],"CellCept","ACTHar gel",{"trials":2760,"activeCount":100},[],{"intervention":925,"totalTrials":226,"cells":2762},{"EARLY_PHASE1":2763,"PHASE1":2765,"PHASE2":2767,"PHASE3":2773,"PHASE4":2775,"NA":2781},{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[2769],{"nctId":915,"briefTitle":916,"status":150,"phases":2770,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":2771,"interventions":2772},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[2777],{"nctId":2418,"briefTitle":2419,"status":119,"phases":2778,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2218,"conditions":2779,"interventions":2780},[91],[2424],[2426,1521,925,2427,927,2188],{"trials":2782,"activeCount":100},[],{"intervention":2188,"totalTrials":226,"cells":2784},{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2795,"PHASE4":2797,"NA":2803},{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[2791],{"nctId":2177,"briefTitle":2178,"status":150,"phases":2792,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":129,"conditions":2793,"interventions":2794},[88,89],[2184],[2186,2187,2188,2189,2190],{"trials":2796,"activeCount":100},[],{"trials":2798,"activeCount":100},[2799],{"nctId":2418,"briefTitle":2419,"status":119,"phases":2800,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2218,"conditions":2801,"interventions":2802},[91],[2424],[2426,1521,925,2427,927,2188],{"trials":2804,"activeCount":100},[],{"intervention":2806,"totalTrials":226,"cells":2807},"Celecoxib",{"EARLY_PHASE1":2808,"PHASE1":2810,"PHASE2":2812,"PHASE3":2826,"PHASE4":2828,"NA":2843},{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[2814],{"nctId":2815,"briefTitle":2816,"status":119,"phases":2817,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2823},"NCT00355576","Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis",[89],"2007-05","2006-07",86,[2822],"Amyotrophic Lateral Sclerosis",[2806,2824,2825],"Creatine","Minocycline",{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[2830],{"nctId":2831,"briefTitle":2832,"status":150,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":737,"conditions":2836,"interventions":2839},"NCT03473665","Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis",[91],"2019-08-02","2018-03-01",[2837,2838],"Ankylosing Spondylitis","Axial Spondyloarthritis",[2840,2841,2842,2806],"Indomethacin","Diclofenac","Meloxicam",{"trials":2844,"activeCount":100},[],{"intervention":2846,"totalTrials":226,"cells":2847},"Morphine",{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2854,"PHASE4":2856,"NA":2876},{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":100},[],{"trials":2853,"activeCount":100},[],{"trials":2855,"activeCount":100},[],{"trials":2857,"activeCount":100},[2858,2866],{"nctId":2859,"briefTitle":2860,"status":119,"phases":2861,"primaryCompletion":2862,"completion":2862,"start":2542,"enrollment":2863,"conditions":2864,"interventions":2865},"NCT01465191","Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section",[91],"2014-05",169,[2630],[2846],{"nctId":2867,"briefTitle":2868,"status":119,"phases":2869,"primaryCompletion":2870,"completion":2870,"start":844,"enrollment":2871,"conditions":2872,"interventions":2874},"NCT02473276","2 Dose Neuraxial Morphine for Prevention of PDPH",[91],"2020-01",44,[2873],"Postdural Puncture Headache",[2846,2875],"Sterile normal saline",{"trials":2877,"activeCount":100},[],{"intervention":261,"totalTrials":226,"cells":2879},{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2898},{"trials":2881,"activeCount":100},[],{"trials":2883,"activeCount":100},[],{"trials":2885,"activeCount":100},[],{"trials":2887,"activeCount":100},[],{"trials":2889,"activeCount":100},[2890,2894],{"nctId":2564,"briefTitle":2565,"status":119,"phases":2891,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":2569,"conditions":2892,"interventions":2893},[91],[2571,2572],[2574,2530,261,2547],{"nctId":252,"briefTitle":253,"status":119,"phases":2895,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":2896,"interventions":2897},[91],[259],[225,261],{"trials":2899,"activeCount":100},[],{"intervention":2714,"totalTrials":129,"cells":2901},{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2916},{"trials":2903,"activeCount":100},[],{"trials":2905,"activeCount":100},[],{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[2912],{"nctId":2708,"briefTitle":2709,"status":150,"phases":2913,"primaryCompletion":2422,"completion":2422,"start":417,"enrollment":737,"conditions":2914,"interventions":2915},[91],[2712],[2695,2714],{"trials":2917,"activeCount":100},[],{"intervention":2919,"totalTrials":129,"cells":2920},"Intralesional Triamcinolone 2.5 mg\u002Fml",{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2941},{"trials":2922,"activeCount":100},[],{"trials":2924,"activeCount":100},[],{"trials":2926,"activeCount":100},[],{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":100},[2931],{"nctId":2932,"briefTitle":2933,"status":150,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2744,"enrollment":1394,"conditions":2936,"interventions":2937},"NCT01898806","Intralesional Steroids in the Treatment of Alopecia Areata",[91],"2018-01",[2667],[2919,2938,2939,2940],"Intralesional Triamcinolone 5 mg\u002Fml","Intralesional Triamcinolone 10 mg\u002Fml","Intralesional Saline",{"trials":2942,"activeCount":100},[],{"intervention":2938,"totalTrials":129,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2951,"PHASE4":2953,"NA":2959},{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[],{"trials":2952,"activeCount":100},[],{"trials":2954,"activeCount":100},[2955],{"nctId":2932,"briefTitle":2933,"status":150,"phases":2956,"primaryCompletion":2935,"completion":2935,"start":2744,"enrollment":1394,"conditions":2957,"interventions":2958},[91],[2667],[2919,2938,2939,2940],{"trials":2960,"activeCount":100},[],{"intervention":2939,"totalTrials":129,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2969,"PHASE4":2971,"NA":2977},{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":100},[],{"trials":2972,"activeCount":100},[2973],{"nctId":2932,"briefTitle":2933,"status":150,"phases":2974,"primaryCompletion":2935,"completion":2935,"start":2744,"enrollment":1394,"conditions":2975,"interventions":2976},[91],[2667],[2919,2938,2939,2940],{"trials":2978,"activeCount":100},[],{"intervention":2940,"totalTrials":129,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":2995},{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[2991],{"nctId":2932,"briefTitle":2933,"status":150,"phases":2992,"primaryCompletion":2935,"completion":2935,"start":2744,"enrollment":1394,"conditions":2993,"interventions":2994},[91],[2667],[2919,2938,2939,2940],{"trials":2996,"activeCount":100},[],{"intervention":2998,"totalTrials":129,"cells":2999},"Clonidine or fentanyl",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3008,"NA":3017},{"trials":3001,"activeCount":100},[],{"trials":3003,"activeCount":100},[],{"trials":3005,"activeCount":100},[],{"trials":3007,"activeCount":100},[],{"trials":3009,"activeCount":100},[3010],{"nctId":3011,"briefTitle":3012,"status":415,"phases":3013,"completion":3014,"enrollment":100,"conditions":3015,"interventions":3016},"NCT00691795","Epidural Fentanyl-bupivacaine Versus Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor",[91],"2011-12",[259],[2998],{"trials":3018,"activeCount":100},[],{"intervention":3020,"totalTrials":129,"cells":3021},"Denosumab",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3040},{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[],{"trials":3027,"activeCount":100},[],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[3032],{"nctId":3033,"briefTitle":3034,"status":150,"phases":3035,"primaryCompletion":907,"completion":907,"start":3036,"enrollment":836,"conditions":3037,"interventions":3039},"NCT01558115","Denosumab in Primary Hyperparathyroidism",[91],"2012-01",[3038],"Primary Hyperparathyroidism",[3020],{"trials":3041,"activeCount":100},[],{"intervention":3043,"totalTrials":129,"cells":3044},"Amantadine Hydrochloride",{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3064},{"trials":3046,"activeCount":100},[],{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[3055],{"nctId":3056,"briefTitle":3057,"status":150,"phases":3058,"primaryCompletion":3059,"completion":3059,"start":3060,"enrollment":1394,"conditions":3061,"interventions":3063},"NCT04273737","Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy",[91],"2022-02-22","2020-02-28",[3062],"Cerebral Palsy",[3043],{"trials":3065,"activeCount":100},[],{"intervention":3067,"totalTrials":129,"cells":3068},"10,000 IU Vitamin D3",{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3075,"PHASE4":3077,"NA":3087},{"trials":3070,"activeCount":100},[],{"trials":3072,"activeCount":100},[],{"trials":3074,"activeCount":100},[],{"trials":3076,"activeCount":100},[],{"trials":3078,"activeCount":100},[3079],{"nctId":3080,"briefTitle":3081,"status":119,"phases":3082,"primaryCompletion":3083,"completion":3083,"start":794,"enrollment":737,"conditions":3084,"interventions":3086},"NCT01306656","Vitamin D Repletion in Primary Hyperparathyroidism",[91],"2017-02",[3038,3085],"Vitamin D Deficiency",[3067],{"trials":3088,"activeCount":100},[],{"intervention":3090,"totalTrials":129,"cells":3091},"Pyridium",{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3098,"PHASE4":3100,"NA":3112},{"trials":3093,"activeCount":100},[],{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[3102],{"nctId":3103,"briefTitle":3104,"status":119,"phases":3105,"primaryCompletion":2673,"completion":2673,"start":2721,"enrollment":3106,"conditions":3107,"interventions":3109},"NCT02677623","Evaluation of Ureteral Patency in the Post-indigo Carmine Era",[91],140,[3108],"Ureteral Patency",[3090,3110,3111],"Sodium Fluorescein","Mannitol",{"trials":3113,"activeCount":100},[],{"intervention":3110,"totalTrials":129,"cells":3115},{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3120,"PHASE3":3122,"PHASE4":3124,"NA":3130},{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[],{"trials":3125,"activeCount":100},[3126],{"nctId":3103,"briefTitle":3104,"status":119,"phases":3127,"primaryCompletion":2673,"completion":2673,"start":2721,"enrollment":3106,"conditions":3128,"interventions":3129},[91],[3108],[3090,3110,3111],{"trials":3131,"activeCount":100},[],{"intervention":3111,"totalTrials":129,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3140,"PHASE4":3142,"NA":3148},{"trials":3135,"activeCount":100},[],{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[3144],{"nctId":3103,"briefTitle":3104,"status":119,"phases":3145,"primaryCompletion":2673,"completion":2673,"start":2721,"enrollment":3106,"conditions":3146,"interventions":3147},[91],[3108],[3090,3110,3111],{"trials":3149,"activeCount":100},[],{"intervention":3151,"totalTrials":129,"cells":3152},"Empagliflozin",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3171},{"trials":3154,"activeCount":100},[],{"trials":3156,"activeCount":100},[],{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[3163],{"nctId":3164,"briefTitle":3165,"status":119,"phases":3166,"primaryCompletion":350,"completion":350,"start":3167,"enrollment":33,"conditions":3168,"interventions":3170},"NCT05233163","SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy",[91],"2022-03-14",[3169],"Transthyretin Amyloid Cardiomyopathy",[3151],{"trials":3172,"activeCount":100},[],{"intervention":3174,"totalTrials":129,"cells":3175},"Aliskiren",{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3182,"PHASE4":3184,"NA":3201},{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[],{"trials":3181,"activeCount":100},[],{"trials":3183,"activeCount":100},[],{"trials":3185,"activeCount":100},[3186],{"nctId":3187,"briefTitle":3188,"status":150,"phases":3189,"primaryCompletion":3036,"completion":3190,"start":736,"enrollment":9,"conditions":3191,"interventions":3199},"NCT01129557","Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease",[91],"2012-12",[3192,3193,3194,3195,3196,3197,3198],"Proteinuric Kidney Disease","Diabetic Nephropathy","Hypertensive Nephrosclerosis","IgA Nephropathy","Focal Segmental Glomerulosclerosis","Glomerulopathy (Obesity-associated)","Glomerulonephritis, Membranous",[3174,3200],"Valsartan",{"trials":3202,"activeCount":100},[],{"intervention":3200,"totalTrials":129,"cells":3204},{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3219},{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[3215],{"nctId":3187,"briefTitle":3188,"status":150,"phases":3216,"primaryCompletion":3036,"completion":3190,"start":736,"enrollment":9,"conditions":3217,"interventions":3218},[91],[3192,3193,3194,3195,3196,3197,3198],[3174,3200],{"trials":3220,"activeCount":100},[],{"intervention":3222,"totalTrials":129,"cells":3223},"Evolocumab",{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3230,"PHASE4":3232,"NA":3243},{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[3234],{"nctId":3235,"briefTitle":3236,"status":150,"phases":3237,"primaryCompletion":3238,"completion":3238,"start":3239,"enrollment":186,"conditions":3240,"interventions":3242},"NCT03331666","Impact of LDL-cholesterol Lowering on Platelet Activation",[91],"2020-02-04","2018-11-16",[3241],"Familial Hypercholesterolemia",[3222],{"trials":3244,"activeCount":100},[],{"intervention":3246,"totalTrials":129,"cells":3247},"Alendronate 70mg weekly",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3254,"PHASE4":3256,"NA":3265},{"trials":3249,"activeCount":100},[],{"trials":3251,"activeCount":100},[],{"trials":3253,"activeCount":100},[],{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[3258],{"nctId":3259,"briefTitle":3260,"status":415,"phases":3261,"primaryCompletion":736,"completion":736,"start":2819,"enrollment":100,"conditions":3262,"interventions":3264},"NCT00359385","The Effects of Alendronate After Cure of Primary Hyperparathyroidism",[91],[3263],"Hyperparathyroidism",[3246],{"trials":3266,"activeCount":100},[],{"intervention":3268,"totalTrials":129,"cells":3269},"Botulinum toxin, type B",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3276,"PHASE4":3278,"NA":3289},{"trials":3271,"activeCount":100},[],{"trials":3273,"activeCount":100},[],{"trials":3275,"activeCount":100},[],{"trials":3277,"activeCount":100},[],{"trials":3279,"activeCount":100},[3280],{"nctId":3281,"briefTitle":3282,"status":119,"phases":3283,"primaryCompletion":3284,"completion":3284,"start":3285,"enrollment":30,"conditions":3286,"interventions":3288},"NCT00208091","Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia",[91],"2008-05","2003-04",[3287],"Focal Dystonia",[3268],{"trials":3290,"activeCount":100},[],{"intervention":3292,"totalTrials":129,"cells":3293},"Low dose formulation",{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3300,"PHASE4":3302,"NA":3314},{"trials":3295,"activeCount":100},[],{"trials":3297,"activeCount":100},[],{"trials":3299,"activeCount":100},[],{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[3304],{"nctId":3305,"briefTitle":3306,"status":119,"phases":3307,"primaryCompletion":3308,"completion":3308,"start":2819,"enrollment":3309,"conditions":3310,"interventions":3312},"NCT00827632","Obesity, Oral Contraception, and Ovarian Suppression",[91],"2008-12",226,[3311],"Ovarian Suppression",[3292,3313],"High dose formulation",{"trials":3315,"activeCount":100},[],{"intervention":3313,"totalTrials":129,"cells":3317},{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3324,"PHASE4":3326,"NA":3332},{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"trials":3323,"activeCount":100},[],{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[3328],{"nctId":3305,"briefTitle":3306,"status":119,"phases":3329,"primaryCompletion":3308,"completion":3308,"start":2819,"enrollment":3309,"conditions":3330,"interventions":3331},[91],[3311],[3292,3313],{"trials":3333,"activeCount":100},[],{"intervention":3335,"totalTrials":129,"cells":3336},"Bupivacaine Hydrochloride",{"EARLY_PHASE1":3337,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3357},{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[3347],{"nctId":3348,"briefTitle":3349,"status":119,"phases":3350,"primaryCompletion":3351,"completion":3351,"start":3352,"enrollment":2218,"conditions":3353,"interventions":3355},"NCT03360214","PEMF and PEC Blocks in Mastectomy Reconstruction Patients",[91],"2022-03-07","2017-07-05",[3354],"Breast Cancer Female",[3335,3356],"Ropivacaine Hydrochloride",{"trials":3358,"activeCount":100},[],{"intervention":3356,"totalTrials":129,"cells":3360},{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3365,"PHASE3":3367,"PHASE4":3369,"NA":3375},{"trials":3362,"activeCount":100},[],{"trials":3364,"activeCount":100},[],{"trials":3366,"activeCount":100},[],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[3371],{"nctId":3348,"briefTitle":3349,"status":119,"phases":3372,"primaryCompletion":3351,"completion":3351,"start":3352,"enrollment":2218,"conditions":3373,"interventions":3374},[91],[3354],[3335,3356],{"trials":3376,"activeCount":100},[],{"intervention":3378,"totalTrials":129,"cells":3379},"Misoprostol",{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3386,"PHASE4":3388,"NA":3401},{"trials":3381,"activeCount":100},[],{"trials":3383,"activeCount":100},[],{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[3390],{"nctId":3391,"briefTitle":3392,"status":119,"phases":3393,"primaryCompletion":3394,"completion":3394,"start":3395,"enrollment":3396,"conditions":3397,"interventions":3400},"NCT03670836","Comparison of Misoprostol Ripening Efficacy With Dilapan",[91],"2021-07-21","2018-11-15",307,[3398,3399],"Labor Onset and Length Abnormalities","Induced; Birth",[3378],{"trials":3402,"activeCount":100},[],{"intervention":3404,"totalTrials":129,"cells":3405},"Labetalol",{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3429},{"trials":3407,"activeCount":100},[],{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":100},[],{"trials":3413,"activeCount":100},[],{"trials":3415,"activeCount":100},[3416],{"nctId":3417,"briefTitle":3418,"status":150,"phases":3419,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":226,"conditions":3422,"interventions":3427},"NCT05139238","Postpartum Hypertension Study",[91],"2025-08-21","2022-07-04",[3423,3424,3425,3426],"Postpartum Pregnancy-Induced Hypertension","Postpartum Preeclampsia","Pregnancy-Induced Hypertension in Postpartum","Hypertensive Emergency",[3404,3428],"Nifedipine",{"trials":3430,"activeCount":100},[],{"intervention":3428,"totalTrials":129,"cells":3432},{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3437,"PHASE3":3439,"PHASE4":3441,"NA":3447},{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[3443],{"nctId":3417,"briefTitle":3418,"status":150,"phases":3444,"primaryCompletion":3420,"completion":3420,"start":3421,"enrollment":226,"conditions":3445,"interventions":3446},[91],[3423,3424,3425,3426],[3404,3428],{"trials":3448,"activeCount":100},[],{"intervention":3450,"totalTrials":129,"cells":3451},"Tazorac",{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3470},{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[],{"trials":3457,"activeCount":100},[],{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[3462],{"nctId":3463,"briefTitle":3464,"status":119,"phases":3465,"primaryCompletion":3466,"completion":3466,"start":1046,"enrollment":821,"conditions":3467,"interventions":3469},"NCT00648986","Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails",[91],"2006-12",[3468],"Brittle Nails",[3450],{"trials":3471,"activeCount":100},[],{"intervention":2427,"totalTrials":129,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3488},{"trials":3475,"activeCount":100},[],{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[3484],{"nctId":2418,"briefTitle":2419,"status":119,"phases":3485,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":2218,"conditions":3486,"interventions":3487},[91],[2424],[2426,1521,925,2427,927,2188],{"trials":3489,"activeCount":100},[],{"intervention":3491,"totalTrials":129,"cells":3492},"Ropivacaine",{"EARLY_PHASE1":3493,"PHASE1":3495,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3513},{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":100},[],{"trials":3498,"activeCount":100},[],{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[3503],{"nctId":3504,"briefTitle":3505,"status":415,"phases":3506,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":100,"conditions":3509,"interventions":3511},"NCT03506620","The Role of Nerve Blocks in Hip Arthroscopy",[91],"2020-02-07","2019-01",[3510],"Femoroacetabular Impingement",[3491,3512],"Saline Solution for",{"trials":3514,"activeCount":100},[],{"intervention":3512,"totalTrials":129,"cells":3516},{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3523,"PHASE4":3525,"NA":3531},{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[3527],{"nctId":3504,"briefTitle":3505,"status":415,"phases":3528,"primaryCompletion":3507,"completion":3507,"start":3508,"enrollment":100,"conditions":3529,"interventions":3530},[91],[3510],[3491,3512],{"trials":3532,"activeCount":100},[],{"intervention":3534,"totalTrials":129,"cells":3535},"Mupirocin calcium ointment, 2%",{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3540,"PHASE3":3542,"PHASE4":3544,"NA":3555},{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":100},[],{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[],{"trials":3545,"activeCount":100},[3546],{"nctId":3547,"briefTitle":3548,"status":119,"phases":3549,"primaryCompletion":3550,"completion":3550,"start":3551,"enrollment":112,"conditions":3552,"interventions":3554},"NCT00801879","Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection",[91],"2006-04","2003-09",[3553,29],"Staphylococcus Aureus",[3534],{"trials":3556,"activeCount":100},[],{"intervention":2840,"totalTrials":129,"cells":3558},{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3563,"PHASE3":3565,"PHASE4":3567,"NA":3573},{"trials":3560,"activeCount":100},[],{"trials":3562,"activeCount":100},[],{"trials":3564,"activeCount":100},[],{"trials":3566,"activeCount":100},[],{"trials":3568,"activeCount":100},[3569],{"nctId":2831,"briefTitle":2832,"status":150,"phases":3570,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":737,"conditions":3571,"interventions":3572},[91],[2837,2838],[2840,2841,2842,2806],{"trials":3574,"activeCount":100},[],{"intervention":2841,"totalTrials":129,"cells":3576},{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3581,"PHASE3":3583,"PHASE4":3585,"NA":3591},{"trials":3578,"activeCount":100},[],{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[3587],{"nctId":2831,"briefTitle":2832,"status":150,"phases":3588,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":737,"conditions":3589,"interventions":3590},[91],[2837,2838],[2840,2841,2842,2806],{"trials":3592,"activeCount":100},[],{"intervention":2842,"totalTrials":129,"cells":3594},{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3601,"PHASE4":3603,"NA":3609},{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[],{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[3605],{"nctId":2831,"briefTitle":2832,"status":150,"phases":3606,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":737,"conditions":3607,"interventions":3608},[91],[2837,2838],[2840,2841,2842,2806],{"trials":3610,"activeCount":100},[],{"intervention":3612,"totalTrials":129,"cells":3613},"clevidipine butyrate",{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3618,"PHASE3":3620,"PHASE4":3622,"NA":3633},{"trials":3615,"activeCount":100},[],{"trials":3617,"activeCount":100},[],{"trials":3619,"activeCount":100},[],{"trials":3621,"activeCount":100},[],{"trials":3623,"activeCount":100},[3624],{"nctId":3625,"briefTitle":3626,"status":415,"phases":3627,"primaryCompletion":3628,"completion":3629,"start":2542,"enrollment":100,"conditions":3630,"interventions":3632},"NCT01526876","The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients",[91],"2012-11","2012-12-19",[3631],"Hypertension",[3612],{"trials":3634,"activeCount":100},[],{"intervention":3636,"totalTrials":129,"cells":3637},"Methylergonovine",{"EARLY_PHASE1":3638,"PHASE1":3640,"PHASE2":3642,"PHASE3":3644,"PHASE4":3646,"NA":3660},{"trials":3639,"activeCount":100},[],{"trials":3641,"activeCount":100},[],{"trials":3643,"activeCount":100},[],{"trials":3645,"activeCount":100},[],{"trials":3647,"activeCount":100},[3648],{"nctId":3649,"briefTitle":3650,"status":119,"phases":3651,"primaryCompletion":3652,"completion":3653,"start":3654,"enrollment":3655,"conditions":3656,"interventions":3659},"NCT05772156","Prophylactic Methylergonovine for Twin Cesarean",[91],"2024-03-03","2024-03-11","2023-03-07",66,[3657,3658],"Twin; Complicating Pregnancy","Postpartum Hemorrhage",[3636],{"trials":3661,"activeCount":100},[],{"intervention":1493,"totalTrials":129,"cells":3663},{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3670,"PHASE4":3672,"NA":3678},{"trials":3665,"activeCount":100},[],{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"trials":3673,"activeCount":100},[3674],{"nctId":1484,"briefTitle":1485,"status":119,"phases":3675,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":3676,"interventions":3677},[91],[1491],[1493,854,1494,1495,70],{"trials":3679,"activeCount":100},[],{"intervention":1494,"totalTrials":129,"cells":3681},{"EARLY_PHASE1":3682,"PHASE1":3684,"PHASE2":3686,"PHASE3":3688,"PHASE4":3690,"NA":3696},{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"trials":3687,"activeCount":100},[],{"trials":3689,"activeCount":100},[],{"trials":3691,"activeCount":100},[3692],{"nctId":1484,"briefTitle":1485,"status":119,"phases":3693,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":3694,"interventions":3695},[91],[1491],[1493,854,1494,1495,70],{"trials":3697,"activeCount":100},[],{"intervention":1495,"totalTrials":129,"cells":3699},{"EARLY_PHASE1":3700,"PHASE1":3702,"PHASE2":3704,"PHASE3":3706,"PHASE4":3708,"NA":3714},{"trials":3701,"activeCount":100},[],{"trials":3703,"activeCount":100},[],{"trials":3705,"activeCount":100},[],{"trials":3707,"activeCount":100},[],{"trials":3709,"activeCount":100},[3710],{"nctId":1484,"briefTitle":1485,"status":119,"phases":3711,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":3712,"interventions":3713},[91],[1491],[1493,854,1494,1495,70],{"trials":3715,"activeCount":100},[],{"intervention":2757,"totalTrials":129,"cells":3717},{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3732},{"trials":3719,"activeCount":100},[],{"trials":3721,"activeCount":100},[],{"trials":3723,"activeCount":100},[],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[3728],{"nctId":2750,"briefTitle":2751,"status":150,"phases":3729,"primaryCompletion":2753,"completion":2753,"start":907,"enrollment":836,"conditions":3730,"interventions":3731},[91],[2755],[2757,2758],{"trials":3733,"activeCount":100},[],{"intervention":3735,"totalTrials":129,"cells":3736},"nicotine patch",{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3743,"PHASE4":3745,"NA":3755},{"trials":3738,"activeCount":100},[],{"trials":3740,"activeCount":100},[],{"trials":3742,"activeCount":100},[],{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[3747],{"nctId":3748,"briefTitle":3749,"status":119,"phases":3750,"primaryCompletion":3308,"completion":3308,"start":3751,"enrollment":3752,"conditions":3753,"interventions":3754},"NCT00440830","Nicotine Patch as an Analgesic Adjuvant After Surgery",[91],"2005-12",68,[625],[3735,3735],{"trials":3756,"activeCount":100},[],{"intervention":3758,"totalTrials":129,"cells":3759},"growth hormone releasing hormone (GHRH) & arginine",{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3766,"PHASE4":3768,"NA":3778},{"trials":3761,"activeCount":100},[],{"trials":3763,"activeCount":100},[],{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[3770],{"nctId":3771,"briefTitle":3772,"status":150,"phases":3773,"primaryCompletion":3774,"completion":3775,"start":890,"enrollment":446,"conditions":3776,"interventions":3777},"NCT00720902","Adult Growth Hormone Deficiency and Cardiovascular Risk",[91],"2010-03","2011-05",[354],[3758],{"trials":3779,"activeCount":100},[],{"intervention":2875,"totalTrials":129,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3796},{"trials":3783,"activeCount":100},[],{"trials":3785,"activeCount":100},[],{"trials":3787,"activeCount":100},[],{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[3792],{"nctId":2867,"briefTitle":2868,"status":119,"phases":3793,"primaryCompletion":2870,"completion":2870,"start":844,"enrollment":2871,"conditions":3794,"interventions":3795},[91],[2873],[2846,2875],{"trials":3797,"activeCount":100},[],{"intervention":3799,"totalTrials":129,"cells":3800},"Nanodropper and Proparacaine HCl 0.5%",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3807,"PHASE4":3809,"NA":3823},{"trials":3802,"activeCount":100},[],{"trials":3804,"activeCount":100},[],{"trials":3806,"activeCount":100},[],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[3811],{"nctId":3812,"briefTitle":3813,"status":119,"phases":3814,"primaryCompletion":3815,"completion":3815,"start":3816,"enrollment":3817,"conditions":3818,"interventions":3821},"NCT06636708","Efficacy of Nanodropper-mediated Topical Anesthetic",[91],"2025-04-24","2024-12-12",56,[3819,3820],"Corneal Diseases","Effectiveness of Microdrops",[3799,3822],"Standard Eye Drop Bottle with Proparacaine HCl 0.5%",{"trials":3824,"activeCount":100},[],{"intervention":3822,"totalTrials":129,"cells":3826},{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3833,"PHASE4":3835,"NA":3841},{"trials":3828,"activeCount":100},[],{"trials":3830,"activeCount":100},[],{"trials":3832,"activeCount":100},[],{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[3837],{"nctId":3812,"briefTitle":3813,"status":119,"phases":3838,"primaryCompletion":3815,"completion":3815,"start":3816,"enrollment":3817,"conditions":3839,"interventions":3840},[91],[3819,3820],[3799,3822],{"trials":3842,"activeCount":100},[],{"intervention":3844,"totalTrials":129,"cells":3845},"Epidural Morphine",{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3852,"PHASE4":3854,"NA":3865},{"trials":3847,"activeCount":100},[],{"trials":3849,"activeCount":100},[],{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[3856],{"nctId":3857,"briefTitle":3858,"status":150,"phases":3859,"primaryCompletion":1488,"completion":1488,"start":3860,"enrollment":2432,"conditions":3861,"interventions":3863},"NCT01844206","Two Dose Epidural Morphine for Post-cesarean Analgesia",[91],"2013-06",[625,3862],"Morphine Adverse Reaction",[3844,3864],"Epidural Saline",{"trials":3866,"activeCount":100},[],{"intervention":3864,"totalTrials":129,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3873,"PHASE3":3875,"PHASE4":3877,"NA":3883},{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[3879],{"nctId":3857,"briefTitle":3858,"status":150,"phases":3880,"primaryCompletion":1488,"completion":1488,"start":3860,"enrollment":2432,"conditions":3881,"interventions":3882},[91],[625,3862],[3844,3864],{"trials":3884,"activeCount":100},[],{"intervention":3886,"totalTrials":129,"cells":3887},"Morphine PCA",{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3906},{"trials":3889,"activeCount":100},[],{"trials":3891,"activeCount":100},[],{"trials":3893,"activeCount":100},[],{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[3898],{"nctId":3899,"briefTitle":3900,"status":119,"phases":3901,"primaryCompletion":891,"completion":891,"start":879,"enrollment":325,"conditions":3902,"interventions":3904},"NCT00385541","Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)",[91],[3903],"Post Operative Pain",[3886,3905],"Hydromorphone PCA",{"trials":3907,"activeCount":100},[],{"intervention":3905,"totalTrials":129,"cells":3909},{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3916,"PHASE4":3918,"NA":3924},{"trials":3911,"activeCount":100},[],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[],{"trials":3917,"activeCount":100},[],{"trials":3919,"activeCount":100},[3920],{"nctId":3899,"briefTitle":3900,"status":119,"phases":3921,"primaryCompletion":891,"completion":891,"start":879,"enrollment":325,"conditions":3922,"interventions":3923},[91],[3903],[3886,3905],{"trials":3925,"activeCount":100},[],{"intervention":3927,"totalTrials":129,"cells":3928},"Tacrolimus Extended Release Oral",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3950},{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[],{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[3939],{"nctId":3940,"briefTitle":3941,"status":119,"phases":3942,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":325,"conditions":3946,"interventions":3949},"NCT03511560","Envarsus on the Effect of Total Tacrolimus Dose\u002FTrough Level Ratio on Renal Function (eGFR) in Kidney Transplantation",[91],"2020-07-17","2021-07-17","2018-07-26",[3947,3948],"Renal Transplant Rejection","Kidney Transplant Failure and Rejection",[3927,854],{"trials":3951,"activeCount":100},[],{"intervention":3953,"totalTrials":129,"cells":3954},"Nevirapine",{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3961,"PHASE4":3963,"NA":3977},{"trials":3956,"activeCount":100},[],{"trials":3958,"activeCount":100},[],{"trials":3960,"activeCount":100},[],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[3965],{"nctId":3966,"briefTitle":3967,"status":119,"phases":3968,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":3972,"interventions":3973},"NCT02431975","Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial",[91],"2020-04-30","2015-08",73,[21],[3953,3974,3975,3976],"Zidovudine","Lamivudine","LPV\u002Fr",{"trials":3978,"activeCount":100},[],{"intervention":3974,"totalTrials":129,"cells":3980},{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3987,"PHASE4":3989,"NA":3995},{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[3991],{"nctId":3966,"briefTitle":3967,"status":119,"phases":3992,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":3993,"interventions":3994},[91],[21],[3953,3974,3975,3976],{"trials":3996,"activeCount":100},[],{"intervention":3975,"totalTrials":129,"cells":3998},{"EARLY_PHASE1":3999,"PHASE1":4001,"PHASE2":4003,"PHASE3":4005,"PHASE4":4007,"NA":4013},{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":100},[],{"trials":4008,"activeCount":100},[4009],{"nctId":3966,"briefTitle":3967,"status":119,"phases":4010,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":4011,"interventions":4012},[91],[21],[3953,3974,3975,3976],{"trials":4014,"activeCount":100},[],{"intervention":3976,"totalTrials":129,"cells":4016},{"EARLY_PHASE1":4017,"PHASE1":4019,"PHASE2":4021,"PHASE3":4023,"PHASE4":4025,"NA":4031},{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[4027],{"nctId":3966,"briefTitle":3967,"status":119,"phases":4028,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":4029,"interventions":4030},[91],[21],[3953,3974,3975,3976],{"trials":4032,"activeCount":100},[],{"intervention":4034,"totalTrials":129,"cells":4035},"Enoxaparin Prophylactic Dose",{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4061},{"trials":4037,"activeCount":100},[],{"trials":4039,"activeCount":100},[],{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[4046],{"nctId":4047,"briefTitle":4048,"status":119,"phases":4049,"primaryCompletion":4050,"completion":4050,"start":4051,"enrollment":4052,"conditions":4053,"interventions":4057},"NCT04367831","Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19",[91],"2021-05-12","2020-05-02",94,[4054,4055,4056],"COVID-19","Venous Thromboses","Arterial Thrombosis",[4034,4058,4059,4060],"Heparin","Heparin SC","Enoxaparin\u002FLovenox Intermediate Dose",{"trials":4062,"activeCount":100},[],{"intervention":4058,"totalTrials":129,"cells":4064},{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4071,"PHASE4":4073,"NA":4079},{"trials":4066,"activeCount":100},[],{"trials":4068,"activeCount":100},[],{"trials":4070,"activeCount":100},[],{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[4075],{"nctId":4047,"briefTitle":4048,"status":119,"phases":4076,"primaryCompletion":4050,"completion":4050,"start":4051,"enrollment":4052,"conditions":4077,"interventions":4078},[91],[4054,4055,4056],[4034,4058,4059,4060],{"trials":4080,"activeCount":100},[],{"intervention":4059,"totalTrials":129,"cells":4082},{"EARLY_PHASE1":4083,"PHASE1":4085,"PHASE2":4087,"PHASE3":4089,"PHASE4":4091,"NA":4097},{"trials":4084,"activeCount":100},[],{"trials":4086,"activeCount":100},[],{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[4093],{"nctId":4047,"briefTitle":4048,"status":119,"phases":4094,"primaryCompletion":4050,"completion":4050,"start":4051,"enrollment":4052,"conditions":4095,"interventions":4096},[91],[4054,4055,4056],[4034,4058,4059,4060],{"trials":4098,"activeCount":100},[],{"intervention":4060,"totalTrials":129,"cells":4100},{"EARLY_PHASE1":4101,"PHASE1":4103,"PHASE2":4105,"PHASE3":4107,"PHASE4":4109,"NA":4115},{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[],{"trials":4110,"activeCount":100},[4111],{"nctId":4047,"briefTitle":4048,"status":119,"phases":4112,"primaryCompletion":4050,"completion":4050,"start":4051,"enrollment":4052,"conditions":4113,"interventions":4114},[91],[4054,4055,4056],[4034,4058,4059,4060],{"trials":4116,"activeCount":100},[],{"intervention":2691,"totalTrials":129,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4125,"PHASE4":4127,"NA":4133},{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"trials":4128,"activeCount":100},[4129],{"nctId":2682,"briefTitle":2683,"status":150,"phases":4130,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":1394,"conditions":4131,"interventions":4132},[91],[2688,2689],[2653,2691],{"trials":4134,"activeCount":100},[],{"intervention":4136,"totalTrials":129,"cells":4137},"Multi-drug local anesthetics",{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4144,"PHASE4":4146,"NA":4160},{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[],{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[4148],{"nctId":4149,"briefTitle":4150,"status":415,"phases":4151,"primaryCompletion":2719,"completion":4152,"start":4153,"enrollment":100,"conditions":4154,"interventions":4158},"NCT03105674","Multi-Drug Analgesia vs. Standard Solution for Anal Surgery",[91],"2017-12","2017-05-01",[4155,4156,4157],"Hemorrhoids","Fissure in Ano","Fistula;Rectal",[4136,4159],"Standard local anesthetics",{"trials":4161,"activeCount":100},[],{"intervention":4159,"totalTrials":129,"cells":4163},{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4170,"PHASE4":4172,"NA":4178},{"trials":4165,"activeCount":100},[],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"trials":4171,"activeCount":100},[],{"trials":4173,"activeCount":100},[4174],{"nctId":4149,"briefTitle":4150,"status":415,"phases":4175,"primaryCompletion":2719,"completion":4152,"start":4153,"enrollment":100,"conditions":4176,"interventions":4177},[91],[4155,4156,4157],[4136,4159],{"trials":4179,"activeCount":100},[],{"intervention":4181,"totalTrials":129,"cells":4182},"Suvorexant",{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4189,"PHASE4":4191,"NA":4204},{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":100},[],{"trials":4190,"activeCount":100},[],{"trials":4192,"activeCount":100},[4193],{"nctId":4194,"briefTitle":4195,"status":4196,"phases":4197,"primaryCompletion":4198,"completion":4198,"start":350,"enrollment":4199,"conditions":4200,"interventions":4203},"NCT05823844","Efficacy of Suvorexant on Post-operative Sleep Disturbance","UNKNOWN",[91],"2025-05",92,[4201,4202],"Postoperative Insomnia","Postoperative Delirium",[4181],{"trials":4205,"activeCount":100},[],{"intervention":4207,"totalTrials":129,"cells":4208},"Desflurane",{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4217,"NA":4230},{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"trials":4218,"activeCount":100},[4219],{"nctId":4220,"briefTitle":4221,"status":119,"phases":4222,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":864,"conditions":4226,"interventions":4228},"NCT04226625","Effects of Desflurane and Propofol During Lung Volume Reduction Surgery",[91],"2001-03-21","2002-03-21","2000-01-31",[4227],"Lung Volume Reduction Surgery",[4229,4207],"Propofol",{"trials":4231,"activeCount":100},[],{"intervention":4233,"totalTrials":129,"cells":4234},"levonorgestrel IUS",{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4239,"PHASE3":4241,"PHASE4":4243,"NA":4254},{"trials":4236,"activeCount":100},[],{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":100},[],{"trials":4244,"activeCount":100},[4245],{"nctId":4246,"briefTitle":4247,"status":119,"phases":4248,"primaryCompletion":4249,"completion":4249,"start":136,"enrollment":821,"conditions":4250,"interventions":4253},"NCT02362373","Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users",[91],"2014-01",[4251,4252],"Epilepsy","Contraception",[4233],{"trials":4255,"activeCount":100},[],{"intervention":4257,"totalTrials":129,"cells":4258},"Belviq",{"EARLY_PHASE1":4259,"PHASE1":4261,"PHASE2":4263,"PHASE3":4265,"PHASE4":4267,"NA":4277},{"trials":4260,"activeCount":100},[],{"trials":4262,"activeCount":100},[],{"trials":4264,"activeCount":100},[],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[4269],{"nctId":4270,"briefTitle":4271,"status":150,"phases":4272,"primaryCompletion":4273,"completion":4273,"start":4274,"enrollment":2097,"conditions":4275,"interventions":4276},"NCT03353220","Predictors of Lorcaserin-Induced Weight Loss",[91],"2020-02-14","2018-01-03",[1516],[4257],{"trials":4278,"activeCount":100},[],{"intervention":4280,"totalTrials":129,"cells":4281},"capsaicin",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4288,"PHASE4":4290,"NA":4302},{"trials":4283,"activeCount":100},[],{"trials":4285,"activeCount":100},[],{"trials":4287,"activeCount":100},[],{"trials":4289,"activeCount":100},[],{"trials":4291,"activeCount":100},[4292],{"nctId":4293,"briefTitle":4294,"status":415,"phases":4295,"primaryCompletion":4296,"completion":4296,"start":4297,"enrollment":100,"conditions":4298,"interventions":4301},"NCT00771511","Cervical Capsaicin for Labor Induction and Pain Relief",[91],"2011-06","2010-10",[259,4299,4300],"Pregnancy Loss","Labor Induction",[4280],{"trials":4303,"activeCount":100},[],{"intervention":2574,"totalTrials":129,"cells":4305},{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4312,"PHASE4":4314,"NA":4320},{"trials":4307,"activeCount":100},[],{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"trials":4313,"activeCount":100},[],{"trials":4315,"activeCount":100},[4316],{"nctId":2564,"briefTitle":2565,"status":119,"phases":4317,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":2569,"conditions":4318,"interventions":4319},[91],[2571,2572],[2574,2530,261,2547],{"trials":4321,"activeCount":100},[],{"intervention":4323,"totalTrials":129,"cells":4324},"Gardasil ® 9",{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4329,"PHASE3":4331,"PHASE4":4333,"NA":4347},{"trials":4326,"activeCount":100},[],{"trials":4328,"activeCount":100},[],{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":100},[],{"trials":4334,"activeCount":100},[4335],{"nctId":4336,"briefTitle":4337,"status":119,"phases":4338,"primaryCompletion":4339,"completion":4339,"start":4340,"enrollment":4341,"conditions":4342,"interventions":4346},"NCT04982614","HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini",[91],"2024-12-09","2022-04-01",1403,[4343,4344,4345],"HPV Infection","Hiv","HPV Vaccine",[4323],{"trials":4348,"activeCount":100},[],{"intervention":4350,"totalTrials":129,"cells":4351},"Ticagrelor 90 mg twice per day",{"EARLY_PHASE1":4352,"PHASE1":4354,"PHASE2":4356,"PHASE3":4358,"PHASE4":4360,"NA":4373},{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[4362],{"nctId":4363,"briefTitle":4364,"status":119,"phases":4365,"primaryCompletion":4366,"completion":4366,"start":4367,"enrollment":351,"conditions":4368,"interventions":4372},"NCT02518464","Ticagrelor Therapy for RefrACTORy Migraine Study",[91],"2017-10","2015-10",[4369,4370,4371],"Migraine","Headache","Migraine Headache",[4350],{"trials":4374,"activeCount":100},[],{"intervention":4376,"totalTrials":129,"cells":4377},"Choline",{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4384,"PHASE4":4386,"NA":4396},{"trials":4379,"activeCount":100},[],{"trials":4381,"activeCount":100},[],{"trials":4383,"activeCount":100},[],{"trials":4385,"activeCount":100},[],{"trials":4387,"activeCount":100},[4388],{"nctId":4389,"briefTitle":4390,"status":119,"phases":4391,"primaryCompletion":4296,"completion":3190,"start":4392,"enrollment":2218,"conditions":4393,"interventions":4395},"NCT00720343","Effect of Oral Choline Supplementation on Postoperative Pain",[91],"2009-02",[2630,4394],"Inflammation",[4376],{"trials":4397,"activeCount":100},[],{"intervention":4399,"totalTrials":129,"cells":4400},"Tesamorelin",{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4405,"PHASE3":4407,"PHASE4":4409,"NA":4420},{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[],{"trials":4406,"activeCount":100},[],{"trials":4408,"activeCount":100},[],{"trials":4410,"activeCount":100},[4411],{"nctId":4412,"briefTitle":4413,"status":150,"phases":4414,"primaryCompletion":444,"completion":444,"start":4415,"enrollment":96,"conditions":4416,"interventions":4419},"NCT03226821","Body Composition and Adipose Tissue in HIV",[91],"2018-02-07",[4417,354,4418],"HIV Lipodystrophy Syndrome","Body Composition",[4399],{"trials":4421,"activeCount":100},[],{"intervention":4423,"totalTrials":129,"cells":4424},"Intravenous Ibuprofen",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4444},{"trials":4426,"activeCount":100},[],{"trials":4428,"activeCount":100},[],{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"trials":4434,"activeCount":100},[4435],{"nctId":4436,"briefTitle":4437,"status":150,"phases":4438,"primaryCompletion":4439,"completion":4439,"start":735,"enrollment":2466,"conditions":4440,"interventions":4442},"NCT01530880","Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage",[91],"2016-03-17",[4441],"Fever",[4423,4443],"Acetaminophen",{"trials":4445,"activeCount":100},[],{"intervention":4447,"totalTrials":129,"cells":4448},"Choline bitartrate",{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4455,"PHASE4":4457,"NA":4469},{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":100},[],{"trials":4456,"activeCount":100},[],{"trials":4458,"activeCount":100},[4459],{"nctId":4460,"briefTitle":4461,"status":119,"phases":4462,"primaryCompletion":1071,"completion":4463,"start":3190,"enrollment":2218,"conditions":4464,"interventions":4466},"NCT01749982","A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh",[91],"2014-08",[4465],"Arsenic Metabolites Measured in Urine",[4447,4467,4468],"Betaine","Choline bitartrate + Betaine",{"trials":4470,"activeCount":100},[],{"intervention":4467,"totalTrials":129,"cells":4472},{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4477,"PHASE3":4479,"PHASE4":4481,"NA":4487},{"trials":4474,"activeCount":100},[],{"trials":4476,"activeCount":100},[],{"trials":4478,"activeCount":100},[],{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[4483],{"nctId":4460,"briefTitle":4461,"status":119,"phases":4484,"primaryCompletion":1071,"completion":4463,"start":3190,"enrollment":2218,"conditions":4485,"interventions":4486},[91],[4465],[4447,4467,4468],{"trials":4488,"activeCount":100},[],{"intervention":4468,"totalTrials":129,"cells":4490},{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4495,"PHASE3":4497,"PHASE4":4499,"NA":4505},{"trials":4492,"activeCount":100},[],{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[4501],{"nctId":4460,"briefTitle":4461,"status":119,"phases":4502,"primaryCompletion":1071,"completion":4463,"start":3190,"enrollment":2218,"conditions":4503,"interventions":4504},[91],[4465],[4447,4467,4468],{"trials":4506,"activeCount":100},[],{"intervention":4508,"totalTrials":129,"cells":4509},"TNF inhibitors",{"EARLY_PHASE1":4510,"PHASE1":4512,"PHASE2":4514,"PHASE3":4516,"PHASE4":4518,"NA":4530},{"trials":4511,"activeCount":100},[],{"trials":4513,"activeCount":100},[],{"trials":4515,"activeCount":100},[],{"trials":4517,"activeCount":100},[],{"trials":4519,"activeCount":100},[4520],{"nctId":4521,"briefTitle":4522,"status":119,"phases":4523,"primaryCompletion":4524,"completion":4524,"start":4525,"enrollment":4526,"conditions":4527,"interventions":4528},"NCT01548768","RHYTHM (Formerly Escape II Myocardium)",[91],"2019-09","2011-10-10",149,[2688],[4508,4529],"DMARDs",{"trials":4531,"activeCount":100},[],{"intervention":4529,"totalTrials":129,"cells":4533},{"EARLY_PHASE1":4534,"PHASE1":4536,"PHASE2":4538,"PHASE3":4540,"PHASE4":4542,"NA":4548},{"trials":4535,"activeCount":100},[],{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[4544],{"nctId":4521,"briefTitle":4522,"status":119,"phases":4545,"primaryCompletion":4524,"completion":4524,"start":4525,"enrollment":4526,"conditions":4546,"interventions":4547},[91],[2688],[4508,4529],{"trials":4549,"activeCount":100},[],{"intervention":4551,"totalTrials":129,"cells":4552},"Sandostatin LAR",{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4559,"PHASE4":4561,"NA":4572},{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[4563],{"nctId":4564,"briefTitle":4565,"status":119,"phases":4566,"primaryCompletion":1071,"completion":4249,"start":4567,"enrollment":4568,"conditions":4569,"interventions":4571},"NCT01424241","Effects of Sandostatin LAR® in Acromegaly",[91],"2006-10",21,[4570],"Acromegaly",[4551],{"trials":4573,"activeCount":100},[],{"intervention":4575,"totalTrials":129,"cells":4576},"LNG-EC",{"EARLY_PHASE1":4577,"PHASE1":4579,"PHASE2":4581,"PHASE3":4583,"PHASE4":4585,"NA":4598},{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"trials":4584,"activeCount":100},[],{"trials":4586,"activeCount":100},[4587],{"nctId":4588,"briefTitle":4589,"status":119,"phases":4590,"primaryCompletion":4591,"completion":4592,"start":4593,"enrollment":4594,"conditions":4595,"interventions":4596},"NCT02689804","EC PK in Women With Normal and Obese BMI",[91],"2015-12-29","2017-02-03","2015-07-10",34,[4252],[4575,4597],"UPA-EC",{"trials":4599,"activeCount":100},[],{"intervention":4597,"totalTrials":129,"cells":4601},{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4616},{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":100},[],{"trials":4609,"activeCount":100},[],{"trials":4611,"activeCount":100},[4612],{"nctId":4588,"briefTitle":4589,"status":119,"phases":4613,"primaryCompletion":4591,"completion":4592,"start":4593,"enrollment":4594,"conditions":4614,"interventions":4615},[91],[4252],[4575,4597],{"trials":4617,"activeCount":100},[],{"intervention":4619,"totalTrials":846,"cells":4620},"Alendronate",{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4637,"PHASE4":4662,"NA":4664},{"trials":4622,"activeCount":100},[],{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[4627],{"nctId":4628,"briefTitle":4629,"status":119,"phases":4630,"primaryCompletion":4631,"completion":4631,"start":4632,"enrollment":24,"conditions":4633,"interventions":4635},"NCT03396315","Bisphosphonates for Prevention of Post-Denosumab Bone Loss",[89],"2023-06-09","2018-01-29",[4634,2723],"IOP",[4619,4636],"Zoledronic Acid",{"trials":4638,"activeCount":100},[4639,4649],{"nctId":4640,"briefTitle":4641,"status":119,"phases":4642,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4526,"conditions":4645,"interventions":4647},"NCT00000412","Osteoporosis Prevention After Heart Transplant",[90],"2002-04","1997-09",[2723,4646],"Cardiac Transplantation",[4619,4648],"Calcitriol",{"nctId":4650,"briefTitle":4651,"status":119,"phases":4652,"primaryCompletion":4653,"completion":4249,"start":4654,"enrollment":4655,"conditions":4656,"interventions":4660},"NCT00297830","Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation",[89,90],"2010-04","2005-11",111,[4657,4658,4659],"Heart Transplantation","Liver Transplantation","Bone Resorption",[4661,4619],"Zoledronic acid",{"trials":4663,"activeCount":100},[],{"trials":4665,"activeCount":100},[],{"intervention":4648,"totalTrials":226,"cells":4667},{"EARLY_PHASE1":4668,"PHASE1":4670,"PHASE2":4672,"PHASE3":4689,"PHASE4":4695,"NA":4697},{"trials":4669,"activeCount":100},[],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[4674],{"nctId":4675,"briefTitle":4676,"status":119,"phases":4677,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":4680,"conditions":4681,"interventions":4687},"NCT02224144","Bone Mass and Strength After Kidney Transplantation",[89],"2016-10-12","2014-08-18",61,[4682,4683,4684,4685,4686],"End Stage Renal Disease","Kidney Transplantation","Bone Loss","Fractures","Vascular Calcifications",[4688,4648],"Vitamin D3",{"trials":4690,"activeCount":100},[4691],{"nctId":4640,"briefTitle":4641,"status":119,"phases":4692,"primaryCompletion":4643,"completion":4643,"start":4644,"enrollment":4526,"conditions":4693,"interventions":4694},[90],[2723,4646],[4619,4648],{"trials":4696,"activeCount":100},[],{"trials":4698,"activeCount":100},[],{"intervention":4700,"totalTrials":226,"cells":4701},"Hydroxychloroquine",{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4706,"PHASE3":4719,"PHASE4":4730,"NA":4732},{"trials":4703,"activeCount":100},[],{"trials":4705,"activeCount":100},[],{"trials":4707,"activeCount":100},[4708],{"nctId":4709,"briefTitle":4710,"status":150,"phases":4711,"primaryCompletion":4712,"completion":4713,"start":435,"enrollment":19,"conditions":4714,"interventions":4716},"NCT04214418","Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies",[88,89],"2022-04-11","2022-07-01",[4715],"Gastrointestinal Cancer",[4717,4700,4718],"Cobimetinib","Atezolizumab",{"trials":4720,"activeCount":100},[4721],{"nctId":4722,"briefTitle":4723,"status":150,"phases":4724,"primaryCompletion":4725,"completion":4725,"start":4726,"enrollment":1735,"conditions":4727,"interventions":4729},"NCT04318444","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)",[89,90],"2021-03-31","2020-03-29",[4054,4728],"Corona Virus Infection",[4700],{"trials":4731,"activeCount":100},[],{"trials":4733,"activeCount":100},[],{"intervention":4735,"totalTrials":226,"cells":4736},"Sertraline",{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4751,"PHASE3":4753,"PHASE4":4765,"NA":4767},{"trials":4738,"activeCount":100},[],{"trials":4740,"activeCount":100},[4741],{"nctId":4742,"briefTitle":4743,"status":119,"phases":4744,"primaryCompletion":4745,"completion":4745,"start":4746,"enrollment":96,"conditions":4747,"interventions":4749},"NCT02891278","Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML",[88],"2020-11-17","2016-08-11",[4748],"Acute Myeloid Leukemia",[4735,4750],"Cytosine arabinoside",{"trials":4752,"activeCount":100},[],{"trials":4754,"activeCount":100},[4755],{"nctId":4756,"briefTitle":4757,"status":119,"phases":4758,"primaryCompletion":4759,"completion":2645,"start":4760,"enrollment":3106,"conditions":4761,"interventions":4763},"NCT00026637","Depression and Health Outcomes in Refractory Epilepsy",[90],"2007-06","2001-08",[4762,4251],"Depression",[4764],"sertraline",{"trials":4766,"activeCount":100},[],{"trials":4768,"activeCount":100},[],{"intervention":4770,"totalTrials":226,"cells":4771},"Teriparatide",{"EARLY_PHASE1":4772,"PHASE1":4774,"PHASE2":4776,"PHASE3":4778,"PHASE4":4800,"NA":4802},{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":100},[],{"trials":4777,"activeCount":100},[],{"trials":4779,"activeCount":100},[4780,4789],{"nctId":4781,"briefTitle":4782,"status":119,"phases":4783,"primaryCompletion":2542,"completion":2542,"start":4784,"enrollment":4785,"conditions":4786,"interventions":4787},"NCT01611571","Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis",[90],"2003-12",31,[2723],[4788,4770],"Risedronate",{"nctId":4790,"briefTitle":4791,"status":119,"phases":4792,"primaryCompletion":4793,"completion":4793,"start":4794,"enrollment":4795,"conditions":4796,"interventions":4799},"NCT00697463","Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women",[89,90],"2012-01-03","2008-08-20",22,[4797,4798,2723],"Menopause","Fracture",[4770],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[],{"intervention":2446,"totalTrials":226,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4812,"PHASE2":4814,"PHASE3":4816,"PHASE4":4829,"NA":4831},{"trials":4807,"activeCount":100},[4808],{"nctId":2437,"briefTitle":2438,"status":119,"phases":4809,"primaryCompletion":2440,"completion":40,"start":2441,"enrollment":1419,"conditions":4810,"interventions":4811},[87],[23,2443,2444],[2431,2446],{"trials":4813,"activeCount":100},[],{"trials":4815,"activeCount":100},[],{"trials":4817,"activeCount":100},[4818],{"nctId":4819,"briefTitle":4820,"status":150,"phases":4821,"primaryCompletion":4822,"completion":4822,"start":4823,"enrollment":4785,"conditions":4824,"interventions":4827},"NCT02850081","Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes",[90],"2020-03-31","2017-06-01",[4825,4826],"Carotid Artery Stenosis","Strokes",[4828,2446],"Statin",{"trials":4830,"activeCount":100},[],{"trials":4832,"activeCount":100},[],{"intervention":4636,"totalTrials":226,"cells":4834},{"EARLY_PHASE1":4835,"PHASE1":4837,"PHASE2":4839,"PHASE3":4845,"PHASE4":4851,"NA":4853},{"trials":4836,"activeCount":100},[],{"trials":4838,"activeCount":100},[],{"trials":4840,"activeCount":100},[4841],{"nctId":4628,"briefTitle":4629,"status":119,"phases":4842,"primaryCompletion":4631,"completion":4631,"start":4632,"enrollment":24,"conditions":4843,"interventions":4844},[89],[4634,2723],[4619,4636],{"trials":4846,"activeCount":100},[4847],{"nctId":4650,"briefTitle":4651,"status":119,"phases":4848,"primaryCompletion":4653,"completion":4249,"start":4654,"enrollment":4655,"conditions":4849,"interventions":4850},[89,90],[4657,4658,4659],[4661,4619],{"trials":4852,"activeCount":100},[],{"trials":4854,"activeCount":100},[],{"intervention":4856,"totalTrials":129,"cells":4857},"Sodium selenate",{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4864,"PHASE4":4874,"NA":4876},{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[4866],{"nctId":4867,"briefTitle":4868,"status":415,"phases":4869,"primaryCompletion":4870,"completion":4870,"start":4367,"enrollment":100,"conditions":4871,"interventions":4873},"NCT02112643","Selenium in Mild Thyroid Eye Disease in North America",[90],"2016-11-16",[4872],"Thyroid Associated Ophthalmopathies",[4856],{"trials":4875,"activeCount":100},[],{"trials":4877,"activeCount":100},[],{"intervention":4879,"totalTrials":129,"cells":4880},"Furosemide",{"EARLY_PHASE1":4881,"PHASE1":4883,"PHASE2":4885,"PHASE3":4887,"PHASE4":4900,"NA":4902},{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"trials":4886,"activeCount":100},[],{"trials":4888,"activeCount":100},[4889],{"nctId":4890,"briefTitle":4891,"status":119,"phases":4892,"primaryCompletion":4893,"completion":4894,"start":4895,"enrollment":4896,"conditions":4897,"interventions":4899},"NCT04752475","Lasix for the Prevention of De Novo Postpartum Hypertension",[90],"2022-04-18","2022-05-28","2021-10-20",82,[3423,3424,4898,3631],"Hypertension, Pregnancy-Induced",[4879],{"trials":4901,"activeCount":100},[],{"trials":4903,"activeCount":100},[],{"intervention":4905,"totalTrials":129,"cells":4906},"Intranasal Fentanyl",{"EARLY_PHASE1":4907,"PHASE1":4909,"PHASE2":4911,"PHASE3":4913,"PHASE4":4924,"NA":4926},{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[4915],{"nctId":4916,"briefTitle":4917,"status":119,"phases":4918,"primaryCompletion":4919,"completion":4919,"start":3036,"enrollment":821,"conditions":4920,"interventions":4922},"NCT01549002","Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children",[90],"2013-04",[4921,625],"Abscess",[4905,4923],"Intravenous Morphine",{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[],{"intervention":4923,"totalTrials":129,"cells":4929},{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4936,"PHASE4":4942,"NA":4944},{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[4938],{"nctId":4916,"briefTitle":4917,"status":119,"phases":4939,"primaryCompletion":4919,"completion":4919,"start":3036,"enrollment":821,"conditions":4940,"interventions":4941},[90],[4921,625],[4905,4923],{"trials":4943,"activeCount":100},[],{"trials":4945,"activeCount":100},[],{"intervention":4947,"totalTrials":129,"cells":4948},"Ketorolac, intranasal",{"EARLY_PHASE1":4949,"PHASE1":4951,"PHASE2":4953,"PHASE3":4955,"PHASE4":4966,"NA":4968},{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[4957],{"nctId":4958,"briefTitle":4959,"status":119,"phases":4960,"primaryCompletion":4725,"completion":4725,"start":4961,"enrollment":4962,"conditions":4963,"interventions":4964},"NCT02358681","Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children",[90],"2015-06-16",59,[4369],[4947,4965],"Ketorolac, intravenous",{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[],{"intervention":4965,"totalTrials":129,"cells":4971},{"EARLY_PHASE1":4972,"PHASE1":4974,"PHASE2":4976,"PHASE3":4978,"PHASE4":4984,"NA":4986},{"trials":4973,"activeCount":100},[],{"trials":4975,"activeCount":100},[],{"trials":4977,"activeCount":100},[],{"trials":4979,"activeCount":100},[4980],{"nctId":4958,"briefTitle":4959,"status":119,"phases":4981,"primaryCompletion":4725,"completion":4725,"start":4961,"enrollment":4962,"conditions":4982,"interventions":4983},[90],[4369],[4947,4965],{"trials":4985,"activeCount":100},[],{"trials":4987,"activeCount":100},[],{"intervention":4989,"totalTrials":129,"cells":4990},"Neoadjuvant gemcitabine, capecitabine, and docetaxel",{"EARLY_PHASE1":4991,"PHASE1":4993,"PHASE2":4995,"PHASE3":4997,"PHASE4":5008,"NA":5010},{"trials":4992,"activeCount":100},[],{"trials":4994,"activeCount":100},[],{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[4999],{"nctId":5000,"briefTitle":5001,"status":4196,"phases":5002,"primaryCompletion":479,"start":2745,"enrollment":2504,"conditions":5003,"interventions":5006},"NCT01065870","Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II\u002FIII)",[89,90],[5004,5005],"Pancreatic Cancer Stage II","Pancreatic Cancer Stage III",[4989,5007],"Gemcitabine, capecitabine, docetaxel followed by radiotherapy",{"trials":5009,"activeCount":100},[],{"trials":5011,"activeCount":100},[],{"intervention":5007,"totalTrials":129,"cells":5013},{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5018,"PHASE3":5020,"PHASE4":5026,"NA":5028},{"trials":5015,"activeCount":100},[],{"trials":5017,"activeCount":100},[],{"trials":5019,"activeCount":100},[],{"trials":5021,"activeCount":100},[5022],{"nctId":5000,"briefTitle":5001,"status":4196,"phases":5023,"primaryCompletion":479,"start":2745,"enrollment":2504,"conditions":5024,"interventions":5025},[89,90],[5004,5005],[4989,5007],{"trials":5027,"activeCount":100},[],{"trials":5029,"activeCount":100},[],{"intervention":5031,"totalTrials":129,"cells":5032},"Carvedilol-CR",{"EARLY_PHASE1":5033,"PHASE1":5035,"PHASE2":5037,"PHASE3":5039,"PHASE4":5047,"NA":5049},{"trials":5034,"activeCount":100},[],{"trials":5036,"activeCount":100},[],{"trials":5038,"activeCount":100},[],{"trials":5040,"activeCount":100},[5041],{"nctId":5042,"briefTitle":5043,"status":150,"phases":5044,"primaryCompletion":4297,"completion":4297,"start":3308,"enrollment":96,"conditions":5045,"interventions":5046},"NCT00524134","P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.",[89,90],[4251],[5031],{"trials":5048,"activeCount":100},[],{"trials":5050,"activeCount":100},[],{"intervention":4788,"totalTrials":129,"cells":5052},{"EARLY_PHASE1":5053,"PHASE1":5055,"PHASE2":5057,"PHASE3":5059,"PHASE4":5065,"NA":5067},{"trials":5054,"activeCount":100},[],{"trials":5056,"activeCount":100},[],{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":100},[5061],{"nctId":4781,"briefTitle":4782,"status":119,"phases":5062,"primaryCompletion":2542,"completion":2542,"start":4784,"enrollment":4785,"conditions":5063,"interventions":5064},[90],[2723],[4788,4770],{"trials":5066,"activeCount":100},[],{"trials":5068,"activeCount":100},[],{"intervention":5070,"totalTrials":129,"cells":5071},"Dysport Injectable Product",{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5078,"PHASE4":5088,"NA":5090},{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[],{"trials":5077,"activeCount":100},[],{"trials":5079,"activeCount":100},[5080],{"nctId":5081,"briefTitle":5082,"status":119,"phases":5083,"primaryCompletion":5084,"completion":5084,"start":5085,"enrollment":796,"conditions":5086,"interventions":5087},"NCT03469999","Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy",[90],"2021-05-26","2018-12-12",[3062],[5070],{"trials":5089,"activeCount":100},[],{"trials":5091,"activeCount":100},[],{"intervention":5093,"totalTrials":129,"cells":5094},"Milnacipran",{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5101,"PHASE4":5112,"NA":5114},{"trials":5096,"activeCount":100},[],{"trials":5098,"activeCount":100},[],{"trials":5100,"activeCount":100},[],{"trials":5102,"activeCount":100},[5103],{"nctId":5104,"briefTitle":5105,"status":150,"phases":5106,"primaryCompletion":908,"completion":5107,"start":5108,"enrollment":96,"conditions":5109,"interventions":5111},"NCT01288937","A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain",[90],"2014-12-23","2011-04-05",[5110],"Idiopathic Peripheral Neuropathy",[5093],{"trials":5113,"activeCount":100},[],{"trials":5115,"activeCount":100},[],{"intervention":5117,"totalTrials":129,"cells":5118},"Vancomycin",{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5123,"PHASE3":5125,"PHASE4":5139,"NA":5141},{"trials":5120,"activeCount":100},[],{"trials":5122,"activeCount":100},[],{"trials":5124,"activeCount":100},[],{"trials":5126,"activeCount":100},[5127],{"nctId":5128,"briefTitle":5129,"status":119,"phases":5130,"primaryCompletion":5131,"completion":5132,"start":907,"enrollment":5133,"conditions":5134,"interventions":5138},"NCT02284126","Topical Vancomycin for Neurosurgery Wound Prophylaxis",[90],"2019-11","2020-11",1103,[5135,5136,5137],"Infection","Surgery","Nervous System Diseases",[5117],{"trials":5140,"activeCount":100},[],{"trials":5142,"activeCount":100},[],{"intervention":5144,"totalTrials":129,"cells":5145},"Aspirin 650mg Oral",{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5152,"PHASE4":5164,"NA":5166},{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[],{"trials":5153,"activeCount":100},[5154],{"nctId":5155,"briefTitle":5156,"status":119,"phases":5157,"primaryCompletion":5158,"completion":5158,"start":5159,"enrollment":2218,"conditions":5160,"interventions":5162},"NCT03824938","Aspirin for Exercise in Multiple Sclerosis (ASPIRE)",[90],"2022-02-28","2019-04-30",[5161],"Multiple Sclerosis",[5144,5163],"Acetaminophen Tablet 650mg",{"trials":5165,"activeCount":100},[],{"trials":5167,"activeCount":100},[],{"intervention":5163,"totalTrials":129,"cells":5169},{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5176,"PHASE4":5182,"NA":5184},{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[5178],{"nctId":5155,"briefTitle":5156,"status":119,"phases":5179,"primaryCompletion":5158,"completion":5158,"start":5159,"enrollment":2218,"conditions":5180,"interventions":5181},[90],[5161],[5144,5163],{"trials":5183,"activeCount":100},[],{"trials":5185,"activeCount":100},[],{"intervention":5187,"totalTrials":129,"cells":5188},"Active Aspirin",{"EARLY_PHASE1":5189,"PHASE1":5191,"PHASE2":5193,"PHASE3":5195,"PHASE4":5208,"NA":5210},{"trials":5190,"activeCount":100},[],{"trials":5192,"activeCount":100},[],{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[5197],{"nctId":5198,"briefTitle":5199,"status":119,"phases":5200,"primaryCompletion":176,"completion":5201,"start":177,"enrollment":5202,"conditions":5203,"interventions":5204},"NCT00027066","Warfarin Versus Aspirin Recurrent Stroke Study",[90],"2001-11",2206,[18],[5187,5205,5206,5207],"Active Warfarin","Aspirin placebo","Warfarin placebo",{"trials":5209,"activeCount":100},[],{"trials":5211,"activeCount":100},[],{"intervention":5205,"totalTrials":129,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5220,"PHASE4":5226,"NA":5228},{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[],{"trials":5221,"activeCount":100},[5222],{"nctId":5198,"briefTitle":5199,"status":119,"phases":5223,"primaryCompletion":176,"completion":5201,"start":177,"enrollment":5202,"conditions":5224,"interventions":5225},[90],[18],[5187,5205,5206,5207],{"trials":5227,"activeCount":100},[],{"trials":5229,"activeCount":100},[],{"intervention":5206,"totalTrials":129,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5238,"PHASE4":5244,"NA":5246},{"trials":5233,"activeCount":100},[],{"trials":5235,"activeCount":100},[],{"trials":5237,"activeCount":100},[],{"trials":5239,"activeCount":100},[5240],{"nctId":5198,"briefTitle":5199,"status":119,"phases":5241,"primaryCompletion":176,"completion":5201,"start":177,"enrollment":5202,"conditions":5242,"interventions":5243},[90],[18],[5187,5205,5206,5207],{"trials":5245,"activeCount":100},[],{"trials":5247,"activeCount":100},[],{"intervention":5207,"totalTrials":129,"cells":5249},{"EARLY_PHASE1":5250,"PHASE1":5252,"PHASE2":5254,"PHASE3":5256,"PHASE4":5262,"NA":5264},{"trials":5251,"activeCount":100},[],{"trials":5253,"activeCount":100},[],{"trials":5255,"activeCount":100},[],{"trials":5257,"activeCount":100},[5258],{"nctId":5198,"briefTitle":5199,"status":119,"phases":5259,"primaryCompletion":176,"completion":5201,"start":177,"enrollment":5202,"conditions":5260,"interventions":5261},[90],[18],[5187,5205,5206,5207],{"trials":5263,"activeCount":100},[],{"trials":5265,"activeCount":100},[],{"intervention":5267,"totalTrials":129,"cells":5268},"4-aminopyridine",{"EARLY_PHASE1":5269,"PHASE1":5271,"PHASE2":5273,"PHASE3":5275,"PHASE4":5285,"NA":5287},{"trials":5270,"activeCount":100},[],{"trials":5272,"activeCount":100},[],{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[5277],{"nctId":5278,"briefTitle":5279,"status":119,"phases":5280,"primaryCompletion":844,"completion":844,"start":5281,"enrollment":1394,"conditions":5282,"interventions":5284},"NCT01645787","Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients",[89,90],"2012-06-01",[5283],"Spinal Muscular Atrophy",[5267],{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"intervention":5290,"totalTrials":129,"cells":5291},"SSKI- Potassium Iodide",{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5298,"PHASE4":5309,"NA":5311},{"trials":5293,"activeCount":100},[],{"trials":5295,"activeCount":100},[],{"trials":5297,"activeCount":100},[],{"trials":5299,"activeCount":100},[5300],{"nctId":5301,"briefTitle":5302,"status":150,"phases":5303,"primaryCompletion":5304,"completion":5304,"start":5305,"enrollment":1073,"conditions":5306,"interventions":5308},"NCT04080505","Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?",[90],"2023-03-03","2015-02-10",[5307],"Graves Disease",[5290],{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[],{"intervention":954,"totalTrials":129,"cells":5314},{"EARLY_PHASE1":5315,"PHASE1":5317,"PHASE2":5319,"PHASE3":5321,"PHASE4":5327,"NA":5329},{"trials":5316,"activeCount":100},[],{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[],{"trials":5322,"activeCount":100},[5323],{"nctId":942,"briefTitle":943,"status":119,"phases":5324,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":5325,"interventions":5326},[89,90],[949,950,951,952],[851,927,50,853,954,955],{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[],{"intervention":955,"totalTrials":129,"cells":5332},{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5337,"PHASE3":5339,"PHASE4":5345,"NA":5347},{"trials":5334,"activeCount":100},[],{"trials":5336,"activeCount":100},[],{"trials":5338,"activeCount":100},[],{"trials":5340,"activeCount":100},[5341],{"nctId":942,"briefTitle":943,"status":119,"phases":5342,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":5343,"interventions":5344},[89,90],[949,950,951,952],[851,927,50,853,954,955],{"trials":5346,"activeCount":100},[],{"trials":5348,"activeCount":100},[],{"intervention":5350,"totalTrials":129,"cells":5351},"Glutamine and Fish Oil Supplementation",{"EARLY_PHASE1":5352,"PHASE1":5354,"PHASE2":5356,"PHASE3":5358,"PHASE4":5367,"NA":5369},{"trials":5353,"activeCount":100},[],{"trials":5355,"activeCount":100},[],{"trials":5357,"activeCount":100},[],{"trials":5359,"activeCount":100},[5360],{"nctId":5361,"briefTitle":5362,"status":119,"phases":5363,"primaryCompletion":5364,"completion":137,"start":2542,"enrollment":4785,"conditions":5365,"interventions":5366},"NCT01534663","Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure",[89,90],"2013-07",[32],[5350],{"trials":5368,"activeCount":100},[],{"trials":5370,"activeCount":100},[],{"intervention":5372,"totalTrials":129,"cells":5373},"Lopinavir\u002Fritonavir",{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5380,"PHASE4":5393,"NA":5395},{"trials":5375,"activeCount":100},[],{"trials":5377,"activeCount":100},[],{"trials":5379,"activeCount":100},[],{"trials":5381,"activeCount":100},[5382],{"nctId":5383,"briefTitle":5384,"status":119,"phases":5385,"primaryCompletion":479,"completion":479,"start":5386,"enrollment":5387,"conditions":5388,"interventions":5389},"NCT01146873","Treatment Options for Protease Inhibitor-exposed Children",[90],"2010-07",300,[26,29],[5390,5372,5391,5392],"Efavirenz","Stavudine","Abacavir",{"trials":5394,"activeCount":100},[],{"trials":5396,"activeCount":100},[],{"intervention":5391,"totalTrials":129,"cells":5398},{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5403,"PHASE3":5405,"PHASE4":5411,"NA":5413},{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[],{"trials":5404,"activeCount":100},[],{"trials":5406,"activeCount":100},[5407],{"nctId":5383,"briefTitle":5384,"status":119,"phases":5408,"primaryCompletion":479,"completion":479,"start":5386,"enrollment":5387,"conditions":5409,"interventions":5410},[90],[26,29],[5390,5372,5391,5392],{"trials":5412,"activeCount":100},[],{"trials":5414,"activeCount":100},[],{"intervention":5392,"totalTrials":129,"cells":5416},{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5421,"PHASE3":5423,"PHASE4":5429,"NA":5431},{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[],{"trials":5422,"activeCount":100},[],{"trials":5424,"activeCount":100},[5425],{"nctId":5383,"briefTitle":5384,"status":119,"phases":5426,"primaryCompletion":479,"completion":479,"start":5386,"enrollment":5387,"conditions":5427,"interventions":5428},[90],[26,29],[5390,5372,5391,5392],{"trials":5430,"activeCount":100},[],{"trials":5432,"activeCount":100},[],{"intervention":5434,"totalTrials":129,"cells":5435},"LOVAZA",{"EARLY_PHASE1":5436,"PHASE1":5438,"PHASE2":5440,"PHASE3":5442,"PHASE4":5453,"NA":5455},{"trials":5437,"activeCount":100},[],{"trials":5439,"activeCount":100},[],{"trials":5441,"activeCount":100},[],{"trials":5443,"activeCount":100},[5444],{"nctId":5445,"briefTitle":5446,"status":150,"phases":5447,"primaryCompletion":5448,"completion":5448,"start":5449,"enrollment":5450,"conditions":5451,"interventions":5452},"NCT00944229","The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure",[90],"2014-03","2010-01",58,[32],[5434],{"trials":5454,"activeCount":100},[],{"trials":5456,"activeCount":100},[],{"intervention":4828,"totalTrials":129,"cells":5458},{"EARLY_PHASE1":5459,"PHASE1":5461,"PHASE2":5463,"PHASE3":5465,"PHASE4":5471,"NA":5473},{"trials":5460,"activeCount":100},[],{"trials":5462,"activeCount":100},[],{"trials":5464,"activeCount":100},[],{"trials":5466,"activeCount":100},[5467],{"nctId":4819,"briefTitle":4820,"status":150,"phases":5468,"primaryCompletion":4822,"completion":4822,"start":4823,"enrollment":4785,"conditions":5469,"interventions":5470},[90],[4825,4826],[4828,2446],{"trials":5472,"activeCount":100},[],{"trials":5474,"activeCount":100},[],{"intervention":5476,"totalTrials":129,"cells":5477},"albendazole",{"EARLY_PHASE1":5478,"PHASE1":5480,"PHASE2":5482,"PHASE3":5484,"PHASE4":5496,"NA":5498},{"trials":5479,"activeCount":100},[],{"trials":5481,"activeCount":100},[],{"trials":5483,"activeCount":100},[],{"trials":5485,"activeCount":100},[5486],{"nctId":5487,"briefTitle":5488,"status":119,"phases":5489,"primaryCompletion":5490,"completion":5490,"start":5491,"enrollment":5492,"conditions":5493,"interventions":5495},"NCT00283699","A Pilot Study of Neurocysticercosis Treatment",[90],"2005-02","2001-02",178,[5494],"Neurocysticercosis",[5476],{"trials":5497,"activeCount":100},[],{"trials":5499,"activeCount":100},[],{"intervention":5501,"totalTrials":129,"cells":5502},"open-label PTH",{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5507,"PHASE3":5509,"PHASE4":5520,"NA":5522},{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[5511],{"nctId":5512,"briefTitle":5513,"status":119,"phases":5514,"primaryCompletion":5515,"completion":5515,"start":2745,"enrollment":5516,"conditions":5517,"interventions":5519},"NCT01199614","HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism",[90],"2017-06-26",62,[5518],"Hypoparathyroidism",[5501],{"trials":5521,"activeCount":100},[],{"trials":5523,"activeCount":100},[],{"intervention":5525,"totalTrials":129,"cells":5526},"Spironolactone 100mg",{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5531,"PHASE3":5533,"PHASE4":5544,"NA":5546},{"trials":5528,"activeCount":100},[],{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[5535],{"nctId":5536,"briefTitle":5537,"status":119,"phases":5538,"primaryCompletion":5539,"completion":5539,"start":5540,"enrollment":821,"conditions":5541,"interventions":5542},"NCT02585843","Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance",[89,90],"2017-03-31","2015-11",[32],[5525,5543],"Spironolactone 25mg",{"trials":5545,"activeCount":100},[],{"trials":5547,"activeCount":100},[],{"intervention":5543,"totalTrials":129,"cells":5549},{"EARLY_PHASE1":5550,"PHASE1":5552,"PHASE2":5554,"PHASE3":5556,"PHASE4":5562,"NA":5564},{"trials":5551,"activeCount":100},[],{"trials":5553,"activeCount":100},[],{"trials":5555,"activeCount":100},[],{"trials":5557,"activeCount":100},[5558],{"nctId":5536,"briefTitle":5537,"status":119,"phases":5559,"primaryCompletion":5539,"completion":5539,"start":5540,"enrollment":821,"conditions":5560,"interventions":5561},[89,90],[32],[5525,5543],{"trials":5563,"activeCount":100},[],{"trials":5565,"activeCount":100},[],{"intervention":5567,"totalTrials":129,"cells":5568},"Conivaptan",{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5575,"PHASE4":5586,"NA":5588},{"trials":5570,"activeCount":100},[],{"trials":5572,"activeCount":100},[],{"trials":5574,"activeCount":100},[],{"trials":5576,"activeCount":100},[5577],{"nctId":5578,"briefTitle":5579,"status":415,"phases":5580,"primaryCompletion":5581,"completion":5582,"start":3284,"enrollment":100,"conditions":5583,"interventions":5585},"NCT00684164","Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients",[90],"2009-11","2010-06",[5584],"Hyponatremia",[5567],{"trials":5587,"activeCount":100},[],{"trials":5589,"activeCount":100},[],{"intervention":5591,"totalTrials":129,"cells":5592},"Chlorhexidine-alcohol",{"EARLY_PHASE1":5593,"PHASE1":5595,"PHASE2":5597,"PHASE3":5599,"PHASE4":5614,"NA":5616},{"trials":5594,"activeCount":100},[],{"trials":5596,"activeCount":100},[],{"trials":5598,"activeCount":100},[],{"trials":5600,"activeCount":100},[5601],{"nctId":5602,"briefTitle":5603,"status":119,"phases":5604,"primaryCompletion":5605,"completion":5606,"start":5607,"enrollment":770,"conditions":5608,"interventions":5611},"NCT03640507","Vaginal Preparation With Chlorhexidine-alcohol vs. Povidine-iodine vs. Saline",[89,90],"2019-05-08","2019-06-14","2018-10-01",[5609,5610],"Cesarean Section; Infection","Surgical Site Infection",[5591,5612,5613],"Povidine-iodine","Sterile saline",{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"intervention":5612,"totalTrials":129,"cells":5619},{"EARLY_PHASE1":5620,"PHASE1":5622,"PHASE2":5624,"PHASE3":5626,"PHASE4":5632,"NA":5634},{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[5628],{"nctId":5602,"briefTitle":5603,"status":119,"phases":5629,"primaryCompletion":5605,"completion":5606,"start":5607,"enrollment":770,"conditions":5630,"interventions":5631},[89,90],[5609,5610],[5591,5612,5613],{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":100},[],{"intervention":5613,"totalTrials":129,"cells":5637},{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5644,"PHASE4":5650,"NA":5652},{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[5646],{"nctId":5602,"briefTitle":5603,"status":119,"phases":5647,"primaryCompletion":5605,"completion":5606,"start":5607,"enrollment":770,"conditions":5648,"interventions":5649},[89,90],[5609,5610],[5591,5612,5613],{"trials":5651,"activeCount":100},[],{"trials":5653,"activeCount":100},[],{"intervention":2403,"totalTrials":186,"cells":5655},{"EARLY_PHASE1":5656,"PHASE1":5658,"PHASE2":5672,"PHASE3":5699,"PHASE4":5701,"NA":5703},{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[5660],{"nctId":5661,"briefTitle":5662,"status":119,"phases":5663,"primaryCompletion":5664,"completion":5664,"start":5665,"enrollment":5666,"conditions":5667,"interventions":5670},"NCT02632071","ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer",[88],"2020-09-30","2016-03-01",17,[5668,5669],"Metastatic Breast Cancer","Breast Carcinoma",[5671,2403],"ACY-1215",{"trials":5673,"activeCount":100},[5674,5685,5695],{"nctId":5675,"briefTitle":5676,"status":150,"phases":5677,"primaryCompletion":5678,"completion":5678,"start":5679,"enrollment":27,"conditions":5680,"interventions":5682},"NCT02710396","Genetic Predictors of Benefit to Pembrolizumab",[89],"2021-03-10","2016-05-31",[5681],"Carcinoma, Non-Small-Cell Lung",[5683,5684,2403,764],"Pembrolizumab","Carboplatin",{"nctId":5686,"briefTitle":5687,"status":119,"phases":5688,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":5691,"conditions":5692,"interventions":5693},"NCT02716038","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",[89],"2022-10-01","2016-06-07",39,[5681],[5694,5684,2403],"MPDL3280A",{"nctId":2393,"briefTitle":2394,"status":119,"phases":5696,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":5697,"interventions":5698},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[],{"trials":5704,"activeCount":100},[],{"intervention":754,"totalTrials":186,"cells":5706},{"EARLY_PHASE1":5707,"PHASE1":5709,"PHASE2":5715,"PHASE3":5729,"PHASE4":5731,"NA":5733},{"trials":5708,"activeCount":100},[],{"trials":5710,"activeCount":100},[5711],{"nctId":2374,"briefTitle":2375,"status":119,"phases":5712,"primaryCompletion":2377,"completion":2378,"start":736,"enrollment":446,"conditions":5713,"interventions":5714},[88],[23],[2381,754,927],{"trials":5716,"activeCount":100},[5717,5721,5725],{"nctId":746,"briefTitle":747,"status":150,"phases":5718,"primaryCompletion":749,"completion":749,"start":417,"enrollment":186,"conditions":5719,"interventions":5720},[89],[751,752],[724,754],{"nctId":756,"briefTitle":757,"status":150,"phases":5722,"primaryCompletion":759,"completion":759,"start":760,"enrollment":737,"conditions":5723,"interventions":5724},[89],[762],[754,724,764],{"nctId":2393,"briefTitle":2394,"status":119,"phases":5726,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":5727,"interventions":5728},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"trials":5734,"activeCount":100},[],{"intervention":1064,"totalTrials":846,"cells":5736},{"EARLY_PHASE1":5737,"PHASE1":5739,"PHASE2":5745,"PHASE3":5757,"PHASE4":5759,"NA":5761},{"trials":5738,"activeCount":100},[],{"trials":5740,"activeCount":100},[5741],{"nctId":2500,"briefTitle":2501,"status":119,"phases":5742,"primaryCompletion":2503,"completion":2503,"start":1046,"enrollment":2504,"conditions":5743,"interventions":5744},[88],[399],[2426,1064,2507],{"trials":5746,"activeCount":100},[5747,5753],{"nctId":5748,"briefTitle":5749,"status":150,"phases":5750,"primaryCompletion":3774,"completion":3774,"start":2819,"enrollment":186,"conditions":5751,"interventions":5752},"NCT00996502","Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer",[88,89],[399],[1064,800,742,2507],{"nctId":1056,"briefTitle":1057,"status":119,"phases":5754,"primaryCompletion":907,"completion":907,"start":1059,"enrollment":1060,"conditions":5755,"interventions":5756},[89],[1062],[787,1064,1065],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[],{"intervention":742,"totalTrials":846,"cells":5764},{"EARLY_PHASE1":5765,"PHASE1":5767,"PHASE2":5777,"PHASE3":5783,"PHASE4":5785,"NA":5787},{"trials":5766,"activeCount":100},[],{"trials":5768,"activeCount":100},[5769,5773],{"nctId":2450,"briefTitle":2451,"status":119,"phases":5770,"primaryCompletion":2453,"completion":2453,"start":2454,"enrollment":836,"conditions":5771,"interventions":5772},[88],[23],[2431,742],{"nctId":731,"briefTitle":732,"status":119,"phases":5774,"primaryCompletion":734,"completion":735,"start":736,"enrollment":737,"conditions":5775,"interventions":5776},[88],[739],[741,724,742],{"trials":5778,"activeCount":100},[5779],{"nctId":5748,"briefTitle":5749,"status":150,"phases":5780,"primaryCompletion":3774,"completion":3774,"start":2819,"enrollment":186,"conditions":5781,"interventions":5782},[88,89],[399],[1064,800,742,2507],{"trials":5784,"activeCount":100},[],{"trials":5786,"activeCount":100},[],{"trials":5788,"activeCount":100},[],{"intervention":5683,"totalTrials":846,"cells":5790},{"EARLY_PHASE1":5791,"PHASE1":5802,"PHASE2":5804,"PHASE3":5820,"PHASE4":5822,"NA":5824},{"trials":5792,"activeCount":100},[5793],{"nctId":5794,"briefTitle":5795,"status":150,"phases":5796,"primaryCompletion":5797,"completion":5797,"start":4367,"enrollment":96,"conditions":5798,"interventions":5800},"NCT02591654","MRI and PET to Assess Pembrolizumab Response",[87],"2022-10",[5799],"Malignant Melanoma, Metastatic",[5683,5801],"FLT PET",{"trials":5803,"activeCount":100},[],{"trials":5805,"activeCount":100},[5806,5810],{"nctId":5675,"briefTitle":5676,"status":150,"phases":5807,"primaryCompletion":5678,"completion":5678,"start":5679,"enrollment":27,"conditions":5808,"interventions":5809},[89],[5681],[5683,5684,2403,764],{"nctId":5811,"briefTitle":5812,"status":150,"phases":5813,"primaryCompletion":5814,"completion":5814,"start":5815,"enrollment":129,"conditions":5816,"interventions":5818},"NCT03291054","Epacadostat and Pembrolizumab in Patients With GIST",[89],"2020-08-19","2018-02-28",[5817],"Gastrointestinal Stromal Tumors",[5683,5819],"Epacadostat",{"trials":5821,"activeCount":100},[],{"trials":5823,"activeCount":100},[],{"trials":5825,"activeCount":100},[],{"intervention":764,"totalTrials":846,"cells":5827},{"EARLY_PHASE1":5828,"PHASE1":5830,"PHASE2":5832,"PHASE3":5846,"PHASE4":5848,"NA":5850},{"trials":5829,"activeCount":100},[],{"trials":5831,"activeCount":100},[],{"trials":5833,"activeCount":100},[5834,5838,5842],{"nctId":756,"briefTitle":757,"status":150,"phases":5835,"primaryCompletion":759,"completion":759,"start":760,"enrollment":737,"conditions":5836,"interventions":5837},[89],[762],[754,724,764],{"nctId":5675,"briefTitle":5676,"status":150,"phases":5839,"primaryCompletion":5678,"completion":5678,"start":5679,"enrollment":27,"conditions":5840,"interventions":5841},[89],[5681],[5683,5684,2403,764],{"nctId":791,"briefTitle":792,"status":150,"phases":5843,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":5844,"interventions":5845},[89],[798],[764,724,800],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[],{"trials":5851,"activeCount":100},[],{"intervention":800,"totalTrials":226,"cells":5853},{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5868,"PHASE4":5870,"NA":5872},{"trials":5855,"activeCount":100},[],{"trials":5857,"activeCount":100},[],{"trials":5859,"activeCount":100},[5860,5864],{"nctId":5748,"briefTitle":5749,"status":150,"phases":5861,"primaryCompletion":3774,"completion":3774,"start":2819,"enrollment":186,"conditions":5862,"interventions":5863},[88,89],[399],[1064,800,742,2507],{"nctId":791,"briefTitle":792,"status":150,"phases":5865,"primaryCompletion":794,"completion":794,"start":795,"enrollment":796,"conditions":5866,"interventions":5867},[89],[798],[764,724,800],{"trials":5869,"activeCount":100},[],{"trials":5871,"activeCount":100},[],{"trials":5873,"activeCount":100},[],{"intervention":2507,"totalTrials":226,"cells":5875},{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5884,"PHASE3":5890,"PHASE4":5892,"NA":5894},{"trials":5877,"activeCount":100},[],{"trials":5879,"activeCount":100},[5880],{"nctId":2500,"briefTitle":2501,"status":119,"phases":5881,"primaryCompletion":2503,"completion":2503,"start":1046,"enrollment":2504,"conditions":5882,"interventions":5883},[88],[399],[2426,1064,2507],{"trials":5885,"activeCount":100},[5886],{"nctId":5748,"briefTitle":5749,"status":150,"phases":5887,"primaryCompletion":3774,"completion":3774,"start":2819,"enrollment":186,"conditions":5888,"interventions":5889},[88,89],[399],[1064,800,742,2507],{"trials":5891,"activeCount":100},[],{"trials":5893,"activeCount":100},[],{"trials":5895,"activeCount":100},[],{"intervention":872,"totalTrials":226,"cells":5897},{"EARLY_PHASE1":5898,"PHASE1":5900,"PHASE2":5906,"PHASE3":5912,"PHASE4":5914,"NA":5916},{"trials":5899,"activeCount":100},[],{"trials":5901,"activeCount":100},[5902],{"nctId":858,"briefTitle":859,"status":119,"phases":5903,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":5904,"interventions":5905},[88],[866,867,868],[851,50,870,871,872,873],{"trials":5907,"activeCount":100},[5908],{"nctId":904,"briefTitle":905,"status":119,"phases":5909,"primaryCompletion":907,"completion":908,"start":909,"enrollment":770,"conditions":5910,"interventions":5911},[88,89],[911,912],[851,50,872],{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[],{"intervention":5919,"totalTrials":226,"cells":5920},"Copanlisib",{"EARLY_PHASE1":5921,"PHASE1":5923,"PHASE2":5936,"PHASE3":5947,"PHASE4":5949,"NA":5951},{"trials":5922,"activeCount":100},[],{"trials":5924,"activeCount":100},[5925],{"nctId":5926,"briefTitle":5927,"status":415,"phases":5928,"primaryCompletion":5929,"completion":5930,"start":5931,"enrollment":100,"conditions":5932,"interventions":5934},"NCT04233697","Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma",[88],"2022-07-30","2023-07-30","2020-02",[5933],"Lymphoma, T-Cell",[5919,5935],"Romidepsin",{"trials":5937,"activeCount":100},[5938],{"nctId":5939,"briefTitle":5940,"status":150,"phases":5941,"primaryCompletion":4631,"completion":4631,"start":5942,"enrollment":129,"conditions":5943,"interventions":5946},"NCT04750941","Study of Copanlisib and Ketogenic Diet",[89],"2022-02-10",[5944,5945],"Follicular Lymphoma","Endometrial Cancer",[5919],{"trials":5948,"activeCount":100},[],{"trials":5950,"activeCount":100},[],{"trials":5952,"activeCount":100},[],{"intervention":2402,"totalTrials":226,"cells":5954},{"EARLY_PHASE1":5955,"PHASE1":5957,"PHASE2":5959,"PHASE3":5977,"PHASE4":5979,"NA":5981},{"trials":5956,"activeCount":100},[],{"trials":5958,"activeCount":100},[],{"trials":5960,"activeCount":100},[5961,5973],{"nctId":5962,"briefTitle":5963,"status":415,"phases":5964,"primaryCompletion":5965,"completion":5965,"start":5966,"enrollment":100,"conditions":5967,"interventions":5971},"NCT02274012","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment",[89],"2015-08-12","2014-05-29",[5968,5969,5970],"HER-2 Positive Gastric Cancer","Gastrooesophageal Cancer","Esophageal Cancer",[5972,2402],"Afatinib",{"nctId":2393,"briefTitle":2394,"status":119,"phases":5974,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":5975,"interventions":5976},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":5978,"activeCount":100},[],{"trials":5980,"activeCount":100},[],{"trials":5982,"activeCount":100},[],{"intervention":5984,"totalTrials":226,"cells":5985},"AxV-128\u002FTc",{"EARLY_PHASE1":5986,"PHASE1":5988,"PHASE2":5990,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":5987,"activeCount":100},[],{"trials":5989,"activeCount":100},[],{"trials":5991,"activeCount":100},[5992,6001],{"nctId":5993,"briefTitle":5994,"status":150,"phases":5995,"primaryCompletion":5996,"completion":5996,"start":5997,"enrollment":4594,"conditions":5998,"interventions":6000},"NCT02978144","Lung Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)",[89],"2019-10-08","2017-06-15",[5999],"Chronic Obstructive Pulmonary Disease (COPD)",[5984],{"nctId":6002,"briefTitle":6003,"status":150,"phases":6004,"primaryCompletion":6005,"completion":6005,"start":6006,"enrollment":129,"conditions":6007,"interventions":6009},"NCT02978885","Imaging of Peri-operative (periOP) Lung Injury",[89],"2020-02-05","2018-06-11",[6008,5999],"Acute Lung Injury",[5984],{"trials":6011,"activeCount":100},[],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"intervention":2598,"totalTrials":226,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6022,"PHASE3":6040,"PHASE4":6042,"NA":6044},{"trials":6019,"activeCount":100},[],{"trials":6021,"activeCount":100},[],{"trials":6023,"activeCount":100},[6024,6036],{"nctId":6025,"briefTitle":6026,"status":119,"phases":6027,"primaryCompletion":6028,"completion":6028,"start":2454,"enrollment":6029,"conditions":6030,"interventions":6033},"NCT01657331","Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)",[88,89],"2020-04",71,[6031,6032],"Hodgkin Lymphoma","Anaplastic Large Cell Lymphoma",[6034,2598,6035],"Brentuximab Vedotin","Neulasta",{"nctId":2590,"briefTitle":2591,"status":119,"phases":6037,"primaryCompletion":2593,"completion":2594,"start":2514,"enrollment":351,"conditions":6038,"interventions":6039},[89],[2596],[2598,1521],{"trials":6041,"activeCount":100},[],{"trials":6043,"activeCount":100},[],{"trials":6045,"activeCount":100},[],{"intervention":6047,"totalTrials":226,"cells":6048},"Intranasal midazolam",{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6072,"PHASE4":6074,"NA":6076},{"trials":6050,"activeCount":100},[],{"trials":6052,"activeCount":100},[],{"trials":6054,"activeCount":100},[6055,6063],{"nctId":6056,"briefTitle":6057,"status":119,"phases":6058,"primaryCompletion":844,"completion":844,"start":3860,"enrollment":6059,"conditions":6060,"interventions":6062},"NCT01948908","Volumes of Administration for Intranasal Midazolam",[89],99,[6061],"Children Requiring Sedation to Facilitate Laceration Repair",[6047],{"nctId":6064,"briefTitle":6065,"status":119,"phases":6066,"primaryCompletion":6067,"completion":6067,"start":6068,"enrollment":257,"conditions":6069,"interventions":6071},"NCT04586504","Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children",[88,89],"2024-05-14","2021-09-08",[6070],"Procedural Anxiety",[6047],{"trials":6073,"activeCount":100},[],{"trials":6075,"activeCount":100},[],{"trials":6077,"activeCount":100},[],{"intervention":6079,"totalTrials":226,"cells":6080},"Gemcitabine, docetaxel, and capecitabine",{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6085,"PHASE3":6103,"PHASE4":6105,"NA":6107},{"trials":6082,"activeCount":100},[],{"trials":6084,"activeCount":100},[],{"trials":6086,"activeCount":100},[6087,6095],{"nctId":6088,"briefTitle":6089,"status":119,"phases":6090,"primaryCompletion":907,"completion":907,"start":6091,"enrollment":2097,"conditions":6092,"interventions":6094},"NCT00869258","Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar",[89],"2005-06",[6093],"Pancreatic Cancer Stage IVA",[6079],{"nctId":6096,"briefTitle":6097,"status":150,"phases":6098,"primaryCompletion":6099,"completion":4297,"start":1046,"enrollment":186,"conditions":6100,"interventions":6102},"NCT00868998","GTX Regimen for Biliary Cancers",[89],"2010-09",[6101],"Biliary Cancer",[6079],{"trials":6104,"activeCount":100},[],{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[],{"intervention":4688,"totalTrials":226,"cells":6110},{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6131,"PHASE4":6133,"NA":6135},{"trials":6112,"activeCount":100},[],{"trials":6114,"activeCount":100},[],{"trials":6116,"activeCount":100},[6117,6127],{"nctId":6118,"briefTitle":6119,"status":119,"phases":6120,"primaryCompletion":6121,"completion":6121,"start":6122,"enrollment":6123,"conditions":6124,"interventions":6125},"NCT01375010","Vitamin D HIV Study on Postmenopausal Women",[88,89],"2016-02","2011-01",85,[21],[4688,6126],"Vitamin Supplements",{"nctId":4675,"briefTitle":4676,"status":119,"phases":6128,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":4680,"conditions":6129,"interventions":6130},[89],[4682,4683,4684,4685,4686],[4688,4648],{"trials":6132,"activeCount":100},[],{"trials":6134,"activeCount":100},[],{"trials":6136,"activeCount":100},[],{"intervention":5684,"totalTrials":226,"cells":6138},{"EARLY_PHASE1":6139,"PHASE1":6141,"PHASE2":6143,"PHASE3":6153,"PHASE4":6155,"NA":6157},{"trials":6140,"activeCount":100},[],{"trials":6142,"activeCount":100},[],{"trials":6144,"activeCount":100},[6145,6149],{"nctId":5675,"briefTitle":5676,"status":150,"phases":6146,"primaryCompletion":5678,"completion":5678,"start":5679,"enrollment":27,"conditions":6147,"interventions":6148},[89],[5681],[5683,5684,2403,764],{"nctId":5686,"briefTitle":5687,"status":119,"phases":6150,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":5691,"conditions":6151,"interventions":6152},[89],[5681],[5694,5684,2403],{"trials":6154,"activeCount":100},[],{"trials":6156,"activeCount":100},[],{"trials":6158,"activeCount":100},[],{"intervention":2285,"totalTrials":226,"cells":6160},{"EARLY_PHASE1":6161,"PHASE1":6163,"PHASE2":6173,"PHASE3":6179,"PHASE4":6181,"NA":6183},{"trials":6162,"activeCount":100},[],{"trials":6164,"activeCount":100},[6165],{"nctId":6166,"briefTitle":6167,"status":119,"phases":6168,"primaryCompletion":735,"completion":735,"start":891,"enrollment":19,"conditions":6169,"interventions":6171},"NCT00629343","Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide",[88],[6170,1075],"Soft Tissue Sarcoma",[6172,2285],"Azacitidine",{"trials":6174,"activeCount":100},[6175],{"nctId":2277,"briefTitle":2278,"status":119,"phases":6176,"primaryCompletion":2280,"completion":907,"start":1046,"enrollment":2281,"conditions":6177,"interventions":6178},[89],[2283],[1065,2285],{"trials":6180,"activeCount":100},[],{"trials":6182,"activeCount":100},[],{"trials":6184,"activeCount":100},[],{"intervention":6186,"totalTrials":226,"cells":6187},"TGR-1202",{"EARLY_PHASE1":6188,"PHASE1":6190,"PHASE2":6192,"PHASE3":6213,"PHASE4":6215,"NA":6217},{"trials":6189,"activeCount":100},[],{"trials":6191,"activeCount":100},[],{"trials":6193,"activeCount":100},[6194,6202],{"nctId":6195,"briefTitle":6196,"status":150,"phases":6197,"primaryCompletion":6198,"completion":6198,"start":6199,"enrollment":2432,"conditions":6200,"interventions":6201},"NCT03178201","TGR1202 in Relapsed and Refractory Follicular Lymphoma",[89],"2020-06-30","2017-08-20",[5944],[6186],{"nctId":6203,"briefTitle":6204,"status":150,"phases":6205,"primaryCompletion":6198,"completion":6198,"start":6206,"enrollment":6207,"conditions":6208,"interventions":6211},"NCT02867618","Carfilzomib and TGR-1202 in Treatment of R\u002FR Lymphoma",[88,89],"2016-10-16",14,[6209,6210],"Hodgkin Disease","Lymphoma, Non-hodgkin",[6212,6186],"Carfilzomib",{"trials":6214,"activeCount":100},[],{"trials":6216,"activeCount":100},[],{"trials":6218,"activeCount":100},[],{"intervention":6220,"totalTrials":226,"cells":6221},"Ruxolitinib",{"EARLY_PHASE1":6222,"PHASE1":6224,"PHASE2":6226,"PHASE3":6245,"PHASE4":6247,"NA":6249},{"trials":6223,"activeCount":100},[],{"trials":6225,"activeCount":100},[],{"trials":6227,"activeCount":100},[6228,6238],{"nctId":6229,"briefTitle":6230,"status":150,"phases":6231,"primaryCompletion":6232,"completion":6233,"start":6234,"enrollment":846,"conditions":6235,"interventions":6237},"NCT04807777","Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma",[89],"2023-04-04","2023-10-04","2022-04-07",[6236],"Advanced Cutaneous Squamous Cell Carcinoma",[6220],{"nctId":6239,"briefTitle":6240,"status":119,"phases":6241,"primaryCompletion":6242,"completion":6242,"start":2674,"enrollment":796,"conditions":6243,"interventions":6244},"NCT01950780","Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata",[89],"2016-04",[2667],[6220],{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"intervention":2401,"totalTrials":226,"cells":6252},{"EARLY_PHASE1":6253,"PHASE1":6255,"PHASE2":6257,"PHASE3":6272,"PHASE4":6274,"NA":6276},{"trials":6254,"activeCount":100},[],{"trials":6256,"activeCount":100},[],{"trials":6258,"activeCount":100},[6259,6263],{"nctId":2393,"briefTitle":2394,"status":119,"phases":6260,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":6261,"interventions":6262},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"nctId":6264,"briefTitle":6265,"status":150,"phases":6266,"primaryCompletion":6267,"completion":6267,"start":6268,"enrollment":129,"conditions":6269,"interventions":6271},"NCT02595996","Propranolol Dose Escalation in Lymphedema in Patients",[89],"2020-10-08","2017-06-07",[6270],"Primary Lymphedema",[2401],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[],{"trials":6277,"activeCount":100},[],{"intervention":6279,"totalTrials":129,"cells":6280},"YF476",{"EARLY_PHASE1":6281,"PHASE1":6283,"PHASE2":6285,"PHASE3":6294,"PHASE4":6296,"NA":6298},{"trials":6282,"activeCount":100},[],{"trials":6284,"activeCount":100},[],{"trials":6286,"activeCount":100},[6287],{"nctId":6288,"briefTitle":6289,"status":119,"phases":6290,"primaryCompletion":4152,"completion":4152,"start":5582,"enrollment":19,"conditions":6291,"interventions":6293},"NCT01298999","Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus",[89],[6292],"Barrett's Esophagus",[6279],{"trials":6295,"activeCount":100},[],{"trials":6297,"activeCount":100},[],{"trials":6299,"activeCount":100},[],{"intervention":6301,"totalTrials":129,"cells":6302},"Cholecalciferol",{"EARLY_PHASE1":6303,"PHASE1":6305,"PHASE2":6307,"PHASE3":6316,"PHASE4":6318,"NA":6320},{"trials":6304,"activeCount":100},[],{"trials":6306,"activeCount":100},[],{"trials":6308,"activeCount":100},[6309],{"nctId":6310,"briefTitle":6311,"status":119,"phases":6312,"primaryCompletion":6313,"completion":6313,"start":795,"enrollment":821,"conditions":6314,"interventions":6315},"NCT00859651","Vitamin D in Postmenopausal Women at High Risk for Breast Cancer",[89],"2015-04",[23],[6301],{"trials":6317,"activeCount":100},[],{"trials":6319,"activeCount":100},[],{"trials":6321,"activeCount":100},[],{"intervention":6323,"totalTrials":129,"cells":6324},"Revlimid",{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6340,"PHASE4":6342,"NA":6344},{"trials":6326,"activeCount":100},[],{"trials":6328,"activeCount":100},[],{"trials":6330,"activeCount":100},[6331],{"nctId":6332,"briefTitle":6333,"status":119,"phases":6334,"primaryCompletion":6335,"completion":6336,"start":6337,"enrollment":1489,"conditions":6338,"interventions":6339},"NCT01178814","Revlimid in Transfusion Dependent Patients",[89],"2022-09-01","2022-12-07","2009-06-01",[867],[6323],{"trials":6341,"activeCount":100},[],{"trials":6343,"activeCount":100},[],{"trials":6345,"activeCount":100},[],{"intervention":896,"totalTrials":129,"cells":6347},{"EARLY_PHASE1":6348,"PHASE1":6350,"PHASE2":6352,"PHASE3":6358,"PHASE4":6360,"NA":6362},{"trials":6349,"activeCount":100},[],{"trials":6351,"activeCount":100},[],{"trials":6353,"activeCount":100},[6354],{"nctId":887,"briefTitle":888,"status":415,"phases":6355,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":6356,"interventions":6357},[88,89],[894],[896,897,898,899,900,901,902],{"trials":6359,"activeCount":100},[],{"trials":6361,"activeCount":100},[],{"trials":6363,"activeCount":100},[],{"intervention":897,"totalTrials":129,"cells":6365},{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6376,"PHASE4":6378,"NA":6380},{"trials":6367,"activeCount":100},[],{"trials":6369,"activeCount":100},[],{"trials":6371,"activeCount":100},[6372],{"nctId":887,"briefTitle":888,"status":415,"phases":6373,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":6374,"interventions":6375},[88,89],[894],[896,897,898,899,900,901,902],{"trials":6377,"activeCount":100},[],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[],{"intervention":900,"totalTrials":129,"cells":6383},{"EARLY_PHASE1":6384,"PHASE1":6386,"PHASE2":6388,"PHASE3":6394,"PHASE4":6396,"NA":6398},{"trials":6385,"activeCount":100},[],{"trials":6387,"activeCount":100},[],{"trials":6389,"activeCount":100},[6390],{"nctId":887,"briefTitle":888,"status":415,"phases":6391,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":6392,"interventions":6393},[88,89],[894],[896,897,898,899,900,901,902],{"trials":6395,"activeCount":100},[],{"trials":6397,"activeCount":100},[],{"trials":6399,"activeCount":100},[],{"intervention":901,"totalTrials":129,"cells":6401},{"EARLY_PHASE1":6402,"PHASE1":6404,"PHASE2":6406,"PHASE3":6412,"PHASE4":6414,"NA":6416},{"trials":6403,"activeCount":100},[],{"trials":6405,"activeCount":100},[],{"trials":6407,"activeCount":100},[6408],{"nctId":887,"briefTitle":888,"status":415,"phases":6409,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":6410,"interventions":6411},[88,89],[894],[896,897,898,899,900,901,902],{"trials":6413,"activeCount":100},[],{"trials":6415,"activeCount":100},[],{"trials":6417,"activeCount":100},[],{"intervention":902,"totalTrials":129,"cells":6419},{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6430,"PHASE4":6432,"NA":6434},{"trials":6421,"activeCount":100},[],{"trials":6423,"activeCount":100},[],{"trials":6425,"activeCount":100},[6426],{"nctId":887,"briefTitle":888,"status":415,"phases":6427,"primaryCompletion":890,"completion":891,"start":892,"enrollment":100,"conditions":6428,"interventions":6429},[88,89],[894],[896,897,898,899,900,901,902],{"trials":6431,"activeCount":100},[],{"trials":6433,"activeCount":100},[],{"trials":6435,"activeCount":100},[],{"intervention":6437,"totalTrials":129,"cells":6438},"phosphatidylcholine-curcumin complex supplement",{"EARLY_PHASE1":6439,"PHASE1":6441,"PHASE2":6443,"PHASE3":6455,"PHASE4":6457,"NA":6459},{"trials":6440,"activeCount":100},[],{"trials":6442,"activeCount":100},[],{"trials":6444,"activeCount":100},[6445],{"nctId":6446,"briefTitle":6447,"status":415,"phases":6448,"primaryCompletion":6449,"completion":6449,"start":6450,"enrollment":100,"conditions":6451,"interventions":6454},"NCT04109742","Curcumin for Pediatric Nonalcoholic Fatty Liver Disease",[89],"2020-04-22","2019-12-09",[6452,6453],"NAFLD - Nonalcoholic Fatty Liver Disease","NASH - Nonalcoholic Steatohepatitis",[6437],{"trials":6456,"activeCount":100},[],{"trials":6458,"activeCount":100},[],{"trials":6460,"activeCount":100},[],{"intervention":4717,"totalTrials":129,"cells":6462},{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6467,"PHASE3":6473,"PHASE4":6475,"NA":6477},{"trials":6464,"activeCount":100},[],{"trials":6466,"activeCount":100},[],{"trials":6468,"activeCount":100},[6469],{"nctId":4709,"briefTitle":4710,"status":150,"phases":6470,"primaryCompletion":4712,"completion":4713,"start":435,"enrollment":19,"conditions":6471,"interventions":6472},[88,89],[4715],[4717,4700,4718],{"trials":6474,"activeCount":100},[],{"trials":6476,"activeCount":100},[],{"trials":6478,"activeCount":100},[],{"intervention":4718,"totalTrials":129,"cells":6480},{"EARLY_PHASE1":6481,"PHASE1":6483,"PHASE2":6485,"PHASE3":6491,"PHASE4":6493,"NA":6495},{"trials":6482,"activeCount":100},[],{"trials":6484,"activeCount":100},[],{"trials":6486,"activeCount":100},[6487],{"nctId":4709,"briefTitle":4710,"status":150,"phases":6488,"primaryCompletion":4712,"completion":4713,"start":435,"enrollment":19,"conditions":6489,"interventions":6490},[88,89],[4715],[4717,4700,4718],{"trials":6492,"activeCount":100},[],{"trials":6494,"activeCount":100},[],{"trials":6496,"activeCount":100},[],{"intervention":5972,"totalTrials":129,"cells":6498},{"EARLY_PHASE1":6499,"PHASE1":6501,"PHASE2":6503,"PHASE3":6509,"PHASE4":6511,"NA":6513},{"trials":6500,"activeCount":100},[],{"trials":6502,"activeCount":100},[],{"trials":6504,"activeCount":100},[6505],{"nctId":5962,"briefTitle":5963,"status":415,"phases":6506,"primaryCompletion":5965,"completion":5965,"start":5966,"enrollment":100,"conditions":6507,"interventions":6508},[89],[5968,5969,5970],[5972,2402],{"trials":6510,"activeCount":100},[],{"trials":6512,"activeCount":100},[],{"trials":6514,"activeCount":100},[],{"intervention":6516,"totalTrials":129,"cells":6517},"Metformin hydrochloride",{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6532,"PHASE4":6534,"NA":6536},{"trials":6519,"activeCount":100},[],{"trials":6521,"activeCount":100},[],{"trials":6523,"activeCount":100},[6524],{"nctId":6525,"briefTitle":6526,"status":150,"phases":6527,"primaryCompletion":6528,"completion":6528,"start":6529,"enrollment":96,"conditions":6530,"interventions":6531},"NCT03331861","Metformin in Heart Failure Without Diabetes",[89],"2021-08-20","2019-02-15",[32],[6516],{"trials":6533,"activeCount":100},[],{"trials":6535,"activeCount":100},[],{"trials":6537,"activeCount":100},[],{"intervention":6539,"totalTrials":129,"cells":6540},"Fexofenadine Hcl 180Mg Tab",{"EARLY_PHASE1":6541,"PHASE1":6543,"PHASE2":6545,"PHASE3":6557,"PHASE4":6559,"NA":6561},{"trials":6542,"activeCount":100},[],{"trials":6544,"activeCount":100},[],{"trials":6546,"activeCount":100},[6547],{"nctId":6548,"briefTitle":6549,"status":119,"phases":6550,"primaryCompletion":6551,"completion":6551,"start":6552,"enrollment":6553,"conditions":6554,"interventions":6556},"NCT04726345","Effect of Antihistamines on Ureteral Stent-Related Symptoms",[89],"2024-06-30","2021-06-29",78,[6555],"Nephrolithiasis",[6539],{"trials":6558,"activeCount":100},[],{"trials":6560,"activeCount":100},[],{"trials":6562,"activeCount":100},[],{"intervention":6564,"totalTrials":129,"cells":6565},"18F-AV-1451",{"EARLY_PHASE1":6566,"PHASE1":6568,"PHASE2":6570,"PHASE3":6582,"PHASE4":6584,"NA":6586},{"trials":6567,"activeCount":100},[],{"trials":6569,"activeCount":100},[],{"trials":6571,"activeCount":100},[6572],{"nctId":6573,"briefTitle":6574,"status":119,"phases":6575,"primaryCompletion":6576,"completion":6576,"start":6242,"enrollment":446,"conditions":6577,"interventions":6581},"NCT02676843","Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations",[89],"2018-11-25",[6578,6579,6580],"Frontotemporal Lobar Degeneration (FTLD)","Frontotemporal Dementia (FTD)","Tauopathies",[6564],{"trials":6583,"activeCount":100},[],{"trials":6585,"activeCount":100},[],{"trials":6587,"activeCount":100},[],{"intervention":6589,"totalTrials":129,"cells":6590},"Intramyocardial injection of bone marrow mononuclear cells",{"EARLY_PHASE1":6591,"PHASE1":6593,"PHASE2":6595,"PHASE3":6606,"PHASE4":6608,"NA":6610},{"trials":6592,"activeCount":100},[],{"trials":6594,"activeCount":100},[],{"trials":6596,"activeCount":100},[6597],{"nctId":6598,"briefTitle":6599,"status":150,"phases":6600,"primaryCompletion":3308,"completion":3308,"start":6601,"enrollment":129,"conditions":6602,"interventions":6604},"NCT00383630","Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure",[89],"2007-09",[6603],"Heart Failure, Congestive",[6589,6605],"Intramyocardial injection of CD34+ selected bone marrow mononuclear cells",{"trials":6607,"activeCount":100},[],{"trials":6609,"activeCount":100},[],{"trials":6611,"activeCount":100},[],{"intervention":6605,"totalTrials":129,"cells":6613},{"EARLY_PHASE1":6614,"PHASE1":6616,"PHASE2":6618,"PHASE3":6624,"PHASE4":6626,"NA":6628},{"trials":6615,"activeCount":100},[],{"trials":6617,"activeCount":100},[],{"trials":6619,"activeCount":100},[6620],{"nctId":6598,"briefTitle":6599,"status":150,"phases":6621,"primaryCompletion":3308,"completion":3308,"start":6601,"enrollment":129,"conditions":6622,"interventions":6623},[89],[6603],[6589,6605],{"trials":6625,"activeCount":100},[],{"trials":6627,"activeCount":100},[],{"trials":6629,"activeCount":100},[],{"intervention":6631,"totalTrials":129,"cells":6632},"Tolcapone",{"EARLY_PHASE1":6633,"PHASE1":6635,"PHASE2":6637,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6634,"activeCount":100},[],{"trials":6636,"activeCount":100},[],{"trials":6638,"activeCount":100},[6639],{"nctId":6640,"briefTitle":6641,"status":119,"phases":6642,"primaryCompletion":6643,"completion":6643,"start":6644,"enrollment":16,"conditions":6645,"interventions":6647},"NCT00604591","Effects of Tolcapone on Frontotemporal Dementia",[89],"2016-06-16","2008-01-30",[6646],"Frontotemporal Lobar Degeneration",[6631],{"trials":6649,"activeCount":100},[],{"trials":6651,"activeCount":100},[],{"trials":6653,"activeCount":100},[],{"intervention":6034,"totalTrials":129,"cells":6655},{"EARLY_PHASE1":6656,"PHASE1":6658,"PHASE2":6660,"PHASE3":6666,"PHASE4":6668,"NA":6670},{"trials":6657,"activeCount":100},[],{"trials":6659,"activeCount":100},[],{"trials":6661,"activeCount":100},[6662],{"nctId":6025,"briefTitle":6026,"status":119,"phases":6663,"primaryCompletion":6028,"completion":6028,"start":2454,"enrollment":6029,"conditions":6664,"interventions":6665},[88,89],[6031,6032],[6034,2598,6035],{"trials":6667,"activeCount":100},[],{"trials":6669,"activeCount":100},[],{"trials":6671,"activeCount":100},[],{"intervention":6035,"totalTrials":129,"cells":6673},{"EARLY_PHASE1":6674,"PHASE1":6676,"PHASE2":6678,"PHASE3":6684,"PHASE4":6686,"NA":6688},{"trials":6675,"activeCount":100},[],{"trials":6677,"activeCount":100},[],{"trials":6679,"activeCount":100},[6680],{"nctId":6025,"briefTitle":6026,"status":119,"phases":6681,"primaryCompletion":6028,"completion":6028,"start":2454,"enrollment":6029,"conditions":6682,"interventions":6683},[88,89],[6031,6032],[6034,2598,6035],{"trials":6685,"activeCount":100},[],{"trials":6687,"activeCount":100},[],{"trials":6689,"activeCount":100},[],{"intervention":6691,"totalTrials":129,"cells":6692},"Abraxane",{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6706,"PHASE4":6708,"NA":6710},{"trials":6694,"activeCount":100},[],{"trials":6696,"activeCount":100},[],{"trials":6698,"activeCount":100},[6699],{"nctId":6700,"briefTitle":6701,"status":119,"phases":6702,"primaryCompletion":1071,"completion":6703,"start":3308,"enrollment":9,"conditions":6704,"interventions":6705},"NCT00583349","Intravesicular Abraxane for Treatment-Refractory Bladder Cancer",[88,89],"2014-02",[784],[6691],{"trials":6707,"activeCount":100},[],{"trials":6709,"activeCount":100},[],{"trials":6711,"activeCount":100},[],{"intervention":6713,"totalTrials":129,"cells":6714},"RomiDEPsin 10 MG\u002FM2",{"EARLY_PHASE1":6715,"PHASE1":6717,"PHASE2":6719,"PHASE3":6735,"PHASE4":6737,"NA":6739},{"trials":6716,"activeCount":100},[],{"trials":6718,"activeCount":100},[],{"trials":6720,"activeCount":100},[6721],{"nctId":6722,"briefTitle":6723,"status":150,"phases":6724,"primaryCompletion":6725,"completion":6725,"start":6726,"enrollment":5450,"conditions":6727,"interventions":6730},"NCT01998035","Romidepsin Plus Oral 5-Azacitidine in Relapsed\u002FRefractory Lymphoid Malignancies",[88,89],"2020-01-06","2013-11",[6728,921,6031,6729],"Lymphoid Malignancies","Non-hodgkin Lymphoma",[6713,6731,6732,6733,6734],"Oral 5-Azacitidine 100 MG","Romidepsin 14 MG\u002FM2","Oral 5-Azacitidine 200 MG","Oral 5-Azacitidine 300 MG",{"trials":6736,"activeCount":100},[],{"trials":6738,"activeCount":100},[],{"trials":6740,"activeCount":100},[],{"intervention":6731,"totalTrials":129,"cells":6742},{"EARLY_PHASE1":6743,"PHASE1":6745,"PHASE2":6747,"PHASE3":6753,"PHASE4":6755,"NA":6757},{"trials":6744,"activeCount":100},[],{"trials":6746,"activeCount":100},[],{"trials":6748,"activeCount":100},[6749],{"nctId":6722,"briefTitle":6723,"status":150,"phases":6750,"primaryCompletion":6725,"completion":6725,"start":6726,"enrollment":5450,"conditions":6751,"interventions":6752},[88,89],[6728,921,6031,6729],[6713,6731,6732,6733,6734],{"trials":6754,"activeCount":100},[],{"trials":6756,"activeCount":100},[],{"trials":6758,"activeCount":100},[],{"intervention":6732,"totalTrials":129,"cells":6760},{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6765,"PHASE3":6771,"PHASE4":6773,"NA":6775},{"trials":6762,"activeCount":100},[],{"trials":6764,"activeCount":100},[],{"trials":6766,"activeCount":100},[6767],{"nctId":6722,"briefTitle":6723,"status":150,"phases":6768,"primaryCompletion":6725,"completion":6725,"start":6726,"enrollment":5450,"conditions":6769,"interventions":6770},[88,89],[6728,921,6031,6729],[6713,6731,6732,6733,6734],{"trials":6772,"activeCount":100},[],{"trials":6774,"activeCount":100},[],{"trials":6776,"activeCount":100},[],{"intervention":6733,"totalTrials":129,"cells":6778},{"EARLY_PHASE1":6779,"PHASE1":6781,"PHASE2":6783,"PHASE3":6789,"PHASE4":6791,"NA":6793},{"trials":6780,"activeCount":100},[],{"trials":6782,"activeCount":100},[],{"trials":6784,"activeCount":100},[6785],{"nctId":6722,"briefTitle":6723,"status":150,"phases":6786,"primaryCompletion":6725,"completion":6725,"start":6726,"enrollment":5450,"conditions":6787,"interventions":6788},[88,89],[6728,921,6031,6729],[6713,6731,6732,6733,6734],{"trials":6790,"activeCount":100},[],{"trials":6792,"activeCount":100},[],{"trials":6794,"activeCount":100},[],{"intervention":6734,"totalTrials":129,"cells":6796},{"EARLY_PHASE1":6797,"PHASE1":6799,"PHASE2":6801,"PHASE3":6807,"PHASE4":6809,"NA":6811},{"trials":6798,"activeCount":100},[],{"trials":6800,"activeCount":100},[],{"trials":6802,"activeCount":100},[6803],{"nctId":6722,"briefTitle":6723,"status":150,"phases":6804,"primaryCompletion":6725,"completion":6725,"start":6726,"enrollment":5450,"conditions":6805,"interventions":6806},[88,89],[6728,921,6031,6729],[6713,6731,6732,6733,6734],{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[],{"trials":6812,"activeCount":100},[],{"intervention":6126,"totalTrials":129,"cells":6814},{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6825,"PHASE4":6827,"NA":6829},{"trials":6816,"activeCount":100},[],{"trials":6818,"activeCount":100},[],{"trials":6820,"activeCount":100},[6821],{"nctId":6118,"briefTitle":6119,"status":119,"phases":6822,"primaryCompletion":6121,"completion":6121,"start":6122,"enrollment":6123,"conditions":6823,"interventions":6824},[88,89],[21],[4688,6126],{"trials":6826,"activeCount":100},[],{"trials":6828,"activeCount":100},[],{"trials":6830,"activeCount":100},[],{"intervention":6832,"totalTrials":129,"cells":6833},"Clazakizumab",{"EARLY_PHASE1":6834,"PHASE1":6836,"PHASE2":6838,"PHASE3":6848,"PHASE4":6850,"NA":6852},{"trials":6835,"activeCount":100},[],{"trials":6837,"activeCount":100},[],{"trials":6839,"activeCount":100},[6840],{"nctId":6841,"briefTitle":6842,"status":150,"phases":6843,"primaryCompletion":6844,"completion":6844,"start":6845,"enrollment":129,"conditions":6846,"interventions":6847},"NCT04381052","Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection",[89],"2021-04-01","2020-05-18",[4054],[6832],{"trials":6849,"activeCount":100},[],{"trials":6851,"activeCount":100},[],{"trials":6853,"activeCount":100},[],{"intervention":1050,"totalTrials":129,"cells":6855},{"EARLY_PHASE1":6856,"PHASE1":6858,"PHASE2":6860,"PHASE3":6866,"PHASE4":6868,"NA":6870},{"trials":6857,"activeCount":100},[],{"trials":6859,"activeCount":100},[],{"trials":6861,"activeCount":100},[6862],{"nctId":1041,"briefTitle":1042,"status":119,"phases":6863,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":796,"conditions":6864,"interventions":6865},[89],[1048],[1050,787],{"trials":6867,"activeCount":100},[],{"trials":6869,"activeCount":100},[],{"trials":6871,"activeCount":100},[],{"intervention":6873,"totalTrials":129,"cells":6874},"Glutamine",{"EARLY_PHASE1":6875,"PHASE1":6877,"PHASE2":6879,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6876,"activeCount":100},[],{"trials":6878,"activeCount":100},[],{"trials":6880,"activeCount":100},[6881],{"nctId":6882,"briefTitle":6883,"status":119,"phases":6884,"primaryCompletion":734,"completion":734,"start":6885,"enrollment":3817,"conditions":6886,"interventions":6891},"NCT00365768","Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors",[89],"2004-10",[6887,894,921,6888,6889,6890],"Kidney Cancer","Neurotoxicity","Peripheral Neuropathy","Sarcoma",[6873],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[],{"trials":6897,"activeCount":100},[],{"intervention":6899,"totalTrials":129,"cells":6900},"MEDI6012",{"EARLY_PHASE1":6901,"PHASE1":6903,"PHASE2":6905,"PHASE3":6916,"PHASE4":6918,"NA":6920},{"trials":6902,"activeCount":100},[],{"trials":6904,"activeCount":100},[],{"trials":6906,"activeCount":100},[6907],{"nctId":6908,"briefTitle":6909,"status":150,"phases":6910,"primaryCompletion":6911,"completion":6911,"start":6912,"enrollment":446,"conditions":6913,"interventions":6915},"NCT03773172","Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism",[89],"2020-08-31","2019-01-31",[6914],"Cardiovascular Diseases",[6899],{"trials":6917,"activeCount":100},[],{"trials":6919,"activeCount":100},[],{"trials":6921,"activeCount":100},[],{"intervention":6923,"totalTrials":129,"cells":6924},"Vasopressin - Very Low Dose",{"EARLY_PHASE1":6925,"PHASE1":6927,"PHASE2":6929,"PHASE3":6939,"PHASE4":6941,"NA":6943},{"trials":6926,"activeCount":100},[],{"trials":6928,"activeCount":100},[],{"trials":6930,"activeCount":100},[6931],{"nctId":6932,"briefTitle":6933,"status":119,"phases":6934,"primaryCompletion":6935,"completion":6935,"start":4297,"enrollment":796,"conditions":6936,"interventions":6937},"NCT01247090","Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease",[89],"2018-08",[3631,4682],[6923,6938],"Vasopressin - Low Dose",{"trials":6940,"activeCount":100},[],{"trials":6942,"activeCount":100},[],{"trials":6944,"activeCount":100},[],{"intervention":6938,"totalTrials":129,"cells":6946},{"EARLY_PHASE1":6947,"PHASE1":6949,"PHASE2":6951,"PHASE3":6957,"PHASE4":6959,"NA":6961},{"trials":6948,"activeCount":100},[],{"trials":6950,"activeCount":100},[],{"trials":6952,"activeCount":100},[6953],{"nctId":6932,"briefTitle":6933,"status":119,"phases":6954,"primaryCompletion":6935,"completion":6935,"start":4297,"enrollment":796,"conditions":6955,"interventions":6956},[89],[3631,4682],[6923,6938],{"trials":6958,"activeCount":100},[],{"trials":6960,"activeCount":100},[],{"trials":6962,"activeCount":100},[],{"intervention":6964,"totalTrials":129,"cells":6965},"Esomeprazole",{"EARLY_PHASE1":6966,"PHASE1":6968,"PHASE2":6970,"PHASE3":6979,"PHASE4":6981,"NA":6983},{"trials":6967,"activeCount":100},[],{"trials":6969,"activeCount":100},[],{"trials":6971,"activeCount":100},[6972],{"nctId":6973,"briefTitle":6974,"status":119,"phases":6975,"primaryCompletion":136,"completion":136,"start":760,"enrollment":4568,"conditions":6976,"interventions":6978},"NCT01983774","Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations",[89],[6977],"Cystic Fibrosis",[6964],{"trials":6980,"activeCount":100},[],{"trials":6982,"activeCount":100},[],{"trials":6984,"activeCount":100},[],{"intervention":6986,"totalTrials":129,"cells":6987},"coenzyme Q10",{"EARLY_PHASE1":6988,"PHASE1":6990,"PHASE2":6992,"PHASE3":7004,"PHASE4":7006,"NA":7008},{"trials":6989,"activeCount":100},[],{"trials":6991,"activeCount":100},[],{"trials":6993,"activeCount":100},[6994],{"nctId":6995,"briefTitle":6996,"status":119,"phases":6997,"primaryCompletion":6998,"completion":6998,"start":6999,"enrollment":7000,"conditions":7001,"interventions":7003},"NCT00243932","Clinical Trial of High Dose CoQ10 in ALS",[89],"2008-03","2005-04",185,[2822,7002],"Lou Gehrig's Disease",[6986],{"trials":7005,"activeCount":100},[],{"trials":7007,"activeCount":100},[],{"trials":7009,"activeCount":100},[],{"intervention":7011,"totalTrials":129,"cells":7012},"Daily oral vitamin D3, 3,333 IU",{"EARLY_PHASE1":7013,"PHASE1":7015,"PHASE2":7017,"PHASE3":7036,"PHASE4":7038,"NA":7040},{"trials":7014,"activeCount":100},[],{"trials":7016,"activeCount":100},[],{"trials":7018,"activeCount":100},[7019],{"nctId":7020,"briefTitle":7021,"status":119,"phases":7022,"primaryCompletion":7023,"completion":7023,"start":7024,"enrollment":5450,"conditions":7025,"interventions":7034},"NCT04170348","Daily Vitamin D for Sickle-cell Respiratory Complications",[89],"2024-06-18","2020-09-15",[936,2184,7026,7027,7028,7029,7030,35,7031,7032,7033,3085],"Anemia, Hemolytic, Congenital","Respiratory Tract Diseases","Respiration Disorders","Acute Chest Syndrome","Lung Diseases","Respiratory Tract Infections","Nutrition Disorders","Deficiency Diseases Vitamin",[7011,7035],"Monthly oral vitamin D3, 100,000 IU",{"trials":7037,"activeCount":100},[],{"trials":7039,"activeCount":100},[],{"trials":7041,"activeCount":100},[],{"intervention":7035,"totalTrials":129,"cells":7043},{"EARLY_PHASE1":7044,"PHASE1":7046,"PHASE2":7048,"PHASE3":7054,"PHASE4":7056,"NA":7058},{"trials":7045,"activeCount":100},[],{"trials":7047,"activeCount":100},[],{"trials":7049,"activeCount":100},[7050],{"nctId":7020,"briefTitle":7021,"status":119,"phases":7051,"primaryCompletion":7023,"completion":7023,"start":7024,"enrollment":5450,"conditions":7052,"interventions":7053},[89],[936,2184,7026,7027,7028,7029,7030,35,7031,7032,7033,3085],[7011,7035],{"trials":7055,"activeCount":100},[],{"trials":7057,"activeCount":100},[],{"trials":7059,"activeCount":100},[],{"intervention":926,"totalTrials":129,"cells":7061},{"EARLY_PHASE1":7062,"PHASE1":7064,"PHASE2":7066,"PHASE3":7072,"PHASE4":7074,"NA":7076},{"trials":7063,"activeCount":100},[],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":100},[7068],{"nctId":915,"briefTitle":916,"status":150,"phases":7069,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":7070,"interventions":7071},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"trials":7073,"activeCount":100},[],{"trials":7075,"activeCount":100},[],{"trials":7077,"activeCount":100},[],{"intervention":928,"totalTrials":129,"cells":7079},{"EARLY_PHASE1":7080,"PHASE1":7082,"PHASE2":7084,"PHASE3":7090,"PHASE4":7092,"NA":7094},{"trials":7081,"activeCount":100},[],{"trials":7083,"activeCount":100},[],{"trials":7085,"activeCount":100},[7086],{"nctId":915,"briefTitle":916,"status":150,"phases":7087,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":7088,"interventions":7089},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"trials":7091,"activeCount":100},[],{"trials":7093,"activeCount":100},[],{"trials":7095,"activeCount":100},[],{"intervention":929,"totalTrials":129,"cells":7097},{"EARLY_PHASE1":7098,"PHASE1":7100,"PHASE2":7102,"PHASE3":7108,"PHASE4":7110,"NA":7112},{"trials":7099,"activeCount":100},[],{"trials":7101,"activeCount":100},[],{"trials":7103,"activeCount":100},[7104],{"nctId":915,"briefTitle":916,"status":150,"phases":7105,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":7106,"interventions":7107},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"trials":7109,"activeCount":100},[],{"trials":7111,"activeCount":100},[],{"trials":7113,"activeCount":100},[],{"intervention":930,"totalTrials":129,"cells":7115},{"EARLY_PHASE1":7116,"PHASE1":7118,"PHASE2":7120,"PHASE3":7126,"PHASE4":7128,"NA":7130},{"trials":7117,"activeCount":100},[],{"trials":7119,"activeCount":100},[],{"trials":7121,"activeCount":100},[7122],{"nctId":915,"briefTitle":916,"status":150,"phases":7123,"primaryCompletion":918,"completion":918,"start":919,"enrollment":129,"conditions":7124,"interventions":7125},[88,89],[894,921,881,922,923],[853,925,50,926,851,927,928,929,930],{"trials":7127,"activeCount":100},[],{"trials":7129,"activeCount":100},[],{"trials":7131,"activeCount":100},[],{"intervention":7133,"totalTrials":129,"cells":7134},"TXA127",{"EARLY_PHASE1":7135,"PHASE1":7137,"PHASE2":7139,"PHASE3":7149,"PHASE4":7151,"NA":7153},{"trials":7136,"activeCount":100},[],{"trials":7138,"activeCount":100},[],{"trials":7140,"activeCount":100},[7141],{"nctId":7142,"briefTitle":7143,"status":119,"phases":7144,"primaryCompletion":7145,"completion":7145,"start":7146,"enrollment":4795,"conditions":7147,"interventions":7148},"NCT04401423","TXA127 for the Treatment of Severe COVID-19",[89],"2021-06-10","2021-02-10",[4054],[7133],{"trials":7150,"activeCount":100},[],{"trials":7152,"activeCount":100},[],{"trials":7154,"activeCount":100},[],{"intervention":7156,"totalTrials":129,"cells":7157},"Thioguanine",{"EARLY_PHASE1":7158,"PHASE1":7160,"PHASE2":7162,"PHASE3":7172,"PHASE4":7174,"NA":7176},{"trials":7159,"activeCount":100},[],{"trials":7161,"activeCount":100},[],{"trials":7163,"activeCount":100},[7164],{"nctId":7165,"briefTitle":7166,"status":415,"phases":7167,"primaryCompletion":7168,"completion":7168,"start":7168,"enrollment":100,"conditions":7169,"interventions":7170},"NCT06351306","DEC-C and Thioguanine for R\u002FR AML",[89],"2024-04-01",[4748],[7156,7171],"DecitabineCedazuridine",{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[],{"intervention":7171,"totalTrials":129,"cells":7179},{"EARLY_PHASE1":7180,"PHASE1":7182,"PHASE2":7184,"PHASE3":7190,"PHASE4":7192,"NA":7194},{"trials":7181,"activeCount":100},[],{"trials":7183,"activeCount":100},[],{"trials":7185,"activeCount":100},[7186],{"nctId":7165,"briefTitle":7166,"status":415,"phases":7187,"primaryCompletion":7168,"completion":7168,"start":7168,"enrollment":100,"conditions":7188,"interventions":7189},[89],[4748],[7156,7171],{"trials":7191,"activeCount":100},[],{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[],{"intervention":7197,"totalTrials":129,"cells":7198},"Sildenafil",{"EARLY_PHASE1":7199,"PHASE1":7201,"PHASE2":7203,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7200,"activeCount":100},[],{"trials":7202,"activeCount":100},[],{"trials":7204,"activeCount":100},[7205],{"nctId":7206,"briefTitle":7207,"status":119,"phases":7208,"primaryCompletion":7209,"completion":7209,"start":7210,"enrollment":4795,"conditions":7211,"interventions":7217},"NCT04356716","Sildenafil for Treatment of Choroidal Ischemia",[89],"2020-02-18","2014-11-11",[7212,7213,7214,7215,7216],"Choroidal Ischemia","Vitelliform Macular Dystrophy","Age-related Macular Degeneration","Central Serous Retinopathy","Retinitis Pigmentosa",[7197],{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[],{"trials":7223,"activeCount":100},[],{"intervention":7225,"totalTrials":129,"cells":7226},"Denileukin Diftitox",{"EARLY_PHASE1":7227,"PHASE1":7229,"PHASE2":7231,"PHASE3":7241,"PHASE4":7243,"NA":7245},{"trials":7228,"activeCount":100},[],{"trials":7230,"activeCount":100},[],{"trials":7232,"activeCount":100},[7233],{"nctId":7234,"briefTitle":7235,"status":415,"phases":7236,"primaryCompletion":3014,"completion":734,"start":3308,"enrollment":100,"conditions":7237,"interventions":7239},"NCT00801918","Denileukine Diftitox for Relapsed ALCL",[89],[7238],"Anaplastic Large-Cell Lymphoma",[7225,7240],"Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide",{"trials":7242,"activeCount":100},[],{"trials":7244,"activeCount":100},[],{"trials":7246,"activeCount":100},[],{"intervention":7240,"totalTrials":129,"cells":7248},{"EARLY_PHASE1":7249,"PHASE1":7251,"PHASE2":7253,"PHASE3":7259,"PHASE4":7261,"NA":7263},{"trials":7250,"activeCount":100},[],{"trials":7252,"activeCount":100},[],{"trials":7254,"activeCount":100},[7255],{"nctId":7234,"briefTitle":7235,"status":415,"phases":7256,"primaryCompletion":3014,"completion":734,"start":3308,"enrollment":100,"conditions":7257,"interventions":7258},[89],[7238],[7225,7240],{"trials":7260,"activeCount":100},[],{"trials":7262,"activeCount":100},[],{"trials":7264,"activeCount":100},[],{"intervention":7266,"totalTrials":129,"cells":7267},"Valacyclovir",{"EARLY_PHASE1":7268,"PHASE1":7270,"PHASE2":7272,"PHASE3":7284,"PHASE4":7286,"NA":7288},{"trials":7269,"activeCount":100},[],{"trials":7271,"activeCount":100},[],{"trials":7273,"activeCount":100},[7274],{"nctId":7275,"briefTitle":7276,"status":119,"phases":7277,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":301,"conditions":7280,"interventions":7283},"NCT03282916","Anti-viral Therapy in Alzheimer's Disease",[89],"2024-09-05","2018-02-12",[1133,7281,7282],"Herpes Simplex 1","Herpes Simplex 2",[7266],{"trials":7285,"activeCount":100},[],{"trials":7287,"activeCount":100},[],{"trials":7289,"activeCount":100},[],{"intervention":7291,"totalTrials":129,"cells":7292},"MGCD516",{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7309,"PHASE4":7311,"NA":7313},{"trials":7294,"activeCount":100},[],{"trials":7296,"activeCount":100},[],{"trials":7298,"activeCount":100},[7299],{"nctId":7300,"briefTitle":7301,"status":119,"phases":7302,"primaryCompletion":2870,"completion":7303,"start":7304,"enrollment":1073,"conditions":7305,"interventions":7308},"NCT02978859","Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas",[89],"2021-12-20","2016-11",[7306,7307],"Liposarcoma","Metastatic Liposarcoma",[7291],{"trials":7310,"activeCount":100},[],{"trials":7312,"activeCount":100},[],{"trials":7314,"activeCount":100},[],{"intervention":7316,"totalTrials":129,"cells":7317},"Tofacitinib",{"EARLY_PHASE1":7318,"PHASE1":7320,"PHASE2":7322,"PHASE3":7331,"PHASE4":7333,"NA":7335},{"trials":7319,"activeCount":100},[],{"trials":7321,"activeCount":100},[],{"trials":7323,"activeCount":100},[7324],{"nctId":7325,"briefTitle":7326,"status":119,"phases":7327,"primaryCompletion":4152,"completion":4152,"start":7328,"enrollment":796,"conditions":7329,"interventions":7330},"NCT02299297","Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis",[89],"2015-01",[2667],[7316],{"trials":7332,"activeCount":100},[],{"trials":7334,"activeCount":100},[],{"trials":7336,"activeCount":100},[],{"intervention":7338,"totalTrials":129,"cells":7339},"BMS-986253",{"EARLY_PHASE1":7340,"PHASE1":7342,"PHASE2":7344,"PHASE3":7357,"PHASE4":7359,"NA":7361},{"trials":7341,"activeCount":100},[],{"trials":7343,"activeCount":100},[],{"trials":7345,"activeCount":100},[7346],{"nctId":7347,"briefTitle":7348,"status":150,"phases":7349,"primaryCompletion":7350,"completion":7350,"start":7351,"enrollment":2569,"conditions":7352,"interventions":7356},"NCT04347226","Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19",[89],"2021-03-01","2020-04-16",[7353,7354,7355],"Solid Tumor","Sars-CoV2","Hematological Malignancy",[7338],{"trials":7358,"activeCount":100},[],{"trials":7360,"activeCount":100},[],{"trials":7362,"activeCount":100},[],{"intervention":5694,"totalTrials":129,"cells":7364},{"EARLY_PHASE1":7365,"PHASE1":7367,"PHASE2":7369,"PHASE3":7375,"PHASE4":7377,"NA":7379},{"trials":7366,"activeCount":100},[],{"trials":7368,"activeCount":100},[],{"trials":7370,"activeCount":100},[7371],{"nctId":5686,"briefTitle":5687,"status":119,"phases":7372,"primaryCompletion":5689,"completion":5689,"start":5690,"enrollment":5691,"conditions":7373,"interventions":7374},[89],[5681],[5694,5684,2403],{"trials":7376,"activeCount":100},[],{"trials":7378,"activeCount":100},[],{"trials":7380,"activeCount":100},[],{"intervention":7382,"totalTrials":129,"cells":7383},"Velcade",{"EARLY_PHASE1":7384,"PHASE1":7386,"PHASE2":7388,"PHASE3":7397,"PHASE4":7399,"NA":7401},{"trials":7385,"activeCount":100},[],{"trials":7387,"activeCount":100},[],{"trials":7389,"activeCount":100},[7390],{"nctId":7391,"briefTitle":7392,"status":4196,"phases":7393,"primaryCompletion":2503,"completion":7394,"start":736,"enrollment":1073,"conditions":7395,"interventions":7396},"NCT00996385","Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma",[89],"2014-09",[1075],[7382],{"trials":7398,"activeCount":100},[],{"trials":7400,"activeCount":100},[],{"trials":7402,"activeCount":100},[],{"intervention":7404,"totalTrials":129,"cells":7405},"Chloroquine",{"EARLY_PHASE1":7406,"PHASE1":7408,"PHASE2":7410,"PHASE3":7422,"PHASE4":7424,"NA":7426},{"trials":7407,"activeCount":100},[],{"trials":7409,"activeCount":100},[],{"trials":7411,"activeCount":100},[7412],{"nctId":7413,"briefTitle":7414,"status":150,"phases":7415,"primaryCompletion":7416,"completion":7416,"start":7417,"enrollment":2432,"conditions":7418,"interventions":7421},"NCT04349371","Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID",[89],"2021-02-11","2020-04-21",[7419,7420],"COVID","Coronavirus Infection",[7404],{"trials":7423,"activeCount":100},[],{"trials":7425,"activeCount":100},[],{"trials":7427,"activeCount":100},[],{"intervention":7429,"totalTrials":129,"cells":7430},"Lithium Carbonate",{"EARLY_PHASE1":7431,"PHASE1":7433,"PHASE2":7435,"PHASE3":7445,"PHASE4":7447,"NA":7449},{"trials":7432,"activeCount":100},[],{"trials":7434,"activeCount":100},[],{"trials":7436,"activeCount":100},[7437],{"nctId":7438,"briefTitle":7439,"status":119,"phases":7440,"primaryCompletion":7441,"completion":7441,"start":7442,"enrollment":5666,"conditions":7443,"interventions":7444},"NCT02862210","Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia",[89],"2022-11-20","2017-01-27",[6579],[7429],{"trials":7446,"activeCount":100},[],{"trials":7448,"activeCount":100},[],{"trials":7450,"activeCount":100},[],{"intervention":7452,"totalTrials":129,"cells":7453},"topical menthol",{"EARLY_PHASE1":7454,"PHASE1":7456,"PHASE2":7458,"PHASE3":7468,"PHASE4":7470,"NA":7472},{"trials":7455,"activeCount":100},[],{"trials":7457,"activeCount":100},[],{"trials":7459,"activeCount":100},[7460],{"nctId":7461,"briefTitle":7462,"status":150,"phases":7463,"primaryCompletion":7304,"completion":7304,"start":2674,"enrollment":796,"conditions":7464,"interventions":7467},"NCT01855607","Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy",[89],[23,7465,7466],"Colon Cancer","Neuropathy",[7452],{"trials":7469,"activeCount":100},[],{"trials":7471,"activeCount":100},[],{"trials":7473,"activeCount":100},[],{"intervention":7475,"totalTrials":129,"cells":7476},"Adefovir dipivoxil and hepatitis B vaccination",{"EARLY_PHASE1":7477,"PHASE1":7479,"PHASE2":7481,"PHASE3":7490,"PHASE4":7492,"NA":7494},{"trials":7478,"activeCount":100},[],{"trials":7480,"activeCount":100},[],{"trials":7482,"activeCount":100},[7483],{"nctId":7484,"briefTitle":7485,"status":119,"phases":7486,"primaryCompletion":2744,"completion":2422,"start":2627,"enrollment":30,"conditions":7487,"interventions":7489},"NCT01146808","Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver",[88,89],[7488,4658],"Hepatitis B",[7475],{"trials":7491,"activeCount":100},[],{"trials":7493,"activeCount":100},[],{"trials":7495,"activeCount":100},[],{"intervention":7497,"totalTrials":129,"cells":7498},"18F-THK-5351",{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7503,"PHASE3":7513,"PHASE4":7515,"NA":7517},{"trials":7500,"activeCount":100},[],{"trials":7502,"activeCount":100},[],{"trials":7504,"activeCount":100},[7505],{"nctId":7506,"briefTitle":7507,"status":415,"phases":7508,"primaryCompletion":3508,"completion":2870,"start":4152,"enrollment":100,"conditions":7509,"interventions":7512},"NCT03024944","TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind",[89],[7510,7511],"Diabetes Mellitus","Alzheimer Dementia",[7497],{"trials":7514,"activeCount":100},[],{"trials":7516,"activeCount":100},[],{"trials":7518,"activeCount":100},[],{"intervention":7520,"totalTrials":129,"cells":7521},"Nutraceutical supplements",{"EARLY_PHASE1":7522,"PHASE1":7524,"PHASE2":7526,"PHASE3":7536,"PHASE4":7538,"NA":7540},{"trials":7523,"activeCount":100},[],{"trials":7525,"activeCount":100},[],{"trials":7527,"activeCount":100},[7528],{"nctId":7529,"briefTitle":7530,"status":415,"phases":7531,"primaryCompletion":7532,"completion":7532,"start":417,"enrollment":100,"conditions":7533,"interventions":7535},"NCT01471652","Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder",[89],"2013-02",[7534],"Chronic Fatigue Syndrome",[7520],{"trials":7537,"activeCount":100},[],{"trials":7539,"activeCount":100},[],{"trials":7541,"activeCount":100},[],{"intervention":7543,"totalTrials":129,"cells":7544},"Sertraline, citalopram, or bupropion",{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7549,"PHASE3":7558,"PHASE4":7560,"NA":7562},{"trials":7546,"activeCount":100},[],{"trials":7548,"activeCount":100},[],{"trials":7550,"activeCount":100},[7551],{"nctId":7552,"briefTitle":7553,"status":119,"phases":7554,"primaryCompletion":3036,"completion":2454,"start":5449,"enrollment":243,"conditions":7555,"interventions":7557},"NCT01032018","Comparison of Depression Interventions After Acute Coronary Syndrome",[88,89],[7556,4762],"Acute Coronary Syndrome",[7543],{"trials":7559,"activeCount":100},[],{"trials":7561,"activeCount":100},[],{"trials":7563,"activeCount":100},[],{"intervention":7565,"totalTrials":129,"cells":7566},"Low Dose Lovastatin",{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7571,"PHASE3":7584,"PHASE4":7586,"NA":7588},{"trials":7568,"activeCount":100},[],{"trials":7570,"activeCount":100},[],{"trials":7572,"activeCount":100},[7573],{"nctId":7574,"briefTitle":7575,"status":119,"phases":7576,"primaryCompletion":7577,"completion":7577,"start":4392,"enrollment":7578,"conditions":7579,"interventions":7582},"NCT01976936","Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2",[89],"2015-11-30",162,[18,7580,7581],"Rhabdomyolysis","Jaundice",[7565,7583],"High Dose Lovastatin",{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"intervention":7583,"totalTrials":129,"cells":7591},{"EARLY_PHASE1":7592,"PHASE1":7594,"PHASE2":7596,"PHASE3":7602,"PHASE4":7604,"NA":7606},{"trials":7593,"activeCount":100},[],{"trials":7595,"activeCount":100},[],{"trials":7597,"activeCount":100},[7598],{"nctId":7574,"briefTitle":7575,"status":119,"phases":7599,"primaryCompletion":7577,"completion":7577,"start":4392,"enrollment":7578,"conditions":7600,"interventions":7601},[89],[18,7580,7581],[7565,7583],{"trials":7603,"activeCount":100},[],{"trials":7605,"activeCount":100},[],{"trials":7607,"activeCount":100},[],{"intervention":7609,"totalTrials":129,"cells":7610},"Lidocaine",{"EARLY_PHASE1":7611,"PHASE1":7613,"PHASE2":7615,"PHASE3":7628,"PHASE4":7630,"NA":7632},{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[],{"trials":7616,"activeCount":100},[7617],{"nctId":7618,"briefTitle":7619,"status":119,"phases":7620,"primaryCompletion":7621,"completion":7621,"start":7622,"enrollment":7623,"conditions":7624,"interventions":7625},"NCT03054844","PREMIX vs PREMED Intranasal Lidocaine and Midazolam",[89],"2017-10-10","2017-04-03",55,[625],[7609,7626,7627],"Lidocaine and midazolam","Midazolam",{"trials":7629,"activeCount":100},[],{"trials":7631,"activeCount":100},[],{"trials":7633,"activeCount":100},[],{"intervention":7626,"totalTrials":129,"cells":7635},{"EARLY_PHASE1":7636,"PHASE1":7638,"PHASE2":7640,"PHASE3":7646,"PHASE4":7648,"NA":7650},{"trials":7637,"activeCount":100},[],{"trials":7639,"activeCount":100},[],{"trials":7641,"activeCount":100},[7642],{"nctId":7618,"briefTitle":7619,"status":119,"phases":7643,"primaryCompletion":7621,"completion":7621,"start":7622,"enrollment":7623,"conditions":7644,"interventions":7645},[89],[625],[7609,7626,7627],{"trials":7647,"activeCount":100},[],{"trials":7649,"activeCount":100},[],{"trials":7651,"activeCount":100},[],{"intervention":7627,"totalTrials":129,"cells":7653},{"EARLY_PHASE1":7654,"PHASE1":7656,"PHASE2":7658,"PHASE3":7664,"PHASE4":7666,"NA":7668},{"trials":7655,"activeCount":100},[],{"trials":7657,"activeCount":100},[],{"trials":7659,"activeCount":100},[7660],{"nctId":7618,"briefTitle":7619,"status":119,"phases":7661,"primaryCompletion":7621,"completion":7621,"start":7622,"enrollment":7623,"conditions":7662,"interventions":7663},[89],[625],[7609,7626,7627],{"trials":7665,"activeCount":100},[],{"trials":7667,"activeCount":100},[],{"trials":7669,"activeCount":100},[],{"intervention":7671,"totalTrials":129,"cells":7672},"Inulin Oral Suspension",{"EARLY_PHASE1":7673,"PHASE1":7675,"PHASE2":7677,"PHASE3":7694,"PHASE4":7696,"NA":7698},{"trials":7674,"activeCount":100},[],{"trials":7676,"activeCount":100},[],{"trials":7678,"activeCount":100},[7679],{"nctId":7680,"briefTitle":7681,"status":119,"phases":7682,"primaryCompletion":7683,"completion":7684,"start":7685,"enrollment":4052,"conditions":7686,"interventions":7692},"NCT03865706","Inulin for Infections in the Intensive Care Unit",[89],"2023-11-21","2024-07-23","2019-10-14",[7687,7688,7689,7032,7690,7691],"Antibiotic Resistant Infection","Nosocomial Infection","Pathogen Transmission","Critical Illness","Sepsis",[7671,7693],"Broad-spectrum antibiotics",{"trials":7695,"activeCount":100},[],{"trials":7697,"activeCount":100},[],{"trials":7699,"activeCount":100},[],{"intervention":7693,"totalTrials":129,"cells":7701},{"EARLY_PHASE1":7702,"PHASE1":7704,"PHASE2":7706,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7703,"activeCount":100},[],{"trials":7705,"activeCount":100},[],{"trials":7707,"activeCount":100},[7708],{"nctId":7680,"briefTitle":7681,"status":119,"phases":7709,"primaryCompletion":7683,"completion":7684,"start":7685,"enrollment":4052,"conditions":7710,"interventions":7711},[89],[7687,7688,7689,7032,7690,7691],[7671,7693],{"trials":7713,"activeCount":100},[],{"trials":7715,"activeCount":100},[],{"trials":7717,"activeCount":100},[],{"intervention":2404,"totalTrials":129,"cells":7719},{"EARLY_PHASE1":7720,"PHASE1":7722,"PHASE2":7724,"PHASE3":7730,"PHASE4":7732,"NA":7734},{"trials":7721,"activeCount":100},[],{"trials":7723,"activeCount":100},[],{"trials":7725,"activeCount":100},[7726],{"nctId":2393,"briefTitle":2394,"status":119,"phases":7727,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":7728,"interventions":7729},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":7731,"activeCount":100},[],{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"intervention":2405,"totalTrials":129,"cells":7737},{"EARLY_PHASE1":7738,"PHASE1":7740,"PHASE2":7742,"PHASE3":7748,"PHASE4":7750,"NA":7752},{"trials":7739,"activeCount":100},[],{"trials":7741,"activeCount":100},[],{"trials":7743,"activeCount":100},[7744],{"nctId":2393,"briefTitle":2394,"status":119,"phases":7745,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":7746,"interventions":7747},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":7749,"activeCount":100},[],{"trials":7751,"activeCount":100},[],{"trials":7753,"activeCount":100},[],{"intervention":2406,"totalTrials":129,"cells":7755},{"EARLY_PHASE1":7756,"PHASE1":7758,"PHASE2":7760,"PHASE3":7766,"PHASE4":7768,"NA":7770},{"trials":7757,"activeCount":100},[],{"trials":7759,"activeCount":100},[],{"trials":7761,"activeCount":100},[7762],{"nctId":2393,"briefTitle":2394,"status":119,"phases":7763,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":7764,"interventions":7765},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":7767,"activeCount":100},[],{"trials":7769,"activeCount":100},[],{"trials":7771,"activeCount":100},[],{"intervention":2407,"totalTrials":129,"cells":7773},{"EARLY_PHASE1":7774,"PHASE1":7776,"PHASE2":7778,"PHASE3":7784,"PHASE4":7786,"NA":7788},{"trials":7775,"activeCount":100},[],{"trials":7777,"activeCount":100},[],{"trials":7779,"activeCount":100},[7780],{"nctId":2393,"briefTitle":2394,"status":119,"phases":7781,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":7782,"interventions":7783},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":7785,"activeCount":100},[],{"trials":7787,"activeCount":100},[],{"trials":7789,"activeCount":100},[],{"intervention":2408,"totalTrials":129,"cells":7791},{"EARLY_PHASE1":7792,"PHASE1":7794,"PHASE2":7796,"PHASE3":7802,"PHASE4":7804,"NA":7806},{"trials":7793,"activeCount":100},[],{"trials":7795,"activeCount":100},[],{"trials":7797,"activeCount":100},[7798],{"nctId":2393,"briefTitle":2394,"status":119,"phases":7799,"primaryCompletion":2396,"completion":2397,"start":735,"enrollment":1735,"conditions":7800,"interventions":7801},[89],[2399,23],[2401,2402,2403,2404,2405,754,927,2406,2407,2408],{"trials":7803,"activeCount":100},[],{"trials":7805,"activeCount":100},[],{"trials":7807,"activeCount":100},[],{"intervention":1144,"totalTrials":129,"cells":7809},{"EARLY_PHASE1":7810,"PHASE1":7812,"PHASE2":7814,"PHASE3":7820,"PHASE4":7822,"NA":7824},{"trials":7811,"activeCount":100},[],{"trials":7813,"activeCount":100},[],{"trials":7815,"activeCount":100},[7816],{"nctId":1137,"briefTitle":1138,"status":119,"phases":7817,"primaryCompletion":1140,"completion":1140,"start":1141,"enrollment":737,"conditions":7818,"interventions":7819},[88,89],[1133],[1118,1144],{"trials":7821,"activeCount":100},[],{"trials":7823,"activeCount":100},[],{"trials":7825,"activeCount":100},[],{"intervention":7827,"totalTrials":129,"cells":7828},"Crizotinib",{"EARLY_PHASE1":7829,"PHASE1":7831,"PHASE2":7833,"PHASE3":7842,"PHASE4":7844,"NA":7846},{"trials":7830,"activeCount":100},[],{"trials":7832,"activeCount":100},[],{"trials":7834,"activeCount":100},[7835],{"nctId":7836,"briefTitle":7837,"status":119,"phases":7838,"primaryCompletion":2594,"completion":2594,"start":2721,"enrollment":4594,"conditions":7839,"interventions":7841},"NCT02223819","Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy",[89],[7840],"Uveal Melanoma",[7827],{"trials":7843,"activeCount":100},[],{"trials":7845,"activeCount":100},[],{"trials":7847,"activeCount":100},[],{"intervention":7849,"totalTrials":129,"cells":7850},"Durvalumab",{"EARLY_PHASE1":7851,"PHASE1":7853,"PHASE2":7855,"PHASE3":7867,"PHASE4":7869,"NA":7871},{"trials":7852,"activeCount":100},[],{"trials":7854,"activeCount":100},[],{"trials":7856,"activeCount":100},[7857],{"nctId":7858,"briefTitle":7859,"status":415,"phases":7860,"primaryCompletion":7861,"completion":7861,"start":7862,"enrollment":100,"conditions":7863,"interventions":7865},"NCT03130764","Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC",[89],"2017-11-30","2017-03",[7864],"Non-small Cell Lung Cancer",[7849,7866],"Tremelimumab",{"trials":7868,"activeCount":100},[],{"trials":7870,"activeCount":100},[],{"trials":7872,"activeCount":100},[],{"intervention":7866,"totalTrials":129,"cells":7874},{"EARLY_PHASE1":7875,"PHASE1":7877,"PHASE2":7879,"PHASE3":7885,"PHASE4":7887,"NA":7889},{"trials":7876,"activeCount":100},[],{"trials":7878,"activeCount":100},[],{"trials":7880,"activeCount":100},[7881],{"nctId":7858,"briefTitle":7859,"status":415,"phases":7882,"primaryCompletion":7861,"completion":7861,"start":7862,"enrollment":100,"conditions":7883,"interventions":7884},[89],[7864],[7849,7866],{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[],{"trials":7890,"activeCount":100},[],{"intervention":7892,"totalTrials":129,"cells":7893},"Gemcitabine, Docetaxel, Capecitabine",{"EARLY_PHASE1":7894,"PHASE1":7896,"PHASE2":7898,"PHASE3":7907,"PHASE4":7909,"NA":7911},{"trials":7895,"activeCount":100},[],{"trials":7897,"activeCount":100},[],{"trials":7899,"activeCount":100},[7900],{"nctId":7901,"briefTitle":7902,"status":119,"phases":7903,"primaryCompletion":907,"completion":907,"start":909,"enrollment":9,"conditions":7904,"interventions":7906},"NCT00996333","Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)",[89],[7905],"Metastatic Pancreatic Cancer",[7892],{"trials":7908,"activeCount":100},[],{"trials":7910,"activeCount":100},[],{"trials":7912,"activeCount":100},[],{"intervention":7914,"totalTrials":129,"cells":7915},"IVIG",{"EARLY_PHASE1":7916,"PHASE1":7918,"PHASE2":7920,"PHASE3":7931,"PHASE4":7933,"NA":7935},{"trials":7917,"activeCount":100},[],{"trials":7919,"activeCount":100},[],{"trials":7921,"activeCount":100},[7922],{"nctId":7923,"briefTitle":7924,"status":119,"phases":7925,"primaryCompletion":1044,"completion":7926,"start":6091,"enrollment":1394,"conditions":7927,"interventions":7930},"NCT00115778","Intravenous Immunoglobulin (IVIG) in Lung Transplantation",[89],"2010-08",[7928,7929],"Hypogammaglobulinemia","Lung Transplantation",[7914],{"trials":7932,"activeCount":100},[],{"trials":7934,"activeCount":100},[],{"trials":7936,"activeCount":100},[],{"intervention":7938,"totalTrials":129,"cells":7939},"Vismodegib",{"EARLY_PHASE1":7940,"PHASE1":7942,"PHASE2":7944,"PHASE3":7957,"PHASE4":7959,"NA":7961},{"trials":7941,"activeCount":100},[],{"trials":7943,"activeCount":100},[],{"trials":7945,"activeCount":100},[7946],{"nctId":7947,"briefTitle":7948,"status":415,"phases":7949,"primaryCompletion":7950,"completion":5931,"start":7951,"enrollment":100,"conditions":7952,"interventions":7954},"NCT03767439","Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome",[89],"2019-12","2019-07",[7953],"Basal Cell Nevus Syndrome",[7938,7955,7956],"Nivolumab","Ipilimumab",{"trials":7958,"activeCount":100},[],{"trials":7960,"activeCount":100},[],{"trials":7962,"activeCount":100},[],{"intervention":7955,"totalTrials":129,"cells":7964},{"EARLY_PHASE1":7965,"PHASE1":7967,"PHASE2":7969,"PHASE3":7975,"PHASE4":7977,"NA":7979},{"trials":7966,"activeCount":100},[],{"trials":7968,"activeCount":100},[],{"trials":7970,"activeCount":100},[7971],{"nctId":7947,"briefTitle":7948,"status":415,"phases":7972,"primaryCompletion":7950,"completion":5931,"start":7951,"enrollment":100,"conditions":7973,"interventions":7974},[89],[7953],[7938,7955,7956],{"trials":7976,"activeCount":100},[],{"trials":7978,"activeCount":100},[],{"trials":7980,"activeCount":100},[],{"intervention":7956,"totalTrials":129,"cells":7982},{"EARLY_PHASE1":7983,"PHASE1":7985,"PHASE2":7987,"PHASE3":7993,"PHASE4":7995,"NA":7997},{"trials":7984,"activeCount":100},[],{"trials":7986,"activeCount":100},[],{"trials":7988,"activeCount":100},[7989],{"nctId":7947,"briefTitle":7948,"status":415,"phases":7990,"primaryCompletion":7950,"completion":5931,"start":7951,"enrollment":100,"conditions":7991,"interventions":7992},[89],[7953],[7938,7955,7956],{"trials":7994,"activeCount":100},[],{"trials":7996,"activeCount":100},[],{"trials":7998,"activeCount":100},[],{"intervention":6212,"totalTrials":129,"cells":8000},{"EARLY_PHASE1":8001,"PHASE1":8003,"PHASE2":8005,"PHASE3":8011,"PHASE4":8013,"NA":8015},{"trials":8002,"activeCount":100},[],{"trials":8004,"activeCount":100},[],{"trials":8006,"activeCount":100},[8007],{"nctId":6203,"briefTitle":6204,"status":150,"phases":8008,"primaryCompletion":6198,"completion":6198,"start":6206,"enrollment":6207,"conditions":8009,"interventions":8010},[88,89],[6209,6210],[6212,6186],{"trials":8012,"activeCount":100},[],{"trials":8014,"activeCount":100},[],{"trials":8016,"activeCount":100},[],{"intervention":8018,"totalTrials":129,"cells":8019},"Cabergoline",{"EARLY_PHASE1":8020,"PHASE1":8022,"PHASE2":8024,"PHASE3":8035,"PHASE4":8037,"NA":8039},{"trials":8021,"activeCount":100},[],{"trials":8023,"activeCount":100},[],{"trials":8025,"activeCount":100},[8026],{"nctId":8027,"briefTitle":8028,"status":119,"phases":8029,"primaryCompletion":3551,"completion":8030,"start":4643,"enrollment":351,"conditions":8031,"interventions":8034},"NCT01395602","Effect of Cabergoline on Weight and Glucose Tolerance",[88,89],"2011-07",[8032,8033],"Body Weight","Impaired Glucose Tolerance in Obese",[8018],{"trials":8036,"activeCount":100},[],{"trials":8038,"activeCount":100},[],{"trials":8040,"activeCount":100},[],{"intervention":8042,"totalTrials":129,"cells":8043},"11C-PBR28",{"EARLY_PHASE1":8044,"PHASE1":8046,"PHASE2":8048,"PHASE3":8061,"PHASE4":8063,"NA":8065},{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"trials":8049,"activeCount":100},[8050],{"nctId":8051,"briefTitle":8052,"status":119,"phases":8053,"primaryCompletion":8054,"completion":8054,"start":8055,"enrollment":2432,"conditions":8056,"interventions":8060},"NCT02702102","Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",[89],"2019-09-04","2015-12",[8057,8058,8059],"Diffuse Lewy Body Disease","Dementia With Lewy Bodies","Parkinson's Disease Dementia",[8042],{"trials":8062,"activeCount":100},[],{"trials":8064,"activeCount":100},[],{"trials":8066,"activeCount":100},[],{"intervention":1077,"totalTrials":129,"cells":8068},{"EARLY_PHASE1":8069,"PHASE1":8071,"PHASE2":8073,"PHASE3":8079,"PHASE4":8081,"NA":8083},{"trials":8070,"activeCount":100},[],{"trials":8072,"activeCount":100},[],{"trials":8074,"activeCount":100},[8075],{"nctId":1067,"briefTitle":1068,"status":119,"phases":8076,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":8077,"interventions":8078},[89],[1075],[1077,787],{"trials":8080,"activeCount":100},[],{"trials":8082,"activeCount":100},[],{"trials":8084,"activeCount":100},[],{"intervention":8086,"totalTrials":129,"cells":8087},"Ibandronate",{"EARLY_PHASE1":8088,"PHASE1":8090,"PHASE2":8092,"PHASE3":8102,"PHASE4":8104,"NA":8106},{"trials":8089,"activeCount":100},[],{"trials":8091,"activeCount":100},[],{"trials":8093,"activeCount":100},[8094],{"nctId":8095,"briefTitle":8096,"status":119,"phases":8097,"primaryCompletion":8098,"completion":8098,"start":6005,"enrollment":2218,"conditions":8099,"interventions":8101},"NCT04321837","Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate",[89],"2023-03-13",[8100],"Osteoporosis, Postmenopausal",[8086],{"trials":8103,"activeCount":100},[],{"trials":8105,"activeCount":100},[],{"trials":8107,"activeCount":100},[],{"intervention":8109,"totalTrials":129,"cells":8110},"Reduced Intensity Conditioning, Busulfan and Fludarabine",{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8115,"PHASE3":8126,"PHASE4":8128,"NA":8130},{"trials":8112,"activeCount":100},[],{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[8117],{"nctId":8118,"briefTitle":8119,"status":150,"phases":8120,"primaryCompletion":8121,"completion":5582,"start":8122,"enrollment":2432,"conditions":8123,"interventions":8125},"NCT00531310","Reduced Intensity AlloSCT in(CML) With Persistent Disease",[89],"2007-12","2003-01",[8124],"Chronic Myeloid Leukemia",[8109],{"trials":8127,"activeCount":100},[],{"trials":8129,"activeCount":100},[],{"trials":8131,"activeCount":100},[],{"intervention":8133,"totalTrials":129,"cells":8134},"Ropinirole",{"EARLY_PHASE1":8135,"PHASE1":8137,"PHASE2":8139,"PHASE3":8151,"PHASE4":8153,"NA":8155},{"trials":8136,"activeCount":100},[],{"trials":8138,"activeCount":100},[],{"trials":8140,"activeCount":100},[8141],{"nctId":8142,"briefTitle":8143,"status":119,"phases":8144,"primaryCompletion":8145,"completion":8145,"start":8146,"enrollment":30,"conditions":8147,"interventions":8150},"NCT03038308","Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole",[88,89],"2020-11-05","2016-09-16",[8148,8149],"Hyperprolactinemia","Prolactinoma",[8133],{"trials":8152,"activeCount":100},[],{"trials":8154,"activeCount":100},[],{"trials":8156,"activeCount":100},[],{"intervention":8158,"totalTrials":129,"cells":8159},"Sunitinib",{"EARLY_PHASE1":8160,"PHASE1":8162,"PHASE2":8164,"PHASE3":8173,"PHASE4":8175,"NA":8177},{"trials":8161,"activeCount":100},[],{"trials":8163,"activeCount":100},[],{"trials":8165,"activeCount":100},[8166],{"nctId":8167,"briefTitle":8168,"status":150,"phases":8169,"primaryCompletion":3628,"completion":7532,"start":8170,"enrollment":1735,"conditions":8171,"interventions":8172},"NCT00859456","Sunitinib in Certain Subtypes of Soft Tissue Sarcomas",[89],"2007-04",[1048],[8158],{"trials":8174,"activeCount":100},[],{"trials":8176,"activeCount":100},[],{"trials":8178,"activeCount":100},[],{"intervention":8180,"totalTrials":129,"cells":8181},"Hydromorphone",{"EARLY_PHASE1":8182,"PHASE1":8184,"PHASE2":8186,"PHASE3":8196,"PHASE4":8198,"NA":8200},{"trials":8183,"activeCount":100},[],{"trials":8185,"activeCount":100},[],{"trials":8187,"activeCount":100},[8188],{"nctId":8189,"briefTitle":8190,"status":119,"phases":8191,"primaryCompletion":8192,"completion":8192,"start":8193,"enrollment":2466,"conditions":8194,"interventions":8195},"NCT02437669","Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.",[89],"2018-04","2015-05",[625],[8180],{"trials":8197,"activeCount":100},[],{"trials":8199,"activeCount":100},[],{"trials":8201,"activeCount":100},[],{"intervention":8203,"totalTrials":129,"cells":8204},"Nitrous oxide 50%",{"EARLY_PHASE1":8205,"PHASE1":8207,"PHASE2":8209,"PHASE3":8219,"PHASE4":8221,"NA":8223},{"trials":8206,"activeCount":100},[],{"trials":8208,"activeCount":100},[],{"trials":8210,"activeCount":100},[8211],{"nctId":8212,"briefTitle":8213,"status":119,"phases":8214,"primaryCompletion":154,"completion":154,"start":8215,"enrollment":2432,"conditions":8216,"interventions":8218},"NCT01891812","Nitrous Oxide Analgesia Vaso-occlusive Crisis",[89],"2013-11-12",[936,8217],"Vaso-occlusive Crisis",[8203],{"trials":8220,"activeCount":100},[],{"trials":8222,"activeCount":100},[],{"trials":8224,"activeCount":100},[],{"intervention":8226,"totalTrials":129,"cells":8227},"Recombinant Human Growth Hormone",{"EARLY_PHASE1":8228,"PHASE1":8230,"PHASE2":8232,"PHASE3":8242,"PHASE4":8244,"NA":8246},{"trials":8229,"activeCount":100},[],{"trials":8231,"activeCount":100},[],{"trials":8233,"activeCount":100},[8234],{"nctId":8235,"briefTitle":8236,"status":150,"phases":8237,"primaryCompletion":735,"completion":735,"start":8238,"enrollment":2432,"conditions":8239,"interventions":8240},"NCT00684957","Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors",[88,89],"2008-01",[354],[8226,8241],"Recombinant Human IGF-1",{"trials":8243,"activeCount":100},[],{"trials":8245,"activeCount":100},[],{"trials":8247,"activeCount":100},[],{"intervention":8241,"totalTrials":129,"cells":8249},{"EARLY_PHASE1":8250,"PHASE1":8252,"PHASE2":8254,"PHASE3":8260,"PHASE4":8262,"NA":8264},{"trials":8251,"activeCount":100},[],{"trials":8253,"activeCount":100},[],{"trials":8255,"activeCount":100},[8256],{"nctId":8235,"briefTitle":8236,"status":150,"phases":8257,"primaryCompletion":735,"completion":735,"start":8238,"enrollment":2432,"conditions":8258,"interventions":8259},[88,89],[354],[8226,8241],{"trials":8261,"activeCount":100},[],{"trials":8263,"activeCount":100},[],{"trials":8265,"activeCount":100},[],{"intervention":8267,"totalTrials":129,"cells":8268},"I 124-Evuzamitide",{"EARLY_PHASE1":8269,"PHASE1":8271,"PHASE2":8273,"PHASE3":8285,"PHASE4":8287,"NA":8289},{"trials":8270,"activeCount":100},[],{"trials":8272,"activeCount":100},[],{"trials":8274,"activeCount":100},[8275],{"nctId":8276,"briefTitle":8277,"status":119,"phases":8278,"primaryCompletion":8279,"completion":8280,"start":8281,"enrollment":1735,"conditions":8282,"interventions":8284},"NCT05635045","Evuzamitide in PET\u002FCT to Measure Potential Therapeutic Response in ATTR",[89],"2024-05-07","2024-06-12","2022-07-08",[8283],"Transthyretin Amyloidosis",[8267],{"trials":8286,"activeCount":100},[],{"trials":8288,"activeCount":100},[],{"trials":8290,"activeCount":100},[],{"intervention":2186,"totalTrials":129,"cells":8292},{"EARLY_PHASE1":8293,"PHASE1":8295,"PHASE2":8297,"PHASE3":8303,"PHASE4":8305,"NA":8307},{"trials":8294,"activeCount":100},[],{"trials":8296,"activeCount":100},[],{"trials":8298,"activeCount":100},[8299],{"nctId":2177,"briefTitle":2178,"status":150,"phases":8300,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":129,"conditions":8301,"interventions":8302},[88,89],[2184],[2186,2187,2188,2189,2190],{"trials":8304,"activeCount":100},[],{"trials":8306,"activeCount":100},[],{"trials":8308,"activeCount":100},[],{"intervention":2187,"totalTrials":129,"cells":8310},{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8315,"PHASE3":8321,"PHASE4":8323,"NA":8325},{"trials":8312,"activeCount":100},[],{"trials":8314,"activeCount":100},[],{"trials":8316,"activeCount":100},[8317],{"nctId":2177,"briefTitle":2178,"status":150,"phases":8318,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":129,"conditions":8319,"interventions":8320},[88,89],[2184],[2186,2187,2188,2189,2190],{"trials":8322,"activeCount":100},[],{"trials":8324,"activeCount":100},[],{"trials":8326,"activeCount":100},[],{"intervention":2190,"totalTrials":129,"cells":8328},{"EARLY_PHASE1":8329,"PHASE1":8331,"PHASE2":8333,"PHASE3":8339,"PHASE4":8341,"NA":8343},{"trials":8330,"activeCount":100},[],{"trials":8332,"activeCount":100},[],{"trials":8334,"activeCount":100},[8335],{"nctId":2177,"briefTitle":2178,"status":150,"phases":8336,"primaryCompletion":2180,"completion":2181,"start":2182,"enrollment":129,"conditions":8337,"interventions":8338},[88,89],[2184],[2186,2187,2188,2189,2190],{"trials":8340,"activeCount":100},[],{"trials":8342,"activeCount":100},[],{"trials":8344,"activeCount":100},[],{"intervention":5819,"totalTrials":129,"cells":8346},{"EARLY_PHASE1":8347,"PHASE1":8349,"PHASE2":8351,"PHASE3":8357,"PHASE4":8359,"NA":8361},{"trials":8348,"activeCount":100},[],{"trials":8350,"activeCount":100},[],{"trials":8352,"activeCount":100},[8353],{"nctId":5811,"briefTitle":5812,"status":150,"phases":8354,"primaryCompletion":5814,"completion":5814,"start":5815,"enrollment":129,"conditions":8355,"interventions":8356},[89],[5817],[5683,5819],{"trials":8358,"activeCount":100},[],{"trials":8360,"activeCount":100},[],{"trials":8362,"activeCount":100},[],{"intervention":8364,"totalTrials":129,"cells":8365},"Pasireotide LAR",{"EARLY_PHASE1":8366,"PHASE1":8368,"PHASE2":8370,"PHASE3":8381,"PHASE4":8383,"NA":8385},{"trials":8367,"activeCount":100},[],{"trials":8369,"activeCount":100},[],{"trials":8371,"activeCount":100},[8372],{"nctId":8373,"briefTitle":8374,"status":150,"phases":8375,"primaryCompletion":4822,"completion":4822,"start":8376,"enrollment":186,"conditions":8377,"interventions":8380},"NCT02749227","Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors",[89],"2017-07-10",[8378,8379],"Pituitary Tumor","ACTH-producing Pituitary Tumour",[8364],{"trials":8382,"activeCount":100},[],{"trials":8384,"activeCount":100},[],{"trials":8386,"activeCount":100},[],{"intervention":2824,"totalTrials":129,"cells":8388},{"EARLY_PHASE1":8389,"PHASE1":8391,"PHASE2":8393,"PHASE3":8399,"PHASE4":8401,"NA":8403},{"trials":8390,"activeCount":100},[],{"trials":8392,"activeCount":100},[],{"trials":8394,"activeCount":100},[8395],{"nctId":2815,"briefTitle":2816,"status":119,"phases":8396,"completion":2818,"start":2819,"enrollment":2820,"conditions":8397,"interventions":8398},[89],[2822],[2806,2824,2825],{"trials":8400,"activeCount":100},[],{"trials":8402,"activeCount":100},[],{"trials":8404,"activeCount":100},[],{"intervention":2825,"totalTrials":129,"cells":8406},{"EARLY_PHASE1":8407,"PHASE1":8409,"PHASE2":8411,"PHASE3":8417,"PHASE4":8419,"NA":8421},{"trials":8408,"activeCount":100},[],{"trials":8410,"activeCount":100},[],{"trials":8412,"activeCount":100},[8413],{"nctId":2815,"briefTitle":2816,"status":119,"phases":8414,"completion":2818,"start":2819,"enrollment":2820,"conditions":8415,"interventions":8416},[89],[2822],[2806,2824,2825],{"trials":8418,"activeCount":100},[],{"trials":8420,"activeCount":100},[],{"trials":8422,"activeCount":100},[],{"intervention":8424,"totalTrials":129,"cells":8425},"Dapagliflozin",{"EARLY_PHASE1":8426,"PHASE1":8428,"PHASE2":8430,"PHASE3":8440,"PHASE4":8442,"NA":8444},{"trials":8427,"activeCount":100},[],{"trials":8429,"activeCount":100},[],{"trials":8431,"activeCount":100},[8432],{"nctId":8433,"briefTitle":8434,"status":415,"phases":8435,"primaryCompletion":8436,"completion":8436,"start":713,"enrollment":100,"conditions":8437,"interventions":8439},"NCT04640493","SGLT2-Inhibitors for Sleep Apnea in Heart Failure",[89],"2025-08",[32,8438],"Sleep Disordered Breathing",[8424],{"trials":8441,"activeCount":100},[],{"trials":8443,"activeCount":100},[],{"trials":8445,"activeCount":100},[],{"intervention":8447,"totalTrials":226,"cells":8448},"Gadolinium",{"EARLY_PHASE1":8449,"PHASE1":8461,"PHASE2":8472,"PHASE3":8474,"PHASE4":8476,"NA":8478},{"trials":8450,"activeCount":100},[8451],{"nctId":8452,"briefTitle":8453,"status":119,"phases":8454,"primaryCompletion":1162,"completion":1162,"start":8455,"enrollment":796,"conditions":8456,"interventions":8459},"NCT02783768","Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study",[87],"2017-03-01",[8457,8458],"Pulmonary Disease, Chronic Obstructive","E-cigarettes",[8460,8447],"Hyperpolarized 3-Helium",{"trials":8462,"activeCount":100},[8463],{"nctId":8464,"briefTitle":8465,"status":119,"phases":8466,"primaryCompletion":6528,"completion":6528,"start":8467,"enrollment":2432,"conditions":8468,"interventions":8470},"NCT03154996","Chronic Convection Enhanced Delivery of Topotecan",[88],"2018-01-18",[8469],"Gliomas",[8471,8447],"Topotecan",{"trials":8473,"activeCount":100},[],{"trials":8475,"activeCount":100},[],{"trials":8477,"activeCount":100},[],{"trials":8479,"activeCount":100},[],{"intervention":8481,"totalTrials":129,"cells":8482},"lovastatin",{"EARLY_PHASE1":8483,"PHASE1":8485,"PHASE2":8495,"PHASE3":8497,"PHASE4":8499,"NA":8501},{"trials":8484,"activeCount":100},[],{"trials":8486,"activeCount":100},[8487],{"nctId":8488,"briefTitle":8489,"status":119,"phases":8490,"primaryCompletion":3284,"completion":3284,"start":8491,"enrollment":8492,"conditions":8493,"interventions":8494},"NCT00243880","Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START)",[88],"2005-09",33,[18],[8481],{"trials":8496,"activeCount":100},[],{"trials":8498,"activeCount":100},[],{"trials":8500,"activeCount":100},[],{"trials":8502,"activeCount":100},[],{"intervention":8504,"totalTrials":129,"cells":8505},"NY-ESO-1 peptide vaccine",{"EARLY_PHASE1":8506,"PHASE1":8508,"PHASE2":8518,"PHASE3":8520,"PHASE4":8522,"NA":8524},{"trials":8507,"activeCount":100},[],{"trials":8509,"activeCount":100},[8510],{"nctId":8511,"briefTitle":8512,"status":150,"phases":8513,"primaryCompletion":6091,"completion":6091,"start":8514,"conditions":8515,"interventions":8516},"NCT00027911","Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma",[88],"2001-04",[6890],[8504,8517],"sargramostim",{"trials":8519,"activeCount":100},[],{"trials":8521,"activeCount":100},[],{"trials":8523,"activeCount":100},[],{"trials":8525,"activeCount":100},[],{"intervention":8517,"totalTrials":129,"cells":8527},{"EARLY_PHASE1":8528,"PHASE1":8530,"PHASE2":8536,"PHASE3":8538,"PHASE4":8540,"NA":8542},{"trials":8529,"activeCount":100},[],{"trials":8531,"activeCount":100},[8532],{"nctId":8511,"briefTitle":8512,"status":150,"phases":8533,"primaryCompletion":6091,"completion":6091,"start":8514,"conditions":8534,"interventions":8535},[88],[6890],[8504,8517],{"trials":8537,"activeCount":100},[],{"trials":8539,"activeCount":100},[],{"trials":8541,"activeCount":100},[],{"trials":8543,"activeCount":100},[],{"intervention":5671,"totalTrials":129,"cells":8545},{"EARLY_PHASE1":8546,"PHASE1":8548,"PHASE2":8554,"PHASE3":8556,"PHASE4":8558,"NA":8560},{"trials":8547,"activeCount":100},[],{"trials":8549,"activeCount":100},[8550],{"nctId":5661,"briefTitle":5662,"status":119,"phases":8551,"primaryCompletion":5664,"completion":5664,"start":5665,"enrollment":5666,"conditions":8552,"interventions":8553},[88],[5668,5669],[5671,2403],{"trials":8555,"activeCount":100},[],{"trials":8557,"activeCount":100},[],{"trials":8559,"activeCount":100},[],{"trials":8561,"activeCount":100},[],{"intervention":8563,"totalTrials":129,"cells":8564},"nasal Midazolam",{"EARLY_PHASE1":8565,"PHASE1":8567,"PHASE2":8575,"PHASE3":8577,"PHASE4":8579,"NA":8581},{"trials":8566,"activeCount":100},[],{"trials":8568,"activeCount":100},[8569],{"nctId":8570,"briefTitle":8571,"status":150,"phases":8572,"primaryCompletion":6703,"completion":6703,"start":8030,"enrollment":737,"conditions":8573,"interventions":8574},"NCT01316445","Pharmacodynamics of Nasal and Buccal Midazolam Using EEG",[88],[4251],[8563],{"trials":8576,"activeCount":100},[],{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"intervention":8584,"totalTrials":129,"cells":8585},"50% Nitrous oxide",{"EARLY_PHASE1":8586,"PHASE1":8588,"PHASE2":8597,"PHASE3":8599,"PHASE4":8601,"NA":8603},{"trials":8587,"activeCount":100},[],{"trials":8589,"activeCount":100},[8590],{"nctId":8591,"briefTitle":8592,"status":150,"phases":8593,"primaryCompletion":3083,"completion":3083,"start":7532,"enrollment":446,"conditions":8594,"interventions":8596},"NCT01785030","Nitrous Oxide Vasodilation Healthy Adult Volunteers",[88],[8595],"Peripheral Vein Vasodilation",[8584],{"trials":8598,"activeCount":100},[],{"trials":8600,"activeCount":100},[],{"trials":8602,"activeCount":100},[],{"trials":8604,"activeCount":100},[],{"intervention":870,"totalTrials":129,"cells":8606},{"EARLY_PHASE1":8607,"PHASE1":8609,"PHASE2":8615,"PHASE3":8617,"PHASE4":8619,"NA":8621},{"trials":8608,"activeCount":100},[],{"trials":8610,"activeCount":100},[8611],{"nctId":858,"briefTitle":859,"status":119,"phases":8612,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":8613,"interventions":8614},[88],[866,867,868],[851,50,870,871,872,873],{"trials":8616,"activeCount":100},[],{"trials":8618,"activeCount":100},[],{"trials":8620,"activeCount":100},[],{"trials":8622,"activeCount":100},[],{"intervention":871,"totalTrials":129,"cells":8624},{"EARLY_PHASE1":8625,"PHASE1":8627,"PHASE2":8633,"PHASE3":8635,"PHASE4":8637,"NA":8639},{"trials":8626,"activeCount":100},[],{"trials":8628,"activeCount":100},[8629],{"nctId":858,"briefTitle":859,"status":119,"phases":8630,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":8631,"interventions":8632},[88],[866,867,868],[851,50,870,871,872,873],{"trials":8634,"activeCount":100},[],{"trials":8636,"activeCount":100},[],{"trials":8638,"activeCount":100},[],{"trials":8640,"activeCount":100},[],{"intervention":873,"totalTrials":129,"cells":8642},{"EARLY_PHASE1":8643,"PHASE1":8645,"PHASE2":8651,"PHASE3":8653,"PHASE4":8655,"NA":8657},{"trials":8644,"activeCount":100},[],{"trials":8646,"activeCount":100},[8647],{"nctId":858,"briefTitle":859,"status":119,"phases":8648,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":8649,"interventions":8650},[88],[866,867,868],[851,50,870,871,872,873],{"trials":8652,"activeCount":100},[],{"trials":8654,"activeCount":100},[],{"trials":8656,"activeCount":100},[],{"trials":8658,"activeCount":100},[],{"intervention":741,"totalTrials":129,"cells":8660},{"EARLY_PHASE1":8661,"PHASE1":8663,"PHASE2":8669,"PHASE3":8671,"PHASE4":8673,"NA":8675},{"trials":8662,"activeCount":100},[],{"trials":8664,"activeCount":100},[8665],{"nctId":731,"briefTitle":732,"status":119,"phases":8666,"primaryCompletion":734,"completion":735,"start":736,"enrollment":737,"conditions":8667,"interventions":8668},[88],[739],[741,724,742],{"trials":8670,"activeCount":100},[],{"trials":8672,"activeCount":100},[],{"trials":8674,"activeCount":100},[],{"trials":8676,"activeCount":100},[],{"intervention":8678,"totalTrials":129,"cells":8679},"Oral Cinnamon Extract",{"EARLY_PHASE1":8680,"PHASE1":8682,"PHASE2":8691,"PHASE3":8693,"PHASE4":8695,"NA":8697},{"trials":8681,"activeCount":100},[],{"trials":8683,"activeCount":100},[8684],{"nctId":8685,"briefTitle":8686,"status":119,"phases":8687,"primaryCompletion":8491,"completion":8688,"start":1046,"enrollment":129,"conditions":8689,"interventions":8690},"NCT00331279","The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study",[88],"2006-02",[2488],[8678],{"trials":8692,"activeCount":100},[],{"trials":8694,"activeCount":100},[],{"trials":8696,"activeCount":100},[],{"trials":8698,"activeCount":100},[],{"intervention":883,"totalTrials":129,"cells":8700},{"EARLY_PHASE1":8701,"PHASE1":8703,"PHASE2":8709,"PHASE3":8711,"PHASE4":8713,"NA":8715},{"trials":8702,"activeCount":100},[],{"trials":8704,"activeCount":100},[8705],{"nctId":875,"briefTitle":876,"status":150,"phases":8706,"primaryCompletion":878,"completion":878,"start":879,"enrollment":33,"conditions":8707,"interventions":8708},[88],[881],[50,883,851],{"trials":8710,"activeCount":100},[],{"trials":8712,"activeCount":100},[],{"trials":8714,"activeCount":100},[],{"trials":8716,"activeCount":100},[],{"intervention":8718,"totalTrials":129,"cells":8719},"NKX019",{"EARLY_PHASE1":8720,"PHASE1":8722,"PHASE2":8734,"PHASE3":8736,"PHASE4":8738,"NA":8740},{"trials":8721,"activeCount":100},[],{"trials":8723,"activeCount":100},[8724],{"nctId":8725,"briefTitle":8726,"status":8727,"phases":8728,"primaryCompletion":110,"completion":8729,"start":1511,"enrollment":96,"conditions":8730,"interventions":8732},"NCT06518668","A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus","SUSPENDED",[88],"2040-12",[8731],"Systemic Lupus Erythematosus",[8718,8733],"Cyclophosphamide LD",{"trials":8735,"activeCount":100},[],{"trials":8737,"activeCount":100},[],{"trials":8739,"activeCount":100},[],{"trials":8741,"activeCount":100},[],{"intervention":8733,"totalTrials":129,"cells":8743},{"EARLY_PHASE1":8744,"PHASE1":8746,"PHASE2":8752,"PHASE3":8754,"PHASE4":8756,"NA":8758},{"trials":8745,"activeCount":100},[],{"trials":8747,"activeCount":100},[8748],{"nctId":8725,"briefTitle":8726,"status":8727,"phases":8749,"primaryCompletion":110,"completion":8729,"start":1511,"enrollment":96,"conditions":8750,"interventions":8751},[88],[8731],[8718,8733],{"trials":8753,"activeCount":100},[],{"trials":8755,"activeCount":100},[],{"trials":8757,"activeCount":100},[],{"trials":8759,"activeCount":100},[],{"intervention":4750,"totalTrials":129,"cells":8761},{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8770,"PHASE3":8772,"PHASE4":8774,"NA":8776},{"trials":8763,"activeCount":100},[],{"trials":8765,"activeCount":100},[8766],{"nctId":4742,"briefTitle":4743,"status":119,"phases":8767,"primaryCompletion":4745,"completion":4745,"start":4746,"enrollment":96,"conditions":8768,"interventions":8769},[88],[4748],[4735,4750],{"trials":8771,"activeCount":100},[],{"trials":8773,"activeCount":100},[],{"trials":8775,"activeCount":100},[],{"trials":8777,"activeCount":100},[],{"intervention":8779,"totalTrials":129,"cells":8780},"Ketorolac",{"EARLY_PHASE1":8781,"PHASE1":8783,"PHASE2":8794,"PHASE3":8796,"PHASE4":8798,"NA":8800},{"trials":8782,"activeCount":100},[],{"trials":8784,"activeCount":100},[8785],{"nctId":8786,"briefTitle":8787,"status":150,"phases":8788,"primaryCompletion":8789,"completion":8789,"start":8790,"enrollment":864,"conditions":8791,"interventions":8793},"NCT02297906","Pharmacokinetics of Intranasal Ketorolac in Children",[88],"2017-11-29","2015-02",[8792,625],"Evaluating Pharmacokinetics of Intranasal Ketorolac",[8779],{"trials":8795,"activeCount":100},[],{"trials":8797,"activeCount":100},[],{"trials":8799,"activeCount":100},[],{"trials":8801,"activeCount":100},[],{"intervention":8803,"totalTrials":129,"cells":8804},"Mycophenolate mofetil",{"EARLY_PHASE1":8805,"PHASE1":8807,"PHASE2":8817,"PHASE3":8819,"PHASE4":8821,"NA":8823},{"trials":8806,"activeCount":100},[],{"trials":8808,"activeCount":100},[8809],{"nctId":8810,"briefTitle":8811,"status":119,"phases":8812,"primaryCompletion":891,"completion":8813,"start":8814,"enrollment":796,"conditions":8815,"interventions":8816},"NCT00997958","Study of CellCept for Advanced Pancreatic Cancer",[88],"2009-01","2004-06",[1062],[8803],{"trials":8818,"activeCount":100},[],{"trials":8820,"activeCount":100},[],{"trials":8822,"activeCount":100},[],{"trials":8824,"activeCount":100},[],{"intervention":8826,"totalTrials":129,"cells":8827},"Lactobacillus plantarum strains 299 and 299v",{"EARLY_PHASE1":8828,"PHASE1":8830,"PHASE2":8840,"PHASE3":8842,"PHASE4":8844,"NA":8846},{"trials":8829,"activeCount":100},[],{"trials":8831,"activeCount":100},[8832],{"nctId":8833,"briefTitle":8834,"status":119,"phases":8835,"primaryCompletion":907,"completion":907,"start":8836,"enrollment":4785,"conditions":8837,"interventions":8839},"NCT01010867","Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)",[88],"2010-02",[8838],"Hematopoietic Organs; Disorder",[8826],{"trials":8841,"activeCount":100},[],{"trials":8843,"activeCount":100},[],{"trials":8845,"activeCount":100},[],{"trials":8847,"activeCount":100},[],{"intervention":1679,"totalTrials":129,"cells":8849},{"EARLY_PHASE1":8850,"PHASE1":8852,"PHASE2":8858,"PHASE3":8860,"PHASE4":8862,"NA":8864},{"trials":8851,"activeCount":100},[],{"trials":8853,"activeCount":100},[8854],{"nctId":1672,"briefTitle":1673,"status":119,"phases":8855,"primaryCompletion":1675,"completion":1675,"start":1676,"enrollment":24,"conditions":8856,"interventions":8857},[88],[1530,1513,1515,1514],[1679,1665,1680],{"trials":8859,"activeCount":100},[],{"trials":8861,"activeCount":100},[],{"trials":8863,"activeCount":100},[],{"trials":8865,"activeCount":100},[],{"intervention":1680,"totalTrials":129,"cells":8867},{"EARLY_PHASE1":8868,"PHASE1":8870,"PHASE2":8876,"PHASE3":8878,"PHASE4":8880,"NA":8882},{"trials":8869,"activeCount":100},[],{"trials":8871,"activeCount":100},[8872],{"nctId":1672,"briefTitle":1673,"status":119,"phases":8873,"primaryCompletion":1675,"completion":1675,"start":1676,"enrollment":24,"conditions":8874,"interventions":8875},[88],[1530,1513,1515,1514],[1679,1665,1680],{"trials":8877,"activeCount":100},[],{"trials":8879,"activeCount":100},[],{"trials":8881,"activeCount":100},[],{"trials":8883,"activeCount":100},[],{"intervention":8885,"totalTrials":129,"cells":8886},"Adenosine",{"EARLY_PHASE1":8887,"PHASE1":8889,"PHASE2":8901,"PHASE3":8903,"PHASE4":8905,"NA":8907},{"trials":8888,"activeCount":100},[],{"trials":8890,"activeCount":100},[8891],{"nctId":8892,"briefTitle":8893,"status":119,"phases":8894,"primaryCompletion":6242,"completion":8895,"start":8896,"enrollment":2474,"conditions":8897,"interventions":8900},"NCT02462941","Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart",[88],"2017-07","2015-07",[8898,8899],"Sinus Bradycardia","Atrioventricular Block",[8885],{"trials":8902,"activeCount":100},[],{"trials":8904,"activeCount":100},[],{"trials":8906,"activeCount":100},[],{"trials":8908,"activeCount":100},[],{"intervention":8910,"totalTrials":129,"cells":8911},"Ulipristal Acetate",{"EARLY_PHASE1":8912,"PHASE1":8914,"PHASE2":8925,"PHASE3":8927,"PHASE4":8929,"NA":8931},{"trials":8913,"activeCount":100},[],{"trials":8915,"activeCount":100},[8916],{"nctId":8917,"briefTitle":8918,"status":119,"phases":8919,"primaryCompletion":8920,"completion":8920,"start":8921,"enrollment":1073,"conditions":8922,"interventions":8923},"NCT02922127","Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation",[88],"2019-10-21","2016-12-16",[4252],[8910,8924],"Combined Oral Contraceptive Pill",{"trials":8926,"activeCount":100},[],{"trials":8928,"activeCount":100},[],{"trials":8930,"activeCount":100},[],{"trials":8932,"activeCount":100},[],{"intervention":8924,"totalTrials":129,"cells":8934},{"EARLY_PHASE1":8935,"PHASE1":8937,"PHASE2":8943,"PHASE3":8945,"PHASE4":8947,"NA":8949},{"trials":8936,"activeCount":100},[],{"trials":8938,"activeCount":100},[8939],{"nctId":8917,"briefTitle":8918,"status":119,"phases":8940,"primaryCompletion":8920,"completion":8920,"start":8921,"enrollment":1073,"conditions":8941,"interventions":8942},[88],[4252],[8910,8924],{"trials":8944,"activeCount":100},[],{"trials":8946,"activeCount":100},[],{"trials":8948,"activeCount":100},[],{"trials":8950,"activeCount":100},[],{"intervention":8952,"totalTrials":129,"cells":8953},"Panobinostat 15 MG",{"EARLY_PHASE1":8954,"PHASE1":8956,"PHASE2":8968,"PHASE3":8970,"PHASE4":8972,"NA":8974},{"trials":8955,"activeCount":100},[],{"trials":8957,"activeCount":100},[8958],{"nctId":8959,"briefTitle":8960,"status":150,"phases":8961,"primaryCompletion":8962,"completion":8963,"start":8964,"enrollment":2432,"conditions":8965,"interventions":8967},"NCT04804709","Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)",[88],"2022-03-01","2022-03-31","2021-07-28",[1737,8966,1738],"Diffuse Pontine and Thalamic Gliomas",[8952],{"trials":8969,"activeCount":100},[],{"trials":8971,"activeCount":100},[],{"trials":8973,"activeCount":100},[],{"trials":8975,"activeCount":100},[],{"intervention":8977,"totalTrials":129,"cells":8978},"Valproic Acid",{"EARLY_PHASE1":8979,"PHASE1":8981,"PHASE2":8991,"PHASE3":8993,"PHASE4":8995,"NA":8997},{"trials":8980,"activeCount":100},[],{"trials":8982,"activeCount":100},[8983],{"nctId":8984,"briefTitle":8985,"status":150,"phases":8986,"primaryCompletion":6703,"completion":6703,"start":8987,"enrollment":446,"conditions":8988,"interventions":8990},"NCT01010958","Adjuvant Valproate for High Grade Sarcomas",[88],"2009-10",[8989],"High Grade Sarcoma",[8977],{"trials":8992,"activeCount":100},[],{"trials":8994,"activeCount":100},[],{"trials":8996,"activeCount":100},[],{"trials":8998,"activeCount":100},[],{"intervention":1101,"totalTrials":129,"cells":9000},{"EARLY_PHASE1":9001,"PHASE1":9003,"PHASE2":9009,"PHASE3":9011,"PHASE4":9013,"NA":9015},{"trials":9002,"activeCount":100},[],{"trials":9004,"activeCount":100},[9005],{"nctId":1092,"briefTitle":1093,"status":150,"phases":9006,"primaryCompletion":1095,"completion":1095,"start":1096,"enrollment":129,"conditions":9007,"interventions":9008},[88],[1098,1099],[1101,1085],{"trials":9010,"activeCount":100},[],{"trials":9012,"activeCount":100},[],{"trials":9014,"activeCount":100},[],{"trials":9016,"activeCount":100},[],{"intervention":8471,"totalTrials":129,"cells":9018},{"EARLY_PHASE1":9019,"PHASE1":9021,"PHASE2":9027,"PHASE3":9029,"PHASE4":9031,"NA":9033},{"trials":9020,"activeCount":100},[],{"trials":9022,"activeCount":100},[9023],{"nctId":8464,"briefTitle":8465,"status":119,"phases":9024,"primaryCompletion":6528,"completion":6528,"start":8467,"enrollment":2432,"conditions":9025,"interventions":9026},[88],[8469],[8471,8447],{"trials":9028,"activeCount":100},[],{"trials":9030,"activeCount":100},[],{"trials":9032,"activeCount":100},[],{"trials":9034,"activeCount":100},[],{"intervention":9036,"totalTrials":129,"cells":9037},"PF-05221304",{"EARLY_PHASE1":9038,"PHASE1":9040,"PHASE2":9051,"PHASE3":9053,"PHASE4":9055,"NA":9057},{"trials":9039,"activeCount":100},[],{"trials":9041,"activeCount":100},[9042],{"nctId":9043,"briefTitle":9044,"status":415,"phases":9045,"primaryCompletion":9046,"completion":9046,"start":862,"enrollment":100,"conditions":9047,"interventions":9050},"NCT04395950","Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism",[88],"2021-08-19",[9048,9049],"NASH (Nonalcoholic Steatohepatitis)","NAFLD (Nonalcoholic Fatty Liver Disease)",[9036],{"trials":9052,"activeCount":100},[],{"trials":9054,"activeCount":100},[],{"trials":9056,"activeCount":100},[],{"trials":9058,"activeCount":100},[],{"intervention":1520,"totalTrials":129,"cells":9060},{"EARLY_PHASE1":9061,"PHASE1":9063,"PHASE2":9069,"PHASE3":9071,"PHASE4":9073,"NA":9075},{"trials":9062,"activeCount":100},[],{"trials":9064,"activeCount":100},[9065],{"nctId":1506,"briefTitle":1507,"status":415,"phases":9066,"primaryCompletion":1509,"completion":1510,"start":1511,"enrollment":100,"conditions":9067,"interventions":9068},[88],[1513,1514,1515,1516],[1499,1518,1519,1520,1521,1522],{"trials":9070,"activeCount":100},[],{"trials":9072,"activeCount":100},[],{"trials":9074,"activeCount":100},[],{"trials":9076,"activeCount":100},[],{"intervention":9078,"totalTrials":129,"cells":9079},"Eculizumab",{"EARLY_PHASE1":9080,"PHASE1":9082,"PHASE2":9092,"PHASE3":9094,"PHASE4":9096,"NA":9098},{"trials":9081,"activeCount":100},[],{"trials":9083,"activeCount":100},[9084],{"nctId":9085,"briefTitle":9086,"status":119,"phases":9087,"primaryCompletion":794,"completion":794,"start":5386,"enrollment":96,"conditions":9088,"interventions":9091},"NCT01221181","Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy",[88],[9089,9090],"Dense Deposit Disease","Membranoproliferative Glomerulonephritis",[9078],{"trials":9093,"activeCount":100},[],{"trials":9095,"activeCount":100},[],{"trials":9097,"activeCount":100},[],{"trials":9099,"activeCount":100},[],{"intervention":9101,"totalTrials":129,"cells":9102},"Sorafenib",{"EARLY_PHASE1":9103,"PHASE1":9105,"PHASE2":9114,"PHASE3":9116,"PHASE4":9118,"NA":9120},{"trials":9104,"activeCount":100},[],{"trials":9106,"activeCount":100},[9107],{"nctId":9108,"briefTitle":9109,"status":119,"phases":9110,"primaryCompletion":8193,"completion":8193,"start":2636,"enrollment":6207,"conditions":9111,"interventions":9113},"NCT00997022","Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients",[88],[9112],"Hepatocellular Cancer",[9101],{"trials":9115,"activeCount":100},[],{"trials":9117,"activeCount":100},[],{"trials":9119,"activeCount":100},[],{"trials":9121,"activeCount":100},[],{"intervention":5935,"totalTrials":129,"cells":9123},{"EARLY_PHASE1":9124,"PHASE1":9126,"PHASE2":9132,"PHASE3":9134,"PHASE4":9136,"NA":9138},{"trials":9125,"activeCount":100},[],{"trials":9127,"activeCount":100},[9128],{"nctId":5926,"briefTitle":5927,"status":415,"phases":9129,"primaryCompletion":5929,"completion":5930,"start":5931,"enrollment":100,"conditions":9130,"interventions":9131},[88],[5933],[5919,5935],{"trials":9133,"activeCount":100},[],{"trials":9135,"activeCount":100},[],{"trials":9137,"activeCount":100},[],{"trials":9139,"activeCount":100},[],{"intervention":9141,"totalTrials":129,"cells":9142},"Alpelisib 150 mg [Piqray], 2 overencapsulated",{"EARLY_PHASE1":9143,"PHASE1":9145,"PHASE2":9156,"PHASE3":9158,"PHASE4":9160,"NA":9162},{"trials":9144,"activeCount":100},[],{"trials":9146,"activeCount":100},[9147],{"nctId":9148,"briefTitle":9149,"status":119,"phases":9150,"primaryCompletion":9151,"completion":9151,"start":9152,"enrollment":1419,"conditions":9153,"interventions":9155},"NCT05733455","Effect of Alpelisib in Healthy Volunteers",[88],"2023-12-01","2023-05-09",[1513,1530,9154],"Dyslipidemias",[9141],{"trials":9157,"activeCount":100},[],{"trials":9159,"activeCount":100},[],{"trials":9161,"activeCount":100},[],{"trials":9163,"activeCount":100},[],{"intervention":9165,"totalTrials":129,"cells":9166},"Vorinostat",{"EARLY_PHASE1":9167,"PHASE1":9169,"PHASE2":9180,"PHASE3":9182,"PHASE4":9184,"NA":9186},{"trials":9168,"activeCount":100},[],{"trials":9170,"activeCount":100},[9171],{"nctId":9172,"briefTitle":9173,"status":119,"phases":9174,"primaryCompletion":6703,"completion":2721,"start":2645,"enrollment":351,"conditions":9175,"interventions":9177},"NCT00691210","Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies",[88],[9176,911],"Hodgkin's Disease",[9165,9178,9179],"Niacinamide","Etoposide",{"trials":9181,"activeCount":100},[],{"trials":9183,"activeCount":100},[],{"trials":9185,"activeCount":100},[],{"trials":9187,"activeCount":100},[],{"intervention":9178,"totalTrials":129,"cells":9189},{"EARLY_PHASE1":9190,"PHASE1":9192,"PHASE2":9198,"PHASE3":9200,"PHASE4":9202,"NA":9204},{"trials":9191,"activeCount":100},[],{"trials":9193,"activeCount":100},[9194],{"nctId":9172,"briefTitle":9173,"status":119,"phases":9195,"primaryCompletion":6703,"completion":2721,"start":2645,"enrollment":351,"conditions":9196,"interventions":9197},[88],[9176,911],[9165,9178,9179],{"trials":9199,"activeCount":100},[],{"trials":9201,"activeCount":100},[],{"trials":9203,"activeCount":100},[],{"trials":9205,"activeCount":100},[],{"intervention":9179,"totalTrials":129,"cells":9207},{"EARLY_PHASE1":9208,"PHASE1":9210,"PHASE2":9216,"PHASE3":9218,"PHASE4":9220,"NA":9222},{"trials":9209,"activeCount":100},[],{"trials":9211,"activeCount":100},[9212],{"nctId":9172,"briefTitle":9173,"status":119,"phases":9213,"primaryCompletion":6703,"completion":2721,"start":2645,"enrollment":351,"conditions":9214,"interventions":9215},[88],[9176,911],[9165,9178,9179],{"trials":9217,"activeCount":100},[],{"trials":9219,"activeCount":100},[],{"trials":9221,"activeCount":100},[],{"trials":9223,"activeCount":100},[],{"intervention":6172,"totalTrials":129,"cells":9225},{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9234,"PHASE3":9236,"PHASE4":9238,"NA":9240},{"trials":9227,"activeCount":100},[],{"trials":9229,"activeCount":100},[9230],{"nctId":6166,"briefTitle":6167,"status":119,"phases":9231,"primaryCompletion":735,"completion":735,"start":891,"enrollment":19,"conditions":9232,"interventions":9233},[88],[6170,1075],[6172,2285],{"trials":9235,"activeCount":100},[],{"trials":9237,"activeCount":100},[],{"trials":9239,"activeCount":100},[],{"trials":9241,"activeCount":100},[],{"intervention":2381,"totalTrials":129,"cells":9243},{"EARLY_PHASE1":9244,"PHASE1":9246,"PHASE2":9252,"PHASE3":9254,"PHASE4":9256,"NA":9258},{"trials":9245,"activeCount":100},[],{"trials":9247,"activeCount":100},[9248],{"nctId":2374,"briefTitle":2375,"status":119,"phases":9249,"primaryCompletion":2377,"completion":2378,"start":736,"enrollment":446,"conditions":9250,"interventions":9251},[88],[23],[2381,754,927],{"trials":9253,"activeCount":100},[],{"trials":9255,"activeCount":100},[],{"trials":9257,"activeCount":100},[],{"trials":9259,"activeCount":100},[],{"intervention":9261,"totalTrials":129,"cells":9262},"AEB071",{"EARLY_PHASE1":9263,"PHASE1":9265,"PHASE2":9277,"PHASE3":9279,"PHASE4":9281,"NA":9283},{"trials":9264,"activeCount":100},[],{"trials":9266,"activeCount":100},[9267],{"nctId":9268,"briefTitle":9269,"status":119,"phases":9270,"primaryCompletion":9271,"completion":9272,"start":9273,"enrollment":770,"conditions":9274,"interventions":9275},"NCT02273219","Trial of AEB071 in Combination With BYL719 in Patients With Melanoma",[88],"2017-10-18","2018-07-02","2014-11-19",[7840],[9261,9276],"BYL719",{"trials":9278,"activeCount":100},[],{"trials":9280,"activeCount":100},[],{"trials":9282,"activeCount":100},[],{"trials":9284,"activeCount":100},[],{"intervention":9276,"totalTrials":129,"cells":9286},{"EARLY_PHASE1":9287,"PHASE1":9289,"PHASE2":9295,"PHASE3":9297,"PHASE4":9299,"NA":9301},{"trials":9288,"activeCount":100},[],{"trials":9290,"activeCount":100},[9291],{"nctId":9268,"briefTitle":9269,"status":119,"phases":9292,"primaryCompletion":9271,"completion":9272,"start":9273,"enrollment":770,"conditions":9293,"interventions":9294},[88],[7840],[9261,9276],{"trials":9296,"activeCount":100},[],{"trials":9298,"activeCount":100},[],{"trials":9300,"activeCount":100},[],{"trials":9302,"activeCount":100},[],{"intervention":8460,"totalTrials":129,"cells":9304},{"EARLY_PHASE1":9305,"PHASE1":9311,"PHASE2":9313,"PHASE3":9315,"PHASE4":9317,"NA":9319},{"trials":9306,"activeCount":100},[9307],{"nctId":8452,"briefTitle":8453,"status":119,"phases":9308,"primaryCompletion":1162,"completion":1162,"start":8455,"enrollment":796,"conditions":9309,"interventions":9310},[87],[8457,8458],[8460,8447],{"trials":9312,"activeCount":100},[],{"trials":9314,"activeCount":100},[],{"trials":9316,"activeCount":100},[],{"trials":9318,"activeCount":100},[],{"trials":9320,"activeCount":100},[],{"intervention":9322,"totalTrials":129,"cells":9323},"Losartan",{"EARLY_PHASE1":9324,"PHASE1":9338,"PHASE2":9340,"PHASE3":9342,"PHASE4":9344,"NA":9346},{"trials":9325,"activeCount":100},[9326],{"nctId":9327,"briefTitle":9328,"status":119,"phases":9329,"primaryCompletion":9330,"completion":9331,"start":9332,"enrollment":1735,"conditions":9333,"interventions":9335},"NCT02744456","N-of-1 Trials for Blood Pressure Medications in Adults",[87],"2017-08-31","2017-12-31","2014-08-01",[3631,9334],"High Blood Pressure",[9322,9336,9337],"Amlodipine","Hydrochlorothiazide",{"trials":9339,"activeCount":100},[],{"trials":9341,"activeCount":100},[],{"trials":9343,"activeCount":100},[],{"trials":9345,"activeCount":100},[],{"trials":9347,"activeCount":100},[],{"intervention":9336,"totalTrials":129,"cells":9349},{"EARLY_PHASE1":9350,"PHASE1":9356,"PHASE2":9358,"PHASE3":9360,"PHASE4":9362,"NA":9364},{"trials":9351,"activeCount":100},[9352],{"nctId":9327,"briefTitle":9328,"status":119,"phases":9353,"primaryCompletion":9330,"completion":9331,"start":9332,"enrollment":1735,"conditions":9354,"interventions":9355},[87],[3631,9334],[9322,9336,9337],{"trials":9357,"activeCount":100},[],{"trials":9359,"activeCount":100},[],{"trials":9361,"activeCount":100},[],{"trials":9363,"activeCount":100},[],{"trials":9365,"activeCount":100},[],{"intervention":9337,"totalTrials":129,"cells":9367},{"EARLY_PHASE1":9368,"PHASE1":9374,"PHASE2":9376,"PHASE3":9378,"PHASE4":9380,"NA":9382},{"trials":9369,"activeCount":100},[9370],{"nctId":9327,"briefTitle":9328,"status":119,"phases":9371,"primaryCompletion":9330,"completion":9331,"start":9332,"enrollment":1735,"conditions":9372,"interventions":9373},[87],[3631,9334],[9322,9336,9337],{"trials":9375,"activeCount":100},[],{"trials":9377,"activeCount":100},[],{"trials":9379,"activeCount":100},[],{"trials":9381,"activeCount":100},[],{"trials":9383,"activeCount":100},[],{"intervention":9385,"totalTrials":129,"cells":9386},"Spartalizumab",{"EARLY_PHASE1":9387,"PHASE1":9400,"PHASE2":9402,"PHASE3":9404,"PHASE4":9406,"NA":9408},{"trials":9388,"activeCount":100},[9389],{"nctId":9390,"briefTitle":9391,"status":119,"phases":9392,"primaryCompletion":9393,"completion":9394,"start":9395,"enrollment":5666,"conditions":9396,"interventions":9398},"NCT04028245","A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma",[87],"2025-03-14","2026-03-05","2019-08-15",[9397],"Carcinoma, Renal Cell",[9385,9399],"Canakinumab",{"trials":9401,"activeCount":100},[],{"trials":9403,"activeCount":100},[],{"trials":9405,"activeCount":100},[],{"trials":9407,"activeCount":100},[],{"trials":9409,"activeCount":100},[],{"intervention":9399,"totalTrials":129,"cells":9411},{"EARLY_PHASE1":9412,"PHASE1":9418,"PHASE2":9420,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9413,"activeCount":100},[9414],{"nctId":9390,"briefTitle":9391,"status":119,"phases":9415,"primaryCompletion":9393,"completion":9394,"start":9395,"enrollment":5666,"conditions":9416,"interventions":9417},[87],[9397],[9385,9399],{"trials":9419,"activeCount":100},[],{"trials":9421,"activeCount":100},[],{"trials":9423,"activeCount":100},[],{"trials":9425,"activeCount":100},[],{"trials":9427,"activeCount":100},[],{"intervention":9429,"totalTrials":129,"cells":9430},"Tenofovir (300mg)\u002FEmtricitabine(200mg) [Truvada®]",{"EARLY_PHASE1":9431,"PHASE1":9441,"PHASE2":9443,"PHASE3":9445,"PHASE4":9447,"NA":9449},{"trials":9432,"activeCount":100},[9433],{"nctId":9434,"briefTitle":9435,"status":119,"phases":9436,"primaryCompletion":9437,"completion":9437,"start":9438,"enrollment":301,"conditions":9439,"interventions":9440},"NCT04898699","IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya",[87],"2022-07-19","2021-11-24",[21],[9429],{"trials":9442,"activeCount":100},[],{"trials":9444,"activeCount":100},[],{"trials":9446,"activeCount":100},[],{"trials":9448,"activeCount":100},[],{"trials":9450,"activeCount":100},[],{"intervention":9452,"totalTrials":129,"cells":9453},"Omnipaque 300mg\u002FmL Solution for",{"EARLY_PHASE1":9454,"PHASE1":9467,"PHASE2":9469,"PHASE3":9471,"PHASE4":9473,"NA":9475},{"trials":9455,"activeCount":100},[9456],{"nctId":9457,"briefTitle":9458,"status":150,"phases":9459,"primaryCompletion":9460,"completion":9460,"start":9461,"enrollment":96,"conditions":9462,"interventions":9465},"NCT04199754","IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy",[87],"2021-05-28","2020-10-01",[9463,9464],"Pelvic Cancer","Abdominal Cancer",[9452,9466],"0.9% Saline",{"trials":9468,"activeCount":100},[],{"trials":9470,"activeCount":100},[],{"trials":9472,"activeCount":100},[],{"trials":9474,"activeCount":100},[],{"trials":9476,"activeCount":100},[],{"intervention":9466,"totalTrials":129,"cells":9478},{"EARLY_PHASE1":9479,"PHASE1":9485,"PHASE2":9487,"PHASE3":9489,"PHASE4":9491,"NA":9493},{"trials":9480,"activeCount":100},[9481],{"nctId":9457,"briefTitle":9458,"status":150,"phases":9482,"primaryCompletion":9460,"completion":9460,"start":9461,"enrollment":96,"conditions":9483,"interventions":9484},[87],[9463,9464],[9452,9466],{"trials":9486,"activeCount":100},[],{"trials":9488,"activeCount":100},[],{"trials":9490,"activeCount":100},[],{"trials":9492,"activeCount":100},[],{"trials":9494,"activeCount":100},[],{"intervention":5801,"totalTrials":129,"cells":9496},{"EARLY_PHASE1":9497,"PHASE1":9503,"PHASE2":9505,"PHASE3":9507,"PHASE4":9509,"NA":9511},{"trials":9498,"activeCount":100},[9499],{"nctId":5794,"briefTitle":5795,"status":150,"phases":9500,"primaryCompletion":5797,"completion":5797,"start":4367,"enrollment":96,"conditions":9501,"interventions":9502},[87],[5799],[5683,5801],{"trials":9504,"activeCount":100},[],{"trials":9506,"activeCount":100},[],{"trials":9508,"activeCount":100},[],{"trials":9510,"activeCount":100},[],{"trials":9512,"activeCount":100},[],{"intervention":9514,"totalTrials":129,"cells":9515},"18 F-FP-DTBZ",{"EARLY_PHASE1":9516,"PHASE1":9528,"PHASE2":9530,"PHASE3":9532,"PHASE4":9534,"NA":9536},{"trials":9517,"activeCount":100},[9518],{"nctId":9519,"briefTitle":9520,"status":119,"phases":9521,"primaryCompletion":9522,"completion":9522,"start":9523,"enrollment":1419,"conditions":9524,"interventions":9527},"NCT02236754","Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass",[87],"2014-04-23","2013-07-02",[9525,9526],"Healthy Volunteers","Diabetes Mellitus, Type 1",[9514],{"trials":9529,"activeCount":100},[],{"trials":9531,"activeCount":100},[],{"trials":9533,"activeCount":100},[],{"trials":9535,"activeCount":100},[],{"trials":9537,"activeCount":100},[],{"intervention":9539,"totalTrials":129,"cells":9540},"BMS-986218 and Degarelix",{"EARLY_PHASE1":9541,"PHASE1":9553,"PHASE2":9555,"PHASE3":9557,"PHASE4":9559,"NA":9561},{"trials":9542,"activeCount":100},[9543],{"nctId":9544,"briefTitle":9545,"status":119,"phases":9546,"primaryCompletion":9547,"completion":9547,"start":9548,"enrollment":9549,"conditions":9550,"interventions":9551},"NCT04301414","Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer",[87],"2025-03-13","2020-02-25",26,[399],[9539,9552],"Degarelix",{"trials":9554,"activeCount":100},[],{"trials":9556,"activeCount":100},[],{"trials":9558,"activeCount":100},[],{"trials":9560,"activeCount":100},[],{"trials":9562,"activeCount":100},[],{"intervention":9552,"totalTrials":129,"cells":9564},{"EARLY_PHASE1":9565,"PHASE1":9571,"PHASE2":9573,"PHASE3":9575,"PHASE4":9577,"NA":9579},{"trials":9566,"activeCount":100},[9567],{"nctId":9544,"briefTitle":9545,"status":119,"phases":9568,"primaryCompletion":9547,"completion":9547,"start":9548,"enrollment":9549,"conditions":9569,"interventions":9570},[87],[399],[9539,9552],{"trials":9572,"activeCount":100},[],{"trials":9574,"activeCount":100},[],{"trials":9576,"activeCount":100},[],{"trials":9578,"activeCount":100},[],{"trials":9580,"activeCount":100},[],{"intervention":9582,"totalTrials":129,"cells":9583},"Nicotine Replacement Therapy",{"EARLY_PHASE1":9584,"PHASE1":9593,"PHASE2":9595,"PHASE3":9597,"PHASE4":9599,"NA":9601},{"trials":9585,"activeCount":100},[9586],{"nctId":9587,"briefTitle":9588,"status":119,"phases":9589,"primaryCompletion":5364,"completion":5364,"start":8987,"enrollment":351,"conditions":9590,"interventions":9592},"NCT01329614","Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving",[87],[9591],"Tobacco Use Disorder",[9582],{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[],{"trials":9598,"activeCount":100},[],{"trials":9600,"activeCount":100},[],{"trials":9602,"activeCount":100},[],{"intervention":9604,"totalTrials":129,"cells":9605},"Iron tracer",{"EARLY_PHASE1":9606,"PHASE1":9618,"PHASE2":9620,"PHASE3":9622,"PHASE4":9624,"NA":9626},{"trials":9607,"activeCount":100},[9608],{"nctId":9609,"briefTitle":9610,"status":415,"phases":9611,"primaryCompletion":9612,"completion":2935,"start":8055,"enrollment":100,"conditions":9613,"interventions":9617},"NCT02610920","Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection",[87],"2017-06",[9614,9615,9616],"Breast Neoplasm","Carcinoma, Ductal, Breast","Carcinoma, Intraductal, Noninfiltrating",[9604],{"trials":9619,"activeCount":100},[],{"trials":9621,"activeCount":100},[],{"trials":9623,"activeCount":100},[],{"trials":9625,"activeCount":100},[],{"trials":9627,"activeCount":100},[],{"intervention":9629,"totalTrials":129,"cells":9630},"PBA",{"EARLY_PHASE1":9631,"PHASE1":9642,"PHASE2":9644,"PHASE3":9646,"PHASE4":9648,"NA":9650},{"trials":9632,"activeCount":100},[9633],{"nctId":9634,"briefTitle":9635,"status":8727,"phases":9636,"primaryCompletion":1784,"completion":1784,"start":9637,"enrollment":226,"conditions":9638,"interventions":9641},"NCT04041232","PBA Use for Treatment of ATF6-\u002F- Patients",[87],"2025-04-08",[9639,9640],"ACHROMATOPSIA 7","Achromatopsia",[9629],{"trials":9643,"activeCount":100},[],{"trials":9645,"activeCount":100},[],{"trials":9647,"activeCount":100},[],{"trials":9649,"activeCount":100},[],{"trials":9651,"activeCount":100},[],{"intervention":9653,"totalTrials":129,"cells":9654},"[11C]MPC6827",{"EARLY_PHASE1":9655,"PHASE1":9666,"PHASE2":9668,"PHASE3":9670,"PHASE4":9672,"NA":9674},{"trials":9656,"activeCount":100},[9657],{"nctId":9658,"briefTitle":9659,"status":119,"phases":9660,"primaryCompletion":9661,"completion":9661,"start":9662,"enrollment":5666,"conditions":9663,"interventions":9665},"NCT04575727","Exploratory Evaluation of [11C]MPC6827",[87],"2024-06-21","2021-01-08",[9664,1133,2822],"Neurodegenerative Diseases",[9653],{"trials":9667,"activeCount":100},[],{"trials":9669,"activeCount":100},[],{"trials":9671,"activeCount":100},[],{"trials":9673,"activeCount":100},[],{"trials":9675,"activeCount":100},[],{"intervention":9677,"totalTrials":129,"cells":9678},"Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit",{"EARLY_PHASE1":9679,"PHASE1":9691,"PHASE2":9693,"PHASE3":9695,"PHASE4":9697,"NA":9699},{"trials":9680,"activeCount":100},[9681],{"nctId":9682,"briefTitle":9683,"status":119,"phases":9684,"primaryCompletion":9685,"completion":9685,"start":9686,"enrollment":796,"conditions":9687,"interventions":9690},"NCT03051646","Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis",[87],"2017-05-10","2017-01-13",[9688,9689],"Fatigue","Overheating",[9677],{"trials":9692,"activeCount":100},[],{"trials":9694,"activeCount":100},[],{"trials":9696,"activeCount":100},[],{"trials":9698,"activeCount":100},[],{"trials":9700,"activeCount":100},[],{"intervention":9702,"totalTrials":129,"cells":9703},"Steroid",{"EARLY_PHASE1":9704,"PHASE1":9714,"PHASE2":9716,"PHASE3":9718,"PHASE4":9720,"NA":9722},{"trials":9705,"activeCount":100},[9706],{"nctId":9707,"briefTitle":9708,"status":8727,"phases":9709,"primaryCompletion":110,"completion":110,"start":9710,"enrollment":112,"conditions":9711,"interventions":9713},"NCT03722303","Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome",[87],"2016-12-19",[9712],"Carpal Tunnel Syndrome",[9702],{"trials":9715,"activeCount":100},[],{"trials":9717,"activeCount":100},[],{"trials":9719,"activeCount":100},[],{"trials":9721,"activeCount":100},[],{"trials":9723,"activeCount":100},[],{"intervention":850,"totalTrials":129,"cells":9725},{"EARLY_PHASE1":9726,"PHASE1":9732,"PHASE2":9734,"PHASE3":9736,"PHASE4":9738,"NA":9740},{"trials":9727,"activeCount":100},[9728],{"nctId":841,"briefTitle":842,"status":150,"phases":9729,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":9730,"interventions":9731},[87],[848],[850,851,50,852,853,854],{"trials":9733,"activeCount":100},[],{"trials":9735,"activeCount":100},[],{"trials":9737,"activeCount":100},[],{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[],{"intervention":852,"totalTrials":129,"cells":9743},{"EARLY_PHASE1":9744,"PHASE1":9750,"PHASE2":9752,"PHASE3":9754,"PHASE4":9756,"NA":9758},{"trials":9745,"activeCount":100},[9746],{"nctId":841,"briefTitle":842,"status":150,"phases":9747,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":9748,"interventions":9749},[87],[848],[850,851,50,852,853,854],{"trials":9751,"activeCount":100},[],{"trials":9753,"activeCount":100},[],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[],{"trials":9759,"activeCount":100},[],{"intervention":9761,"totalTrials":129,"cells":9762},"[11C]-NOP46",{"EARLY_PHASE1":9763,"PHASE1":9774,"PHASE2":9776,"PHASE3":9778,"PHASE4":9780,"NA":9782},{"trials":9764,"activeCount":100},[9765],{"nctId":9766,"briefTitle":9767,"status":119,"phases":9768,"primaryCompletion":9769,"completion":9769,"start":9770,"enrollment":1735,"conditions":9771,"interventions":9773},"NCT03705819","Exploratory Evaluation of [11C]-NOP46",[87],"2023-10-30","2019-03-25",[9772],"Chronic Pain",[9761],{"trials":9775,"activeCount":100},[],{"trials":9777,"activeCount":100},[],{"trials":9779,"activeCount":100},[],{"trials":9781,"activeCount":100},[],{"trials":9783,"activeCount":100},[],{"intervention":9785,"totalTrials":129,"cells":9786},"Bethanechol",{"EARLY_PHASE1":9787,"PHASE1":9799,"PHASE2":9801,"PHASE3":9803,"PHASE4":9805,"NA":9807},{"trials":9788,"activeCount":100},[9789],{"nctId":9790,"briefTitle":9791,"status":119,"phases":9792,"primaryCompletion":9793,"completion":9794,"start":9795,"enrollment":5666,"conditions":9796,"interventions":9798},"NCT03572283","Bethanechol Prior to Pancreatic Surgery",[87],"2023-07-25","2023-08-24","2018-04-08",[9797],"Pancreas Cancer",[9785],{"trials":9800,"activeCount":100},[],{"trials":9802,"activeCount":100},[],{"trials":9804,"activeCount":100},[],{"trials":9806,"activeCount":100},[],{"trials":9808,"activeCount":100},[],{"intervention":2547,"totalTrials":2432,"cells":9810},{"EARLY_PHASE1":9811,"PHASE1":9813,"PHASE2":9815,"PHASE3":9830,"PHASE4":9832,"NA":9838},{"trials":9812,"activeCount":100},[],{"trials":9814,"activeCount":100},[],{"trials":9816,"activeCount":100},[9817,9826],{"nctId":9818,"briefTitle":9819,"status":119,"phases":9820,"primaryCompletion":8193,"completion":9821,"start":759,"enrollment":947,"conditions":9822,"interventions":9824},"NCT01558063","Ketamine in the Treatment of Depression",[89],"2019-10",[9823],"Major Depressive Disorder",[9825,2547],"Ketamine",{"nctId":2539,"briefTitle":2540,"status":415,"phases":9827,"primaryCompletion":137,"completion":137,"start":2542,"enrollment":100,"conditions":9828,"interventions":9829},[88,89],[399,2544,2545],[2530,2547],{"trials":9831,"activeCount":100},[],{"trials":9833,"activeCount":100},[9834],{"nctId":2564,"briefTitle":2565,"status":119,"phases":9835,"primaryCompletion":2567,"completion":2567,"start":2568,"enrollment":2569,"conditions":9836,"interventions":9837},[91],[2571,2572],[2574,2530,261,2547],{"trials":9839,"activeCount":100},[9840,9848],{"nctId":9841,"briefTitle":9842,"status":119,"phases":9843,"primaryCompletion":9844,"completion":9844,"start":123,"enrollment":11,"conditions":9845,"interventions":9846},"NCT02889133","Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality",[92],"2021-10-05",[671],[9847,2547],"Iron-dextran",{"nctId":9849,"briefTitle":9850,"status":119,"phases":9851,"primaryCompletion":736,"completion":9852,"start":879,"enrollment":864,"conditions":9853,"interventions":9855},"NCT01129583","Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness",[92],"2010-05",[9854],"Post Traumatic Stiffness",[9856,2547],"Botulinum Toxin Type A",{"intervention":854,"totalTrials":186,"cells":9858},{"EARLY_PHASE1":9859,"PHASE1":9865,"PHASE2":9867,"PHASE3":9869,"PHASE4":9871,"NA":9881},{"trials":9860,"activeCount":100},[9861],{"nctId":841,"briefTitle":842,"status":150,"phases":9862,"primaryCompletion":844,"completion":844,"start":845,"enrollment":846,"conditions":9863,"interventions":9864},[87],[848],[850,851,50,852,853,854],{"trials":9866,"activeCount":100},[],{"trials":9868,"activeCount":100},[],{"trials":9870,"activeCount":100},[],{"trials":9872,"activeCount":100},[9873,9877],{"nctId":1484,"briefTitle":1485,"status":119,"phases":9874,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":1489,"conditions":9875,"interventions":9876},[91],[1491],[1493,854,1494,1495,70],{"nctId":3940,"briefTitle":3941,"status":119,"phases":9878,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":325,"conditions":9879,"interventions":9880},[91],[3947,3948],[3927,854],{"trials":9882,"activeCount":100},[9883],{"nctId":2198,"briefTitle":2199,"status":119,"phases":9884,"primaryCompletion":2201,"completion":2201,"start":417,"enrollment":351,"conditions":9885,"interventions":9886},[92],[2203,2204],[854,2206,2038],{"intervention":4443,"totalTrials":846,"cells":9888},{"EARLY_PHASE1":9889,"PHASE1":9891,"PHASE2":9893,"PHASE3":9895,"PHASE4":9897,"NA":9911},{"trials":9890,"activeCount":100},[],{"trials":9892,"activeCount":100},[],{"trials":9894,"activeCount":100},[],{"trials":9896,"activeCount":100},[],{"trials":9898,"activeCount":100},[9899,9907],{"nctId":9900,"briefTitle":9901,"status":150,"phases":9902,"primaryCompletion":123,"completion":9903,"start":844,"enrollment":1394,"conditions":9904,"interventions":9906},"NCT02498483","Acetaminophen and Post Circumcision Pain Control",[91],"2018-06",[625,9905],"Circumcision",[4443],{"nctId":4436,"briefTitle":4437,"status":150,"phases":9908,"primaryCompletion":4439,"completion":4439,"start":735,"enrollment":2466,"conditions":9909,"interventions":9910},[91],[4441],[4423,4443],{"trials":9912,"activeCount":100},[9913],{"nctId":9914,"briefTitle":9915,"status":119,"phases":9916,"primaryCompletion":749,"completion":749,"start":736,"enrollment":8492,"conditions":9917,"interventions":9919},"NCT02929212","Effect of Number of Meals on Metabolism After Weight Loss Surgery",[92],[9918],"Morbid Obesity",[4443],{"intervention":9825,"totalTrials":846,"cells":9921},{"EARLY_PHASE1":9922,"PHASE1":9924,"PHASE2":9934,"PHASE3":9940,"PHASE4":9942,"NA":9944},{"trials":9923,"activeCount":100},[],{"trials":9925,"activeCount":100},[9926],{"nctId":9927,"briefTitle":9928,"status":150,"phases":9929,"primaryCompletion":9930,"completion":9930,"start":9931,"enrollment":836,"conditions":9932,"interventions":9933},"NCT03977675","The Role of HNKs in the Antidepressant Effect of Ketamine",[88],"2020-07-02","2019-05-15",[9823],[9825],{"trials":9935,"activeCount":100},[9936],{"nctId":9818,"briefTitle":9819,"status":119,"phases":9937,"primaryCompletion":8193,"completion":9821,"start":759,"enrollment":947,"conditions":9938,"interventions":9939},[89],[9823],[9825,2547],{"trials":9941,"activeCount":100},[],{"trials":9943,"activeCount":100},[],{"trials":9945,"activeCount":100},[9946],{"nctId":9947,"briefTitle":9948,"status":119,"phases":9949,"primaryCompletion":8790,"completion":3970,"start":2503,"enrollment":821,"conditions":9950,"interventions":9952},"NCT01938079","Pharmacokinetic Alterations During ECMO",[92],[9951],"Acute Respiratory Failure",[9825],{"intervention":5390,"totalTrials":226,"cells":9954},{"EARLY_PHASE1":9955,"PHASE1":9957,"PHASE2":9959,"PHASE3":9961,"PHASE4":9967,"NA":9969},{"trials":9956,"activeCount":100},[],{"trials":9958,"activeCount":100},[],{"trials":9960,"activeCount":100},[],{"trials":9962,"activeCount":100},[9963],{"nctId":5383,"briefTitle":5384,"status":119,"phases":9964,"primaryCompletion":479,"completion":479,"start":5386,"enrollment":5387,"conditions":9965,"interventions":9966},[90],[26,29],[5390,5372,5391,5392],{"trials":9968,"activeCount":100},[],{"trials":9970,"activeCount":100},[9971],{"nctId":9972,"briefTitle":9973,"status":119,"phases":9974,"primaryCompletion":9975,"completion":9976,"start":9977,"enrollment":9978,"conditions":9979,"interventions":9982},"NCT03336346","Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana",[],"2019-10-30","2019-12-11","2017-11-15",148,[9980,29,9981],"Contraceptive Usage","Drug Interaction",[9983,5390],"dolutegravir",{"intervention":9985,"totalTrials":226,"cells":9986},"Rifaximin",{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":9991,"PHASE3":10001,"PHASE4":10003,"NA":10005},{"trials":9988,"activeCount":100},[],{"trials":9990,"activeCount":100},[],{"trials":9992,"activeCount":100},[9993],{"nctId":9994,"briefTitle":9995,"status":4196,"phases":9996,"primaryCompletion":2201,"completion":9997,"start":417,"enrollment":4962,"conditions":9998,"interventions":10000},"NCT01603108","Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant",[89],"2018-12",[9999],"Hepatitis C",[9985],{"trials":10002,"activeCount":100},[],{"trials":10004,"activeCount":100},[],{"trials":10006,"activeCount":100},[10007],{"nctId":10008,"briefTitle":10009,"status":119,"phases":10010,"primaryCompletion":10011,"completion":10011,"start":4567,"enrollment":325,"conditions":10012,"interventions":10014},"NCT01137955","Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease",[92],"2008-04",[10013],"Celiac Disease",[9985],{"intervention":10016,"totalTrials":226,"cells":10017},"Synthetic Human Secretin",{"EARLY_PHASE1":10018,"PHASE1":10020,"PHASE2":10022,"PHASE3":10024,"PHASE4":10026,"NA":10028},{"trials":10019,"activeCount":100},[],{"trials":10021,"activeCount":100},[],{"trials":10023,"activeCount":100},[],{"trials":10025,"activeCount":100},[],{"trials":10027,"activeCount":100},[],{"trials":10029,"activeCount":100},[10030,10036],{"nctId":10031,"briefTitle":10032,"status":415,"phases":10033,"primaryCompletion":2422,"completion":2422,"start":6601,"enrollment":100,"conditions":10034,"interventions":10035},"NCT01094535","Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery",[92],[1062],[10016],{"nctId":10037,"briefTitle":10038,"status":415,"phases":10039,"primaryCompletion":734,"completion":734,"start":734,"enrollment":100,"conditions":10040,"interventions":10041},"NCT01094600","Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency",[92],[1062],[10016],{"intervention":10043,"totalTrials":226,"cells":10044},"Leptin",{"EARLY_PHASE1":10045,"PHASE1":10047,"PHASE2":10049,"PHASE3":10059,"PHASE4":10061,"NA":10063},{"trials":10046,"activeCount":100},[],{"trials":10048,"activeCount":100},[],{"trials":10050,"activeCount":100},[10051],{"nctId":10052,"briefTitle":10053,"status":119,"phases":10054,"primaryCompletion":10055,"completion":137,"start":10011,"enrollment":4785,"conditions":10056,"interventions":10058},"NCT00710814","Trial of Leptin Administration After Roux-en-Y Gastric Bypass",[88,89],"2012-08",[10057],"Overweight",[10043],{"trials":10060,"activeCount":100},[],{"trials":10062,"activeCount":100},[],{"trials":10064,"activeCount":100},[10065],{"nctId":10066,"briefTitle":10067,"status":150,"phases":10068,"primaryCompletion":5364,"completion":5364,"start":10069,"enrollment":4795,"conditions":10070,"interventions":10072},"NCT00265980","Leptin in Human Energy and Neuroendocrine Homeostasis",[92],"2002-07",[15,10071],"Weight Loss",[10073,10043],"Subcutaneous Placebo",{"intervention":4229,"totalTrials":226,"cells":10075},{"EARLY_PHASE1":10076,"PHASE1":10078,"PHASE2":10080,"PHASE3":10082,"PHASE4":10084,"NA":10090},{"trials":10077,"activeCount":100},[],{"trials":10079,"activeCount":100},[],{"trials":10081,"activeCount":100},[],{"trials":10083,"activeCount":100},[],{"trials":10085,"activeCount":100},[10086],{"nctId":4220,"briefTitle":4221,"status":119,"phases":10087,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":864,"conditions":10088,"interventions":10089},[91],[4227],[4229,4207],{"trials":10091,"activeCount":100},[10092],{"nctId":10093,"briefTitle":10094,"status":150,"phases":10095,"primaryCompletion":4653,"completion":10096,"start":10097,"enrollment":5450,"conditions":10098,"interventions":10100},"NCT00615472","Intravenous Versus Inhalational Anesthesia in Parkinson's Disease",[92],"2011-04","2003-10",[10099],"Parkinson's Disease",[10101,10102,4229],"Isoflurane","Remifentanil",{"intervention":10104,"totalTrials":129,"cells":10105},"Pegvisomant",{"EARLY_PHASE1":10106,"PHASE1":10108,"PHASE2":10110,"PHASE3":10112,"PHASE4":10114,"NA":10116},{"trials":10107,"activeCount":100},[],{"trials":10109,"activeCount":100},[],{"trials":10111,"activeCount":100},[],{"trials":10113,"activeCount":100},[],{"trials":10115,"activeCount":100},[],{"trials":10117,"activeCount":100},[10118],{"nctId":10119,"briefTitle":10120,"status":119,"phases":10121,"primaryCompletion":10122,"completion":10122,"start":10123,"enrollment":10124,"conditions":10125,"interventions":10127},"NCT03225040","Bone MicroArchitecture in Acromegaly",[],"2019-12-21","2016-08-03",77,[4570,10126],"Osteoporosis Risk",[10104],{"intervention":10129,"totalTrials":129,"cells":10130},"Cognitive test + Pupillary measure",{"EARLY_PHASE1":10131,"PHASE1":10133,"PHASE2":10135,"PHASE3":10137,"PHASE4":10139,"NA":10141},{"trials":10132,"activeCount":100},[],{"trials":10134,"activeCount":100},[],{"trials":10136,"activeCount":100},[],{"trials":10138,"activeCount":100},[],{"trials":10140,"activeCount":100},[],{"trials":10142,"activeCount":100},[10143],{"nctId":10144,"briefTitle":10145,"status":119,"phases":10146,"primaryCompletion":10147,"completion":10147,"start":10148,"enrollment":10149,"conditions":10150,"interventions":10152},"NCT05579093","Clinical Investigation of an Eye-Tracking Device as a Predictor of Delirium in the Recovery Room After Surgery With General Anesthesia",[],"2021-09-20","2019-10-01",325,[10151],"Delirium",[10129],{"intervention":9847,"totalTrials":129,"cells":10154},{"EARLY_PHASE1":10155,"PHASE1":10157,"PHASE2":10159,"PHASE3":10161,"PHASE4":10163,"NA":10165},{"trials":10156,"activeCount":100},[],{"trials":10158,"activeCount":100},[],{"trials":10160,"activeCount":100},[],{"trials":10162,"activeCount":100},[],{"trials":10164,"activeCount":100},[],{"trials":10166,"activeCount":100},[10167],{"nctId":9841,"briefTitle":9842,"status":119,"phases":10168,"primaryCompletion":9844,"completion":9844,"start":123,"enrollment":11,"conditions":10169,"interventions":10170},[92],[671],[9847,2547],{"intervention":10172,"totalTrials":129,"cells":10173},"Fluticasone with salmeterol",{"EARLY_PHASE1":10174,"PHASE1":10176,"PHASE2":10178,"PHASE3":10180,"PHASE4":10182,"NA":10184},{"trials":10175,"activeCount":100},[],{"trials":10177,"activeCount":100},[],{"trials":10179,"activeCount":100},[],{"trials":10181,"activeCount":100},[],{"trials":10183,"activeCount":100},[],{"trials":10185,"activeCount":100},[10186],{"nctId":10187,"briefTitle":10188,"status":119,"phases":10189,"primaryCompletion":10190,"completion":10190,"start":4759,"enrollment":10191,"conditions":10192,"interventions":10193},"NCT00521222","Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg\u002FArg or Gly\u002FGly Genotypes",[92],"2010-11",90,[35],[10172,10194,10195,10196],"Fluticasone HFA","Ipratropium HFA","Albuterol HFA",{"intervention":10194,"totalTrials":129,"cells":10198},{"EARLY_PHASE1":10199,"PHASE1":10201,"PHASE2":10203,"PHASE3":10205,"PHASE4":10207,"NA":10209},{"trials":10200,"activeCount":100},[],{"trials":10202,"activeCount":100},[],{"trials":10204,"activeCount":100},[],{"trials":10206,"activeCount":100},[],{"trials":10208,"activeCount":100},[],{"trials":10210,"activeCount":100},[10211],{"nctId":10187,"briefTitle":10188,"status":119,"phases":10212,"primaryCompletion":10190,"completion":10190,"start":4759,"enrollment":10191,"conditions":10213,"interventions":10214},[92],[35],[10172,10194,10195,10196],{"intervention":10195,"totalTrials":129,"cells":10216},{"EARLY_PHASE1":10217,"PHASE1":10219,"PHASE2":10221,"PHASE3":10223,"PHASE4":10225,"NA":10227},{"trials":10218,"activeCount":100},[],{"trials":10220,"activeCount":100},[],{"trials":10222,"activeCount":100},[],{"trials":10224,"activeCount":100},[],{"trials":10226,"activeCount":100},[],{"trials":10228,"activeCount":100},[10229],{"nctId":10187,"briefTitle":10188,"status":119,"phases":10230,"primaryCompletion":10190,"completion":10190,"start":4759,"enrollment":10191,"conditions":10231,"interventions":10232},[92],[35],[10172,10194,10195,10196],{"intervention":10196,"totalTrials":129,"cells":10234},{"EARLY_PHASE1":10235,"PHASE1":10237,"PHASE2":10239,"PHASE3":10241,"PHASE4":10243,"NA":10245},{"trials":10236,"activeCount":100},[],{"trials":10238,"activeCount":100},[],{"trials":10240,"activeCount":100},[],{"trials":10242,"activeCount":100},[],{"trials":10244,"activeCount":100},[],{"trials":10246,"activeCount":100},[10247],{"nctId":10187,"briefTitle":10188,"status":119,"phases":10248,"primaryCompletion":10190,"completion":10190,"start":4759,"enrollment":10191,"conditions":10249,"interventions":10250},[92],[35],[10172,10194,10195,10196],{"intervention":10252,"totalTrials":129,"cells":10253},"APAP and NAC combination",{"EARLY_PHASE1":10254,"PHASE1":10256,"PHASE2":10258,"PHASE3":10260,"PHASE4":10262,"NA":10264},{"trials":10255,"activeCount":100},[],{"trials":10257,"activeCount":100},[],{"trials":10259,"activeCount":100},[],{"trials":10261,"activeCount":100},[],{"trials":10263,"activeCount":100},[],{"trials":10265,"activeCount":100},[10266],{"nctId":10267,"briefTitle":10268,"status":415,"phases":10269,"start":10270,"enrollment":100,"conditions":10271,"interventions":10276},"NCT01137591","Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever",[92],"2009-04",[10272,10273,10274,10275,4441],"Liver Failure","Liver Failure, Acute","Drug Induced Liver Injury","Prevention & Control",[10252,10277],"APAP and Placebo",{"intervention":10277,"totalTrials":129,"cells":10279},{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10286,"PHASE4":10288,"NA":10290},{"trials":10281,"activeCount":100},[],{"trials":10283,"activeCount":100},[],{"trials":10285,"activeCount":100},[],{"trials":10287,"activeCount":100},[],{"trials":10289,"activeCount":100},[],{"trials":10291,"activeCount":100},[10292],{"nctId":10267,"briefTitle":10268,"status":415,"phases":10293,"start":10270,"enrollment":100,"conditions":10294,"interventions":10295},[92],[10272,10273,10274,10275,4441],[10252,10277],{"intervention":9983,"totalTrials":129,"cells":10297},{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10302,"PHASE3":10304,"PHASE4":10306,"NA":10308},{"trials":10299,"activeCount":100},[],{"trials":10301,"activeCount":100},[],{"trials":10303,"activeCount":100},[],{"trials":10305,"activeCount":100},[],{"trials":10307,"activeCount":100},[],{"trials":10309,"activeCount":100},[10310],{"nctId":9972,"briefTitle":9973,"status":119,"phases":10311,"primaryCompletion":9975,"completion":9976,"start":9977,"enrollment":9978,"conditions":10312,"interventions":10313},[],[9980,29,9981],[9983,5390],{"intervention":10315,"totalTrials":129,"cells":10316},"Medications for acromegaly",{"EARLY_PHASE1":10317,"PHASE1":10319,"PHASE2":10321,"PHASE3":10323,"PHASE4":10325,"NA":10327},{"trials":10318,"activeCount":100},[],{"trials":10320,"activeCount":100},[],{"trials":10322,"activeCount":100},[],{"trials":10324,"activeCount":100},[],{"trials":10326,"activeCount":100},[],{"trials":10328,"activeCount":100},[10329],{"nctId":10330,"briefTitle":10331,"status":119,"phases":10332,"primaryCompletion":8436,"completion":8436,"start":3551,"enrollment":10333,"conditions":10334,"interventions":10335},"NCT01809808","A Prospective Study of Outcome After Therapy for Acromegaly",[],280,[4570],[10315],{"intervention":10337,"totalTrials":129,"cells":10338},"human parathyroid hormone",{"EARLY_PHASE1":10339,"PHASE1":10341,"PHASE2":10343,"PHASE3":10345,"PHASE4":10347,"NA":10349},{"trials":10340,"activeCount":100},[],{"trials":10342,"activeCount":100},[],{"trials":10344,"activeCount":100},[],{"trials":10346,"activeCount":100},[],{"trials":10348,"activeCount":100},[],{"trials":10350,"activeCount":100},[10351],{"nctId":10352,"briefTitle":10353,"status":119,"phases":10354,"completion":2637,"start":10355,"enrollment":782,"conditions":10356,"interventions":10357},"NCT00004406","Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis",[92],"1999-10",[2723],[10337],{"intervention":10359,"totalTrials":129,"cells":10360},"Femring®",{"EARLY_PHASE1":10361,"PHASE1":10363,"PHASE2":10365,"PHASE3":10367,"PHASE4":10369,"NA":10371},{"trials":10362,"activeCount":100},[],{"trials":10364,"activeCount":100},[],{"trials":10366,"activeCount":100},[],{"trials":10368,"activeCount":100},[],{"trials":10370,"activeCount":100},[],{"trials":10372,"activeCount":100},[10373],{"nctId":10374,"briefTitle":10375,"status":119,"phases":10376,"primaryCompletion":4392,"completion":4392,"start":6601,"enrollment":6029,"conditions":10377,"interventions":10379},"NCT00563576","Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation",[92],[10378],"Metrorrhagia",[10359,10380],"DepoProvera ®",{"intervention":10380,"totalTrials":129,"cells":10382},{"EARLY_PHASE1":10383,"PHASE1":10385,"PHASE2":10387,"PHASE3":10389,"PHASE4":10391,"NA":10393},{"trials":10384,"activeCount":100},[],{"trials":10386,"activeCount":100},[],{"trials":10388,"activeCount":100},[],{"trials":10390,"activeCount":100},[],{"trials":10392,"activeCount":100},[],{"trials":10394,"activeCount":100},[10395],{"nctId":10374,"briefTitle":10375,"status":119,"phases":10396,"primaryCompletion":4392,"completion":4392,"start":6601,"enrollment":6029,"conditions":10397,"interventions":10398},[92],[10378],[10359,10380],{"intervention":10400,"totalTrials":129,"cells":10401},"2% lidocaine gel",{"EARLY_PHASE1":10402,"PHASE1":10404,"PHASE2":10406,"PHASE3":10408,"PHASE4":10410,"NA":10412},{"trials":10403,"activeCount":100},[],{"trials":10405,"activeCount":100},[],{"trials":10407,"activeCount":100},[],{"trials":10409,"activeCount":100},[],{"trials":10411,"activeCount":100},[],{"trials":10413,"activeCount":100},[10414],{"nctId":10415,"briefTitle":10416,"status":119,"phases":10417,"primaryCompletion":10418,"completion":3860,"start":4297,"enrollment":10419,"conditions":10420,"interventions":10421},"NCT01214161","Intracervical Lidocaine Gel for IUD Insertional Pain",[92],"2011-03",200,[625],[10400],{"intervention":10423,"totalTrials":129,"cells":10424},"Microarray analysis",{"EARLY_PHASE1":10425,"PHASE1":10427,"PHASE2":10429,"PHASE3":10431,"PHASE4":10433,"NA":10435},{"trials":10426,"activeCount":100},[],{"trials":10428,"activeCount":100},[],{"trials":10430,"activeCount":100},[],{"trials":10432,"activeCount":100},[],{"trials":10434,"activeCount":100},[],{"trials":10436,"activeCount":100},[10437],{"nctId":10438,"briefTitle":10439,"status":119,"phases":10440,"primaryCompletion":794,"completion":794,"start":10441,"enrollment":10442,"conditions":10443,"interventions":10445},"NCT01279733","Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis",[],"2008-10",4450,[10444],"Genetic Diseases",[10423],{"intervention":10447,"totalTrials":129,"cells":10448},"proteolytic enzymes",{"EARLY_PHASE1":10449,"PHASE1":10451,"PHASE2":10453,"PHASE3":10455,"PHASE4":10457,"NA":10459},{"trials":10450,"activeCount":100},[],{"trials":10452,"activeCount":100},[],{"trials":10454,"activeCount":100},[],{"trials":10456,"activeCount":100},[],{"trials":10458,"activeCount":100},[],{"trials":10460,"activeCount":100},[10461],{"nctId":10462,"briefTitle":10463,"status":150,"phases":10464,"primaryCompletion":2637,"completion":2637,"start":10465,"enrollment":10191,"conditions":10466,"interventions":10468},"NCT00003851","Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer",[92],"1999-03",[10467,1062],"Malnutrition",[10447,10469],"gemcitabine hydrochloride",{"intervention":10469,"totalTrials":129,"cells":10471},{"EARLY_PHASE1":10472,"PHASE1":10474,"PHASE2":10476,"PHASE3":10478,"PHASE4":10480,"NA":10482},{"trials":10473,"activeCount":100},[],{"trials":10475,"activeCount":100},[],{"trials":10477,"activeCount":100},[],{"trials":10479,"activeCount":100},[],{"trials":10481,"activeCount":100},[],{"trials":10483,"activeCount":100},[10484],{"nctId":10462,"briefTitle":10463,"status":150,"phases":10485,"primaryCompletion":2637,"completion":2637,"start":10465,"enrollment":10191,"conditions":10486,"interventions":10487},[92],[10467,1062],[10447,10469],{"intervention":10489,"totalTrials":129,"cells":10490},"Sufentanil",{"EARLY_PHASE1":10491,"PHASE1":10493,"PHASE2":10495,"PHASE3":10497,"PHASE4":10499,"NA":10501},{"trials":10492,"activeCount":100},[],{"trials":10494,"activeCount":100},[],{"trials":10496,"activeCount":100},[],{"trials":10498,"activeCount":100},[],{"trials":10500,"activeCount":100},[],{"trials":10502,"activeCount":100},[10503],{"nctId":10504,"briefTitle":10505,"status":119,"phases":10506,"completion":4759,"start":10507,"enrollment":96,"conditions":10508,"interventions":10510},"NCT00494598","The Pharmacokinetics of Opioids and Sedative\u002FHypnotics During Selective Cerebral Perfusion",[],"2007-03",[10509],"Aortic Aneurysm",[10489],{"intervention":10512,"totalTrials":129,"cells":10513},"Transfusion of red blood cells",{"EARLY_PHASE1":10514,"PHASE1":10516,"PHASE2":10518,"PHASE3":10520,"PHASE4":10522,"NA":10524},{"trials":10515,"activeCount":100},[],{"trials":10517,"activeCount":100},[],{"trials":10519,"activeCount":100},[],{"trials":10521,"activeCount":100},[],{"trials":10523,"activeCount":100},[],{"trials":10525,"activeCount":100},[10526],{"nctId":10527,"briefTitle":10528,"status":119,"phases":10529,"primaryCompletion":907,"completion":9997,"start":2280,"enrollment":301,"conditions":10530,"interventions":10532},"NCT02087553","PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions",[],[10531],"Iron, Abnormal Blood Level",[10512,10533],"Infusion of albumin\u002Fsaline",{"intervention":10533,"totalTrials":129,"cells":10535},{"EARLY_PHASE1":10536,"PHASE1":10538,"PHASE2":10540,"PHASE3":10542,"PHASE4":10544,"NA":10546},{"trials":10537,"activeCount":100},[],{"trials":10539,"activeCount":100},[],{"trials":10541,"activeCount":100},[],{"trials":10543,"activeCount":100},[],{"trials":10545,"activeCount":100},[],{"trials":10547,"activeCount":100},[10548],{"nctId":10527,"briefTitle":10528,"status":119,"phases":10549,"primaryCompletion":907,"completion":9997,"start":2280,"enrollment":301,"conditions":10550,"interventions":10551},[],[10531],[10512,10533],{"intervention":10553,"totalTrials":129,"cells":10554},"P-IFN alfa 2a",{"EARLY_PHASE1":10555,"PHASE1":10557,"PHASE2":10559,"PHASE3":10561,"PHASE4":10563,"NA":10565},{"trials":10556,"activeCount":100},[],{"trials":10558,"activeCount":100},[],{"trials":10560,"activeCount":100},[],{"trials":10562,"activeCount":100},[],{"trials":10564,"activeCount":100},[],{"trials":10566,"activeCount":100},[10567],{"nctId":10568,"briefTitle":10569,"status":415,"phases":10570,"primaryCompletion":8790,"completion":8790,"start":2515,"enrollment":100,"conditions":10571,"interventions":10573},"NCT02112630","Boceprevir in End Stage Renal Disease (ESRD)",[92],[10572,4682],"Hepatitis C Infection",[10553,10574,10575,10576],"P-IFN alfa 2b","Ribavirin","Boceprevir",{"intervention":10574,"totalTrials":129,"cells":10578},{"EARLY_PHASE1":10579,"PHASE1":10581,"PHASE2":10583,"PHASE3":10585,"PHASE4":10587,"NA":10589},{"trials":10580,"activeCount":100},[],{"trials":10582,"activeCount":100},[],{"trials":10584,"activeCount":100},[],{"trials":10586,"activeCount":100},[],{"trials":10588,"activeCount":100},[],{"trials":10590,"activeCount":100},[10591],{"nctId":10568,"briefTitle":10569,"status":415,"phases":10592,"primaryCompletion":8790,"completion":8790,"start":2515,"enrollment":100,"conditions":10593,"interventions":10594},[92],[10572,4682],[10553,10574,10575,10576],{"intervention":10575,"totalTrials":129,"cells":10596},{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10601,"PHASE3":10603,"PHASE4":10605,"NA":10607},{"trials":10598,"activeCount":100},[],{"trials":10600,"activeCount":100},[],{"trials":10602,"activeCount":100},[],{"trials":10604,"activeCount":100},[],{"trials":10606,"activeCount":100},[],{"trials":10608,"activeCount":100},[10609],{"nctId":10568,"briefTitle":10569,"status":415,"phases":10610,"primaryCompletion":8790,"completion":8790,"start":2515,"enrollment":100,"conditions":10611,"interventions":10612},[92],[10572,4682],[10553,10574,10575,10576],{"intervention":10576,"totalTrials":129,"cells":10614},{"EARLY_PHASE1":10615,"PHASE1":10617,"PHASE2":10619,"PHASE3":10621,"PHASE4":10623,"NA":10625},{"trials":10616,"activeCount":100},[],{"trials":10618,"activeCount":100},[],{"trials":10620,"activeCount":100},[],{"trials":10622,"activeCount":100},[],{"trials":10624,"activeCount":100},[],{"trials":10626,"activeCount":100},[10627],{"nctId":10568,"briefTitle":10569,"status":415,"phases":10628,"primaryCompletion":8790,"completion":8790,"start":2515,"enrollment":100,"conditions":10629,"interventions":10630},[92],[10572,4682],[10553,10574,10575,10576],{"intervention":10632,"totalTrials":129,"cells":10633},"Intranasal dexmedetomidine",{"EARLY_PHASE1":10634,"PHASE1":10636,"PHASE2":10638,"PHASE3":10640,"PHASE4":10642,"NA":10644},{"trials":10635,"activeCount":100},[],{"trials":10637,"activeCount":100},[],{"trials":10639,"activeCount":100},[],{"trials":10641,"activeCount":100},[],{"trials":10643,"activeCount":100},[],{"trials":10645,"activeCount":100},[10646],{"nctId":10647,"briefTitle":10648,"status":119,"phases":10649,"primaryCompletion":2567,"completion":2567,"start":10650,"enrollment":10651,"conditions":10652,"interventions":10654},"NCT03220880","Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures",[],"2018-09-04",578,[248,10653],"Sedation",[10632],{"intervention":10656,"totalTrials":129,"cells":10657},"Isoniazid Prevention Therapy",{"EARLY_PHASE1":10658,"PHASE1":10660,"PHASE2":10662,"PHASE3":10664,"PHASE4":10666,"NA":10668},{"trials":10659,"activeCount":100},[],{"trials":10661,"activeCount":100},[],{"trials":10663,"activeCount":100},[],{"trials":10665,"activeCount":100},[],{"trials":10667,"activeCount":100},[],{"trials":10669,"activeCount":100},[10670],{"nctId":10671,"briefTitle":10672,"status":119,"phases":10673,"primaryCompletion":6121,"completion":1639,"start":5364,"enrollment":10674,"conditions":10675,"interventions":10677},"NCT01926379","ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)",[92],338,[21,10676],"Tuberculosis",[10656],{"intervention":10679,"totalTrials":129,"cells":10680},"Omeprazole",{"EARLY_PHASE1":10681,"PHASE1":10683,"PHASE2":10685,"PHASE3":10687,"PHASE4":10689,"NA":10691},{"trials":10682,"activeCount":100},[],{"trials":10684,"activeCount":100},[],{"trials":10686,"activeCount":100},[],{"trials":10688,"activeCount":100},[],{"trials":10690,"activeCount":100},[],{"trials":10692,"activeCount":100},[10693],{"nctId":10694,"briefTitle":10695,"status":150,"phases":10696,"primaryCompletion":123,"completion":123,"start":10697,"enrollment":446,"conditions":10698,"interventions":10700},"NCT02016820","Effect of Acid Suppression Medication on Pediatric Microbiome",[92],"2014-11",[10699],"Clostridium Difficile Infection",[10679],{"intervention":10702,"totalTrials":129,"cells":10703},"low dose oxytocin",{"EARLY_PHASE1":10704,"PHASE1":10706,"PHASE2":10708,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10705,"activeCount":100},[],{"trials":10707,"activeCount":100},[],{"trials":10709,"activeCount":100},[],{"trials":10711,"activeCount":100},[],{"trials":10713,"activeCount":100},[],{"trials":10715,"activeCount":100},[10716],{"nctId":10717,"briefTitle":10718,"status":119,"phases":10719,"completion":10720,"start":879,"enrollment":10419,"conditions":10721,"interventions":10725},"NCT00468520","Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial",[92],"2005-10",[10722,10723,10724],"Pregnancy","Induced Labor","Cervical Ripening",[10702],{"intervention":10727,"totalTrials":129,"cells":10728},"Fish Oil Supplementation",{"EARLY_PHASE1":10729,"PHASE1":10731,"PHASE2":10733,"PHASE3":10735,"PHASE4":10737,"NA":10739},{"trials":10730,"activeCount":100},[],{"trials":10732,"activeCount":100},[],{"trials":10734,"activeCount":100},[],{"trials":10736,"activeCount":100},[],{"trials":10738,"activeCount":100},[],{"trials":10740,"activeCount":100},[10741],{"nctId":10742,"briefTitle":10743,"status":119,"phases":10744,"primaryCompletion":7394,"completion":7394,"start":1071,"enrollment":836,"conditions":10745,"interventions":10746},"NCT01285362","Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study",[92],[1515],[10727],{"intervention":10073,"totalTrials":129,"cells":10748},{"EARLY_PHASE1":10749,"PHASE1":10751,"PHASE2":10753,"PHASE3":10755,"PHASE4":10757,"NA":10759},{"trials":10750,"activeCount":100},[],{"trials":10752,"activeCount":100},[],{"trials":10754,"activeCount":100},[],{"trials":10756,"activeCount":100},[],{"trials":10758,"activeCount":100},[],{"trials":10760,"activeCount":100},[10761],{"nctId":10066,"briefTitle":10067,"status":150,"phases":10762,"primaryCompletion":5364,"completion":5364,"start":10069,"enrollment":4795,"conditions":10763,"interventions":10764},[92],[15,10071],[10073,10043],{"intervention":10766,"totalTrials":129,"cells":10767},"Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor",{"EARLY_PHASE1":10768,"PHASE1":10770,"PHASE2":10772,"PHASE3":10774,"PHASE4":10776,"NA":10778},{"trials":10769,"activeCount":100},[],{"trials":10771,"activeCount":100},[],{"trials":10773,"activeCount":100},[],{"trials":10775,"activeCount":100},[],{"trials":10777,"activeCount":100},[],{"trials":10779,"activeCount":100},[10780],{"nctId":10781,"briefTitle":10782,"status":150,"phases":10783,"primaryCompletion":10784,"completion":10784,"start":10784,"enrollment":846,"conditions":10785,"interventions":10790},"NCT05571670","Bile Acids in Acute Insulin Resistance",[],"2022-06-10",[10786,10787,10788,10789,1513],"PI3K Gene Mutation","AKT Gene Mutation","MTOR Gene Mutation","Cancer",[10766],{"intervention":10792,"totalTrials":129,"cells":10793},"Sodium Chromate Cr51",{"EARLY_PHASE1":10794,"PHASE1":10796,"PHASE2":10798,"PHASE3":10800,"PHASE4":10802,"NA":10804},{"trials":10795,"activeCount":100},[],{"trials":10797,"activeCount":100},[],{"trials":10799,"activeCount":100},[],{"trials":10801,"activeCount":100},[],{"trials":10803,"activeCount":100},[],{"trials":10805,"activeCount":100},[10806],{"nctId":10807,"briefTitle":10808,"status":119,"phases":10809,"primaryCompletion":10810,"completion":4366,"start":3628,"enrollment":351,"conditions":10811,"interventions":10813},"NCT04081272","Effect of G6PD Deficiency on Red Blood Cell Storage",[],"2017-08",[10812],"G6PD Deficiency",[10792],{"intervention":10815,"totalTrials":129,"cells":10816},"Chlorhexidine gluconate",{"EARLY_PHASE1":10817,"PHASE1":10819,"PHASE2":10821,"PHASE3":10823,"PHASE4":10825,"NA":10827},{"trials":10818,"activeCount":100},[],{"trials":10820,"activeCount":100},[],{"trials":10822,"activeCount":100},[],{"trials":10824,"activeCount":100},[],{"trials":10826,"activeCount":100},[],{"trials":10828,"activeCount":100},[10829],{"nctId":10830,"briefTitle":10831,"status":119,"phases":10832,"primaryCompletion":4152,"completion":4152,"start":3970,"enrollment":821,"conditions":10833,"interventions":10836},"NCT02513784","Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome",[92],[10834,6292,10835],"Esophageal Adenocarcinoma","Reflux Esophagitis",[10815],{"intervention":10838,"totalTrials":129,"cells":10839},"NuvaRing",{"EARLY_PHASE1":10840,"PHASE1":10842,"PHASE2":10844,"PHASE3":10846,"PHASE4":10848,"NA":10850},{"trials":10841,"activeCount":100},[],{"trials":10843,"activeCount":100},[],{"trials":10845,"activeCount":100},[],{"trials":10847,"activeCount":100},[],{"trials":10849,"activeCount":100},[],{"trials":10851,"activeCount":100},[10852],{"nctId":10853,"briefTitle":10854,"status":119,"phases":10855,"primaryCompletion":3308,"completion":3308,"start":2645,"enrollment":351,"conditions":10856,"interventions":10858},"NCT00710606","Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®",[92],[10857],"Pharmacokinetics",[10838,10838],{"intervention":10860,"totalTrials":129,"cells":10861},"Blood",{"EARLY_PHASE1":10862,"PHASE1":10864,"PHASE2":10866,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10863,"activeCount":100},[],{"trials":10865,"activeCount":100},[],{"trials":10867,"activeCount":100},[],{"trials":10869,"activeCount":100},[],{"trials":10871,"activeCount":100},[],{"trials":10873,"activeCount":100},[10874],{"nctId":10875,"briefTitle":10876,"status":150,"phases":10877,"primaryCompletion":1071,"completion":1071,"start":759,"enrollment":846,"conditions":10878,"interventions":10880},"NCT01534676","Effects of Transfusion of Older Stored Red Cells",[92],[936,10879],"Thalassemia",[10860],{"intervention":10882,"totalTrials":129,"cells":10883},"Definity",{"EARLY_PHASE1":10884,"PHASE1":10886,"PHASE2":10888,"PHASE3":10890,"PHASE4":10892,"NA":10894},{"trials":10885,"activeCount":100},[],{"trials":10887,"activeCount":100},[],{"trials":10889,"activeCount":100},[],{"trials":10891,"activeCount":100},[],{"trials":10893,"activeCount":100},[],{"trials":10895,"activeCount":100},[10896],{"nctId":10897,"briefTitle":10898,"status":119,"phases":10899,"primaryCompletion":10900,"completion":10901,"start":10902,"enrollment":96,"conditions":10903,"interventions":10904},"NCT04118764","Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound",[92],"2022-07-11","2022-09-28","2020-08-06",[1133],[10882],{"intervention":9856,"totalTrials":129,"cells":10906},{"EARLY_PHASE1":10907,"PHASE1":10909,"PHASE2":10911,"PHASE3":10913,"PHASE4":10915,"NA":10917},{"trials":10908,"activeCount":100},[],{"trials":10910,"activeCount":100},[],{"trials":10912,"activeCount":100},[],{"trials":10914,"activeCount":100},[],{"trials":10916,"activeCount":100},[],{"trials":10918,"activeCount":100},[10919],{"nctId":9849,"briefTitle":9850,"status":119,"phases":10920,"primaryCompletion":736,"completion":9852,"start":879,"enrollment":864,"conditions":10921,"interventions":10922},[92],[9854],[9856,2547],{"intervention":2206,"totalTrials":129,"cells":10924},{"EARLY_PHASE1":10925,"PHASE1":10927,"PHASE2":10929,"PHASE3":10931,"PHASE4":10933,"NA":10935},{"trials":10926,"activeCount":100},[],{"trials":10928,"activeCount":100},[],{"trials":10930,"activeCount":100},[],{"trials":10932,"activeCount":100},[],{"trials":10934,"activeCount":100},[],{"trials":10936,"activeCount":100},[10937],{"nctId":2198,"briefTitle":2199,"status":119,"phases":10938,"primaryCompletion":2201,"completion":2201,"start":417,"enrollment":351,"conditions":10939,"interventions":10940},[92],[2203,2204],[854,2206,2038],{"intervention":10942,"totalTrials":129,"cells":10943},"Fluoro-L-Thymidine",{"EARLY_PHASE1":10944,"PHASE1":10946,"PHASE2":10948,"PHASE3":10950,"PHASE4":10952,"NA":10954},{"trials":10945,"activeCount":100},[],{"trials":10947,"activeCount":100},[],{"trials":10949,"activeCount":100},[],{"trials":10951,"activeCount":100},[],{"trials":10953,"activeCount":100},[],{"trials":10955,"activeCount":100},[10956],{"nctId":10957,"briefTitle":10958,"status":150,"phases":10959,"primaryCompletion":7532,"completion":7532,"start":1044,"enrollment":96,"conditions":10960,"interventions":10961},"NCT01065818","Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET",[92],[5970,7864],[10942],{"intervention":10963,"totalTrials":129,"cells":10964},"Simvastatin",{"EARLY_PHASE1":10965,"PHASE1":10967,"PHASE2":10969,"PHASE3":10971,"PHASE4":10973,"NA":10975},{"trials":10966,"activeCount":100},[],{"trials":10968,"activeCount":100},[],{"trials":10970,"activeCount":100},[],{"trials":10972,"activeCount":100},[],{"trials":10974,"activeCount":100},[],{"trials":10976,"activeCount":100},[10977],{"nctId":10978,"briefTitle":10979,"status":150,"phases":10980,"primaryCompletion":10981,"completion":10981,"start":8238,"enrollment":846,"conditions":10982,"interventions":10984},"NCT00746603","Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors",[92],"2009-07",[10983],"Carotid Artery Disease",[10963],{"intervention":10986,"totalTrials":129,"cells":10987},"Antidepressant Medication",{"EARLY_PHASE1":10988,"PHASE1":10990,"PHASE2":10992,"PHASE3":10994,"PHASE4":10996,"NA":10998},{"trials":10989,"activeCount":100},[],{"trials":10991,"activeCount":100},[],{"trials":10993,"activeCount":100},[],{"trials":10995,"activeCount":100},[],{"trials":10997,"activeCount":100},[],{"trials":10999,"activeCount":100},[11000],{"nctId":11001,"briefTitle":11002,"status":119,"phases":11003,"primaryCompletion":11004,"completion":11005,"start":6726,"enrollment":11006,"conditions":11007,"interventions":11009},"NCT01993017","Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes",[92],"2018-07-31","2019-07-31",1501,[7556,11008],"Depressive Symptoms",[10986],{"intervention":11011,"totalTrials":129,"cells":11012},"Anastrozole",{"EARLY_PHASE1":11013,"PHASE1":11015,"PHASE2":11017,"PHASE3":11019,"PHASE4":11021,"NA":11023},{"trials":11014,"activeCount":100},[],{"trials":11016,"activeCount":100},[],{"trials":11018,"activeCount":100},[],{"trials":11020,"activeCount":100},[],{"trials":11022,"activeCount":100},[],{"trials":11024,"activeCount":100},[11025],{"nctId":11026,"briefTitle":11027,"status":119,"phases":11028,"primaryCompletion":1044,"completion":1044,"start":11029,"enrollment":1735,"conditions":11030,"interventions":11032},"NCT01004744","Pre-Surgical Intervention for Targeted Therapies for Breast Cancer",[92],"2007-07",[11031],"Invasive Breast Cancer",[11011],{"intervention":10101,"totalTrials":129,"cells":11034},{"EARLY_PHASE1":11035,"PHASE1":11037,"PHASE2":11039,"PHASE3":11041,"PHASE4":11043,"NA":11045},{"trials":11036,"activeCount":100},[],{"trials":11038,"activeCount":100},[],{"trials":11040,"activeCount":100},[],{"trials":11042,"activeCount":100},[],{"trials":11044,"activeCount":100},[],{"trials":11046,"activeCount":100},[11047],{"nctId":10093,"briefTitle":10094,"status":150,"phases":11048,"primaryCompletion":4653,"completion":10096,"start":10097,"enrollment":5450,"conditions":11049,"interventions":11050},[92],[10099],[10101,10102,4229],{"intervention":10102,"totalTrials":129,"cells":11052},{"EARLY_PHASE1":11053,"PHASE1":11055,"PHASE2":11057,"PHASE3":11059,"PHASE4":11061,"NA":11063},{"trials":11054,"activeCount":100},[],{"trials":11056,"activeCount":100},[],{"trials":11058,"activeCount":100},[],{"trials":11060,"activeCount":100},[],{"trials":11062,"activeCount":100},[],{"trials":11064,"activeCount":100},[11065],{"nctId":10093,"briefTitle":10094,"status":150,"phases":11066,"primaryCompletion":4653,"completion":10096,"start":10097,"enrollment":5450,"conditions":11067,"interventions":11068},[92],[10099],[10101,10102,4229],{"intervention":11070,"totalTrials":129,"cells":11071},"Nutraceuticals",{"EARLY_PHASE1":11072,"PHASE1":11074,"PHASE2":11076,"PHASE3":11078,"PHASE4":11080,"NA":11082},{"trials":11073,"activeCount":100},[],{"trials":11075,"activeCount":100},[],{"trials":11077,"activeCount":100},[],{"trials":11079,"activeCount":100},[],{"trials":11081,"activeCount":100},[],{"trials":11083,"activeCount":100},[11084],{"nctId":11085,"briefTitle":11086,"status":415,"phases":11087,"primaryCompletion":3628,"completion":3628,"start":2542,"enrollment":100,"conditions":11088,"interventions":11089},"NCT01872351","Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder",[],[7534],[11070],{"intervention":11091,"totalTrials":129,"cells":11092},"daily oral PrEP (emtricitabine 200 mg\u002Ftenofovir 300 mg) [FTC\u002FTDF]",{"EARLY_PHASE1":11093,"PHASE1":11095,"PHASE2":11097,"PHASE3":11099,"PHASE4":11101,"NA":11103},{"trials":11094,"activeCount":100},[],{"trials":11096,"activeCount":100},[],{"trials":11098,"activeCount":100},[],{"trials":11100,"activeCount":100},[],{"trials":11102,"activeCount":100},[],{"trials":11104,"activeCount":100},[11105],{"nctId":11106,"briefTitle":11107,"status":119,"phases":11108,"primaryCompletion":11109,"completion":11109,"start":11110,"enrollment":10419,"conditions":11111,"interventions":11112},"NCT03988387","IPREP Study #2: Evaluating Enhanced PrEP Packages for Young Female Sex Workers in Kisumu, Kenya",[92],"2022-03-10","2019-10-31",[21],[11091]]